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ABSTRACT 
 
The small molecule Amphotericin B (AmB) is a natural product that is utilized in the 
treatment of systemic fungal infections. AmB is effective against a broad spectrum of fungi, and 
resistance to this potent antifungal agent is rare. However, the use of AmB is limited due to its 
high toxicity. All of the details of the mechanism of AmB have not yet been elucidated, and a 
molecular understanding of the mechanisms and interactions of AmB would be an asset in the 
improvement of the therapeutic index of this antimycotic and in the development of other 
antimicrobials that would be refractory to resistance development.  
 AmB is known to self-assemble into ion channels in phospholipid membranes containing 
sterol. The resulting membrane permeabilization has long been the leading hypothesis for the 
primary mechanism of antifungal activity. Three possible interactions involving the carboxylic 
acid and mycosamine appendages of AmB have been predicted to play important roles in the 
mechanism. To investigate the mode of action of AmB, derivatives of AmB lacking one or both 
of these appendages were synthesized and submitted to biophysical assays to determine their 
roles in the possible mechanistic interactions. It was found that the mycosamine was essential for 
antifungal activity, forming ion channels and mediating a direct interaction with ergosterol. 
 The discovery that AmB directly binds ergosterol pointed to two possible primary 
mechanisms, membrane permeabilization through channel formation or ergosterol sequestration. 
The C35 hydroxyl group on AmB has been predicted to be important in the stabilization of the 
ion channel complex via hydrogen-bonding. A C35-deoxyAmB derivative was synthesized and 
evaluated for its antifungal activity, channel forming ability, and sterol binding capacity. C35-
deoxyAmB was unable to permeablize yeast cells but still retained the ability to bind sterol and 
displayed significant antifungal activity. These findings support the conclusion that the primary 
mechanism of AmB is ergosterol sequestration. 
 Investigation of the mycosamine-sterol interaction is needed to further elucidate the 
mechanism of AmB. The mycosamine subunit contains multiple functional groups that could be 
involved in the AmB-sterol binding event. The C2’ hydroxyl group has been implicated in a 
potential hydrogen-bond interaction with the sterol. Electronic tuning of site-selective acylation 
reactions was developed towards the synthesis of a C2’-deoxyAmB derivative. More electron-
rich acyl donors create a less exothermic reaction in which the transition state is more product-
ii
like according to the Hammond Postulate. This more product-like transition state magnifies the 
site-discriminating interactions between the acylating complex and the substrate thereby 
engendering greater selectivity. The site-selective acylation of the C2’ hydroxyl group allowed 
this hydroxyl to be isolated and deoxygenated. In addition, a hybrid route with a higher yielding 
and streamlined protection-deprotection sequence was also developed to produce the C2’-
deoxyAmB derivative. 
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Chapter 1 
An Introduction to the Antimycotic Amphotericin B 
 
 This chapter discusses the importance of the polyene macrolide amphotericin B and the 
current understanding of the mechanism of its antifungal activity. As the last line of defense in 
the treatment of systemic fungal infections, amphotericin B is a critical therapeutic in the clinic 
despite its high toxicity. Amphotericin B also has a remarkable record of being refractory to 
resistance development. However, after over 50 years of study, many of the mechanistic details 
of how it functions are still unknown. The leading model and its hypothetical interactions are 
presented. Evaluation of the model and these interactions to gain a better understanding of the 
mechanism on a molecular level will be an asset in the improvement of the therapeutic index and 
design of resistance-refractory antimicrobials. 
 
1-1 Amphotericin B is an Important Antimycotic 
 Amphotericin B (AmB, Figure 1.1) is an important antimicrobial agent used for the 
treatment of invasive fungal infections.1-3 Systemic fungal infections represent a serious problem 
in human health. Systemic fungal infections afflict a large number of people, and the mortality 
rates are often quite high (Table 1.1).4 This is 
especially true of immunocompromised patients 
who are particularly susceptible to contracting 
systemic fungal infections.5 In addition, the 
incidence of systemic fungal infections is 
increasing.6 AmB is a member of the class of 
antifungal agents known as the polyene 
macrolides. Isolated in the 1950’s from Streptomyces nodosus,7 AmB has been used in the clinic 
for over fifty years. It is effective across a broad range of fungi and yeast and is quite potent. 
Also, drug resistance to AmB is quite rare; this is in contrast to many other antimicrobials where 
drug resistance development is a growing problem and a major concern in the healthcare 
system.8-10 
 
 
Figure 1.1. The polyene macrolide antimycotic 
amphotericin B. 
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AmB, however, does have drawbacks associated with it that limit its use, namely high 
toxicity and poor pharmacological properties.11 Even after over fifty years of study, the 
mechanistic details of how AmB functions have yet to be fully elucidated.12-14 A detailed 
understanding of how AmB operates on a molecular level would be beneficial to human health in 
terms of improving its therapeutic index and applying the underlying principles that bestow 
potency and resistance-refractory traits to the development of future antimicrobials. 
 
1-2 Early studies and the Development of the Leading Model 
 Early studies with AmB and A. laidlawii cells that do not produce their own sterols 
demonstrated that the activity of AmB was sterol dependent. A. laidlawii cells that were grown 
without sterols were not susceptible to AmB; however, if the cells were grown in the presence of 
cholesterol that they could uptake, they were susceptible to AmB.15 While the activity of AmB 
has been linked to a sterol dependence in the membrane, the exact function of the sterol is 
unknown. Additional studies with the A. laidlawii cells showed that when sterols are present in 
the membrane, AmB induces membrane permeability.16 The sterol dependence of the activity 
and membrane permeabilization abilities of AmB has been shown in numerous other studies with 
cells, liposomes, and planar lipid bilayers.17-26 Addition of extra sterols can diminish the efficacy 
of AmB.18 While AmB caused increased permeability of ions and small solutes, increased 
permeability of glucose and larger molecules was not observed.17 A significant advance came 
with the observation of single ion channels in planar lipid bilayers upon addition of AmB.27,28 All 
of these early biophysical experiments created the foundation of the leading theory in which 
AmB associates with the membrane and self assembles into a channel complex with a 7-10 
 
Table 1.1. Estimated world incidence and mortality rates of some systemic fungal infections. 
Data from the Fungal Research Trust, How common are fungal diseases? Fungal Research Trust 20th Anniversary 
Meeting. June 18th 2011. 
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angstrom pore causing membrane permeabilization that leads to cell death. Other mechanisms 
based upon AmB-induced oxidative damage have also been proposed.29 
The structure of the ion channel is not known. It is proposed that eight AmB molecules 
come together to forming a barrel-stave like structure with the polyol portion lining the inside 
and the polyene facing the lipid matrix (Figure 1.2).30-32 The role of the sterol and whether it is 
directly bound or part of the channel complex has long been a matter of debate in the literature. 
In one model, there is a direct interaction with the sterol that stabilizes the channel structure. In 
the opposing model, the sterol doesn’t associate with AmB but instead preorganizes the 
membrane to allow channel formation. While the activity of AmB has been shown to be 
dependent upon the specific sterol, experiments with different sterols and sterol derivatives are 
inconclusive when resolving the direct versus indirect models because the change in sterol can 
affect the direct binding event and/or change the global membrane properties. Several molecular 
modeling and computational studies have also been done to investigate possible properties of this 
channel model.33-37 
 
1-3 Predicted Interactions of the Leading Model 
 Several interactions have been proposed to be active in the membrane permeability 
mechanism (Figure 1.3). These interactions are centered around two functional group 
appendages on the AmB macrolide, the C41 carboxylic acid and the C19 mycosamine sugar. 
These two groups are installed by enzymes post polyketide synthase construction of the 
macrocycle.38 Under physiological conditions, the C41 acid exists as the carboxylate and the 
amine on the C19 mycosamine unit is protonated, making AmB zwitterionic. The first 
Figure 1.2. Hypothetical models of AmB ion channels. A. AmB (blue) assembled into an ion channel 
complex directly interacting with sterols (green). B. AmB ion channel formation supported by indirect 
membrane preorganization by sterols. C. Top down view of hypothetical AmB ion channel model.   
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interaction in the channel model involves a salt-bridge between the charged carboxylate of an 
AmB molecule and the protonated amine on the mycosamine of the adjacent AmB molecule in 
the complex.33-37,39,42,43 This interaction would create a ring of stabilization around the channel 
complex. The second potential interaction is between the phospholipid headgroups and the 
carboxylate and/or mycosamine.40,44,45 This interaction would play an important role anchoring 
the ion channel complex to the membrane. A possible third interaction is the direct binding of 
sterol to the carboxylate and/or mycosamine.21,33-37,41,46,47 
 Insights into the possible mechanism of AmB can be obtained by probing the roles of 
these two functional appendages on the AmB macrolide skeleton through biophysical studies. 
The carboxylic acid and amine have unique reactivities that have been taken advantage of in the 
synthesis of derivatives of AmB that are covalently modified at these two positions.12,13,14 
However, the conclusions that can be made from biophysical experiments with these derivatives 
can be limited by the possible effects due to additional steric bulk being introduced and 
remaining abilities to hydrogen bond. Computer modeling has also been utilized to support the 
possibility of the existence of these mechanistic interactions.33-37 Biophysical evaluation of AmB 
derivatives that lack the C41 carboxylate and/or the C19 mycosamine would be an effective way 
Figure 1.3. Possible interactions of the leading AmB ion channel model. A. Intermolecular AmB 
interaction between the C41 carboxylate and the C19 mycosamine. B. AmB binding to phospholipid 
headgroups C. Direct binding interaction between AmB and ergosterol. Figure adapted from ref. 48. 
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to evaluate their contributions to the mechanism48 in a similar fashion to alanine scanning in 
protein science. 
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Chapter 2 
Discovery of a Critical Mycosamine-Mediated Sterol Interaction 
 
 This chapter details the investigation of the roles of the C41 carboxylate and the C19 
mycosamine in the mechanism of amphotericin B. The synthesis of functional-group deficient 
derivatives and subsequent biophysical studies allowed the evaluation of hypothetical 
interactions in the leading model for amphotericin B antifungal activity. This resulted in the 
discovery that the mycosamine appendage of AmB is required for a direct interaction with 
ergosterol, channel formation, and antifungal activity. Dan Palacios developed the synthetic 
routes to the AmB derivatives. The AmB derivatives were prepared by Dan Palacios and 
Brandon Wilcock. Membrane binding and MIC experiments were performed by Dan Palacios 
and Dave Siebert. Voltage clamp and yeast potassium efflux experiments were done by Dan 
Palacios. ITC experiments were conducted by Dan Palacios and Ian Dailey. Portions of this 
chapter have been adapted from Palacios, D. S.; Dailey, I.; Siebert, D. M.; Wilcock, B. C.; Burke, 
M. D. Proc. Natl. Acad. Sci. U. S. A. 2011, 108, 6733-6738. 
 
2-1 C41 Carboxylic Acid and C19 Mycosamine Functional-Group Deficient Derivatives  
In order to provide clean experiments to investigate the hypothetical interactions 
pertaining to the roles of the carboxylic acid and mycosamine in the mechanism (see Chapter 1), 
derivatives of AmB where these groups are removed or “synthetically deleted” were envisioned. 
Removal of these groups would reveal if the groups were essential to the proposed interactions in 
the mechanistic model (Figure 1.3) without the complications of steric perturbations or 
remaining hydrogen-bonding ability. My colleague Dan Palacios therefore expanded upon 
previous degradative synthetic studies on AmB carried out by Nicolaou1 and the Smith-Kline 
Beecham group2 to develop a mild and modular synthesis of three derivatives of AmB: the C41-
methyl amphotericin B (MeAmB) lacking oxidation at C41, amphoteronolide B (AmdeB) with 
no mycosamine sugar, and C41-methyl amphoteronolide B (MeAmdeB) missing both groups 
(Scheme 2.1). Dan Palacios and I were able to synthesize large quantities of these derivatives for 
biophysical studies conducted by my coworkers Dan Palacios, Ian Dailey, and David Siebert.3 
 Global protection of AmB via Fmoc protection of the amine, conversion of the hemi ketal 
to the methyl ketal, and silylation of the hydroxyl groups creates a common intermediate. The  
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C41 carboxylic acid can be reduced to an alcohol via activation as a thioester. The alcohol can 
then be transformed to an iodide and reductively displaced to create a methyl group at C41. The 
mycosamine can be removed, after acid protection, via oxidative cleavage. Subsequent reduction 
of the conjugated enone results in the allylic alcohol at C19. Employing one or both of these 
modules in conjunction with global deprotection allows for the synthesis of the functional-group 
deficient derivatives MeAmB, AmdeB, and MeAmdeB (Scheme 2.1).3,4    
 The consequences of deleting these 
groups on the antifungal activity was 
determined by the minimum inhibitory 
concentration (MIC) against the growth of 
two yeast strains, S. cerevisiae and the 
pathogenic C. albicans (Table 2.1).3 It was discovered that MeAmB was equipotent to the 
natural product AmB. However, AmdeB was found to be inactive displaying no antifungal 
activity. This allows us to conclude that the carboxylic acid oxidation state at C41 is not required 
for antifungal activity and the mycosamine sugar is essential for antifungal activity. Further 
biophysical studies were undertaken to investigate the predicted interactions in order to 
determine what role the mycosamine was playing that caused the loss of activity. 
 
 
Scheme 2.1. Synthesis of C41-methyl amphotericin B (MeAmB), amphoteronolide B (AmdeB), and C41-
methyl amphoteronolide B (MeAmdeB). Scheme adapted from ref. 3 
Table 2.1. MIC values for AmB and derivatives. 
Table adapted from ref. 3.
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2-2 Membrane Permeabilization and Channel Formation 
 Membrane permeabilization via channel formation has long been a popular hypothesis as 
a main component of the antifungal activity for the mechanism of AmB. There are, however, 
some reports that question whether channel formation is the cause of cell death.5-7 At 
physiological pH, the C41 acid exists as the carboxylate and the C3’ amine on the mycosamine is 
protonated. One of the key predicted stabilizing interactions of the leading theoretical channel 
complex model is an electrostatic bond between these two charged groups. Computational 
modeling studies are in agreement with the existence of this interaction.8-13 
 Covalent derivatives of AmB have been employed to investigate this interaction. For 
instance, the C41 ester of AmB still displayed potent membrane permeabilization and antifungal 
activity against yeast.14,15 However, acylating the amine results in a reduction in activity and 
membrane permeablization.14,15 Caution must be exercised in the interpretation of these results 
due to the ester and amide derivatives still retain the ability to have a polar interaction. In 
addition, small molecule assembly is known to often be sensitive to steric effects, and the added 
steric bulk of these derivatives may be contributing to reduced capacity to self assemble into ion 
channels. We therefore decided to determine the channel forming and membrane 
permeabilization abilities of the functional-group deficient derivatives we synthesized. 
 I conducted some preliminary membrane permeabilization studies with AmB, AmdeB, 
and MeAmB. Potassium efflux experiments with egg yolk phosphatidylcholine (EYPC) large 
unilamellar vesicles (LUVs) containing 10% ergosterol were performed with a range of 
concentrations of the polyene macrolides to determine the required concentrations for membrane 
permeabilization. I found robust efflux was observed for AmB and MeAmB at 1 μM; in contrast, 
AmdeB showed no efflux. These membrane experiments were further continued and expanded 
into potassium efflux from yeast cells by Dan Palacios. The results from the yeast potassium 
efflux assays paralleled the LUV experiments with the compounds containing the mycosamine 
inducing membrane permeabilization and the compounds lacking the mycosamine causing no 
efflux (Figure 2.1 A, B).3 
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 To further investigate the channel forming capacity and confirm that the potassium efflux 
activity was due to channel formation and not indiscriminate membrane defects, Dan Palacios 
also conducted voltage clamp recordings with the polyene macrolides and planar lipid bilayers 
containing ergosterol (Figure 2.2).3 These experiments showed single ion channel recordings for 
AmB and MeAmB and not for AmdeB or MeAmdeB. Collectively, efflux and voltage clamp 
experiments demonstrate the mycosamine is required for the channel formation of AmB. The 
A 
  
B 
 
Figure 2.1. Membrane Permeabilization Studies. A. Potassium efflux in yeast (S. cerevisiae) after 
addition of polyene macrolides (3 μM). B. Potassium efflux in 10% ergosterol LUVs after addition of 
polyene macrolides (1 μM). Figure adapted from ref. 3. 
 
Figure 2.2. Voltage clamp recordings with planar lipid bilayers containing ergosterol after addition of 
polyene macrolides at an applied potential of 150 mV. AmB (10 nM), MeAmB (75 nM), AmdeB (100 
nM), MeAmdeB (50 nM). Figure adapted from ref. 3. 
10
fact that MeAmB, which lacks the carboxylate and thus is unable to create the stabilizing ring of 
electrostatic interactions with the C3’ amine, forms channels supports the conclusion that the 
salt-bridge interaction is not necessary to stabilize the channel complex. 
  
2-3 Membrane and Ergosterol Binding 
 Missing interactions with the phospholipid head groups could also underlie the observed 
lack of activity and channel formation of these mycosamine-deficient derivatives. Previous 
reports, including NMR and computational experiments, have suggested that AmB forms a 
complex with the lipids.9-11,16-18 This interaction would play a crucial role in anchoring AmB and 
the complex to membrane and/or stabilizing the complex. This was investigated by David Siebert 
and Dan Palacios by determining the ability of the derivatives to bind LUVs containing 
ergosterol and yeast membranes. It was found that all the compounds incorporated and bound to 
both LUVs and yeast membranes indicating that neither the C41 carboxylic acid nor the 
mycosamine are essential for AmB to associate with membranes (Figure 2.3 A, B).3 
 The roles of the sterol in the mechanism are poorly understood. There are reports 
supporting both indirect sterol effects and the direct binding of sterol.10,12,16,19-26 In addition, there 
are also some reports of membrane permeabilization in sterol free membranes,27-29 but these were 
done at super-physiological concentrations of AmB or with strained small liposome vesicles. To 
elucidate whether a direct binding event was occurring between AmB and the sterol, Ian Dailey 
and Dan Palacios conducted isothermal titration calorimetry (ITC) with the derivatives and both 
liposomes containing ergosterol and liposomes devoid of ergosterol.3 The net isotherm was 
calculated from the isotherms of the ergosterol-containing liposomes and the ergosterol-free 
A 
  
B  
 
Figure 2.3. Polyene macrolide binding to phospholipid membranes. A. Binding to S. cerevisiae. B. 
Binding to 10% ergosterol LUVs. Figure adapted from ref. 3. 
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liposomes. A significant exotherm was observed 
with AmB and MeAmB with the erosterol-
containing liposomes indicating a direct binding 
event. AmdeB and MeAmdeB did not produce 
significant exotherms (Figure 2.4). The 
conclusion drawn from these experiments is that 
the mycosamine is required to meditate a direct 
interaction between the sterol and AmB. To 
investigate whether this exotherm was due to 
changes in global membrane properties, the 
same experiment was conducted with 10% 
lanosterol instead of 10% ergosterol LUVs. 
Lanosterol and ergosterol cause very similar changes in global membrane properties.30-32 No 
significant net exotherm was observed with AmB and the lanosterol containing LUVs. This 
supports our previous conclusion of a direct binding event between AmB and ergosterol. 
 
2-4 Summary 
 The experiments we conducted elucidated some critical points of the mechanism of 
AmB: The mycosamine appendage is essential for antifungal activity, channel formation, and a 
direct binding event with ergosterol. 
However, these findings do not fully 
address the question of how AmB is 
achieving cell death, specifically, is 
the primary mode of action based in 
ergosterol sequestration through the 
direct binding event or cell gradient 
disruption driven by channel formation 
(Figure 2.5). In order to investigate this, a derivative of AmB that could still bind sterol but is 
incapable of forming ion channels is needed. 
 
 
 
Figure 2.4. Net exotherm for polyene macrolides 
titrated with sterol-free LUVs followed by 10% 
ergosterol LUVs. Figure adapted from ref. 3. 
Figure 2.5. Two possible mechanisms of AmB, ergosterol 
sequestration and membrane permeabilization. 
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2-5 Experimental 
The experimental section is adapted from ref. 3. 
 
General Methods 
Materials  
Commercially available materials were purchased from Aldrich Chemical Co. 
(Milwaukee, WI), Fisher Scientific (Hampton, NH), Avanti Polar Lipids (Alabaster, AL), and 
Small Parts Inc. (Miramar, FL) and were used without further purification unless noted otherwise. 
Amphotericin B was a generous gift from Bristol-Myers Squibb and was purified by preparative 
RP-HPLC using an Agilent (Santa Clara, CA) 1100 series HPLC system equipped with a Waters 
(Milford, MA) Sunfire Prep C18 30 x 150 mm column. Ergosterol and camphorsulfonic acid were 
recrystallized from ethyl acetate. Water was obtained from a Millipore (Billerica, MA) Gradient 
A10 water purification system.  
 
Antifungal Assays 
Growth Conditions for S. cerevisiae  
S. cerevisiae was maintained with yeast peptone dextrose (YPD) growth media consisting 
of 10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose, and 20 g/L agar for solid media. The 
media was sterilized by autoclaving at 250 °F for 30 min.  Dextrose was subsequently added as a 
sterile 40% w/v solution in water (dextrose solutions were filter sterilized). Solid media was 
prepared by pouring sterile media containing agar (20 g/L) onto Corning (Corning, NY) 100 x 20 
mm polystyrene plates. Liquid cultures were incubated at 30 °C on a rotary shaker and solid 
cultures were maintained at 30 °C in an incubator.  
 
Growth Conditions for C. albicans 
C. albicans was cultured in a similar manner to S. cerevisiae except both liquid and solid 
cultures were incubated at 37 °C. 
 
Broth Microdilution Minimum Inhibitory Concentration (MIC) Assay  
The protocol for the broth microdilution assay was adapted from the Clinical and 
Laboratory Standards Institute document M27-A2.33 50 mL of YPD media was inoculated and 
13
incubated overnight at either 30 °C (S. cerevisiae) or 37 °C (C. albicans) in a shaker incubator. 
The cell suspension was then diluted with YPD to an OD600 of 0.10 (~5 x 106 cfu/mL) as 
measured by a Shimadzu (Kyoto, Japan) PharmaSpec UV-1700 UV/Vis spectrophotometer. The 
solution was diluted 10-fold with YPD, and 195 μL aliquots of the dilute cell suspension were 
added to sterile Falcon (Franklin Lakes, NJ) Microtest 96 well plates in triplicate. Compounds 
were prepared either as 400 μM (AmB, MeAmB) or 2 mM (AmdeB, MeAmdeB) stock solutions 
in DMSO and serially diluted to the following concentrations with DMSO: 1600, 1200, 800, 400, 
320, 240, 200, 160, 120, 80, 40, 20, 10 and 5 μM. 5 μL aliquots of each solution were added to 
the 96 well plate in triplicate, with each column representing a different concentration of the test 
compound. The concentration of DMSO in each well was 2.5% and a control well to confirm 
viability using only 2.5% DMSO was also performed in triplicate. This 40-fold dilution gave the 
following final concentrations: 50, 40, 30, 20, 10, 8, 6, 4, 1, 0.5, 0.25 and 0.125 μM. The plates 
were covered and incubated at 30 °C (S. cerevisiae) or 37 °C (C. albicans) for 24 hours prior to 
analysis. The MIC was determined to be the concentration of compound that resulted in no 
visible growth of the yeast. The experiments were performed in duplicate and the reported MIC 
represents an average of two experiments.   
  
Potassium Efflux Assays 
General Information 
 Ion selective measurements were obtained using a Denver Instruments (Denver, CO) 
Model 225 pH meter equipped with a Denver Instruments potassium selective electrode. The pH 
meter was connected to a desktop computer by an RS232 connection and the data were collected 
using Labtronics (Guleph, Ontario) Collect SL software. The electrode was conditioned in a 
1000 ppm KCl standard solution overnight prior to ion selective measurements. Measurements 
were made on 15 mL solutions that were magnetically stirred in 40 mL I-Chem (Rockwood, TN) 
vials incubated in a 30 °C stirred water bath (S. cerevisiae) or at 23 °C (LUVs). The instrument 
was calibrated daily with KCl standard solutions to 10, 100, and 1000 ppm potassium. The 
potassium concentration was sampled every 30 seconds throughout the course of the efflux 
experiments. 
  
Potassium Efflux from S. cerevisiae 
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 The protocol to determine potassium efflux from S. cerevisiae was adapted from a similar 
experiment utilizing C. albicans.34 An overnight culture of S. cerevisiae in YPD was centrifuged 
at 1200 g for 5 minutes at 4 C. The supernatant was decanted and the cells were washed twice 
with sterile water. After the second wash step, the cells were suspended in 150 mM NaCl, 5 mM 
HEPES pH 7.4 (Na buffer) to an OD600 of 1.5 (~1x109 CFU/mL). A 15 mL sample of the cell 
suspension was then incubated in a 30 °C water bath with stirring for approximately 10 minutes 
before data collection. The probe was then inserted and data was collected for 5 minutes before 
adding 150 μL of the compound in question as a 300 M solution in DMSO. The cell suspension 
was stirred and data were collected for 30 minutes and then 150 μL of a 1% aqueous solution of 
digitonin was added to effect complete potassium release and data were collected for an 
additional 15 minutes. The experiment was performed independently three times for each small 
molecule.  
 
Data Analysis 
 The data from each run was normalized to the percent of total potassium release, from 0 
to 100%. Thus for each experiment a scaling factor S was calculated using the following 
relationship: 
K  final
K  initial 1







 S 100 
Each concentration data point was then multiplied by S before plotting as a function of time. 
 
Efflux from 10% ergosterol LUVs 
LUV Preparation  
Egg yolk phosphatidylcholine (EYPC) was obtained as a 10 mg/mL solution in CHCl3 
from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 C under an atmosphere of dry 
argon and used within 3 months. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at -20 C under an atmosphere of dry argon. Prior to preparing a lipid film, 
the solutions were warmed to ambient temperature to prevent condensation from contaminating 
the solutions. A 13 x 100 mm test tube was charged with 1.6 mL EYPC and 230 L of the 
ergosterol solution. The solvent was removed with a gentle stream of nitrogen and the resulting 
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lipid film was stored under high vacuum for a minimum of eight hours prior to use. The film was 
then hydrated with 1 mL of 150 mM KCl, 5 mM HEPES pH 7.4 (K buffer) and vortexed 
vigorously for approximately 1 minute to form a suspension of multilamellar vesicles (MLVs). 
The resulting lipid suspension was pulled into a Hamilton (Reno, NV) 1 mL gastight syringe and 
the syringe was placed in an Avanti Polar Lipids Mini-Extruder. The lipid solution was then 
passed through a 0.20 μm Millipore (Billerica, MA) polycarbonate filter 21 times, the newly 
formed large unilamellar vesicle (LUV) suspension being collected in the syringe that did not 
contain the original suspension of MLVs to prevent the carryover of MLVs into the LUV 
solution. To obtain a sufficient quantity of LUVs, three independent 1 mL preparations were 
pooled together for the dialysis and subsequent potassium efflux experiments. The newly formed 
LUVs were dialyzed using Pierce (Rockford, IL) Slide-A-Lyzer MWCO 3,500 dialysis cassettes. 
The samples were dialyzed three times against 600 mL of Na buffer. The first two dialyses were 
two hours long, while the final dialysis was performed overnight. 
  
Determination of Phosphorus Content  
Determination of total phosphorus was adapted from the report of Chen and coworkers.35 
The LUV solution was diluted tenfold with Na buffer and three 10 μL samples of the diluted 
LUV suspension were added to three separate 7 mL vials. Subsequently, the solvent was 
removed with a stream of N2. To each dried LUV film, and a fourth vial containing no lipids that 
was used as a blank, was added 450 μL of 8.9 M H2SO4. The four samples were incubated open 
to ambient atmosphere in a 225 °C aluminum heating block for 25 min and then removed to 
23 °C and cooled for 5 minutes. After cooling, 150 μL of 30% w/v aqueous hydrogen peroxide 
was added to each sample, and the vials were returned to the 225 °C heating block for 30 
minutes. The samples were then removed to 23 °C and cooled for 5 minutes before the addition 
of 3.9 mL water. Then 500 μL of 2.5% w/v ammonium molybdate was added to each vial and 
the resulting mixtures were then vortexed briefly and vigorously five times. Subsequently, 500 
μL of 10% w/v ascorbic acid was added to each vial and the resulting mixtures were then 
vortexed briefly and vigorously five times. The vials were enclosed with a PTFE lined cap and 
then placed in a 100 °C aluminum heating block for 7 minutes. The samples were removed to 
23 °C and cooled for approximately 15 minutes prior to analysis by UV/Vis spectroscopy. Total 
phosphorus was determined by observing the absorbance at 820 nm and comparing this value to 
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a standard curve obtained through this method and a standard phosphorus solution of known 
concentration. 
 
Determination of Ergosterol Content 
Ergosterol content was determined spectrophotometrically. The LUV solution was 
diluted tenfold with Na buffer, and 50 μL of the dilute LUV suspension was added to 450 μL 
2:18:9 hexane:isopropanol:water (v/v/v). Three independent samples were prepared and then 
vortexed vigorously for approximately one minute. The solutions were then analyzed by UV/Vis 
spectroscopy and the concentration of ergosterol in solution was determined by the extinction 
coefficient of 10400 L mol-1 cm-1 at the UVmax of 282 nm and was compared to the concentration 
of phosphorus to determine the percent sterol content. The extinction coefficient was determined 
independently in the above ternary solvent system. LUVs prepared by this method contained 
between 7 and 14% ergosterol. 
  
Efflux from LUVs  
The LUV solutions were adjusted to 1 mM in phosphorus using Na buffer. 15 mL of the 
1 mM LUV suspension was added to a 40 mL I-Chem vial and the solution was gently stirred. 
The potassium ISE probe was inserted and data were collected for one minute prior to the 
addition of the compound. Then, 150 μL of a 100 μM DMSO solution of the compound in 
question was added and data were collected for five minutes. Then to effect complete potassium 
release, 150 μL of a 10% v/v solution of triton X-100 was added and data were collected for an 
additional five minutes. The experiment was duplicated with similar results. 
 
Data Analysis 
 The data from each run were analyzed in the same manner as the efflux data from S. 
cerevisiae. 
 
Planar Lipid Bilayer Experiments 
General Information  
All data were acquired using a Warner Instruments (Hamden, CT) BC-535 amplifier and 
the data were filtered using a built in 4 pole Bessel filter with a cutoff frequency of 5 kHz. The 
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headstage and delrin cell were housed within a Warner Instruments model FC-1 Faraday cage. 
The solutions were stirred using a Warner Instruments SUNstir-3 stirplate. The signal was passed 
through a Warner Instruments low pass 8 pole Bessel filter with a frequency cutoff of 1 kHz. The 
filtered data were sampled at a rate of 10 kHz using a Molecular Devices (Sunnyvale, CA) 
Digidata 1440 data acquisition system and the data were analyzed using Molecular Devices 
pClamp 10 software. Following acquisition, the data were digitally filtered to 20 Hz. Salt bridges 
were prepared monthly and were fabricated from 1.5 mm OD, 0.86 mm ID borosilicate capillary 
tubing and were filled with 1 M aqueous KCl with 2.5% agar. Prior to a day’s experiments, silver 
electrodes were plated by submerging in commercial bleach for 15 to 30 minutes. The electrodes 
were plated periodically throughout the day. 
 
Preparation of Teflon® Sheets  
Prior to use, Teflon® sheets of 125 M thickness (Small Parts Inc, Miramar, FL) were 
washed sequentially with 10 mM tribasic sodium phosphate, 1% HCl and then MilliQ water. 
Pores of approximately 100-150 m in diameter were formed with the spark method36 using a 
home built sparking apparatus. The Teflon® sheet was scored with a sewing needle and then the 
sheet was placed on a grounded sheet of copper and the Teflon® was sparked 10 times. The sheet 
was then flipped over and sparked an additional 10 times. Pore sizes were analyzed via light 
microscopy. 
 
Preparation of Lipid Solution   
Lipids were obtained from Avanti Polar Lipids as 10 mg/ml solutions in CHCl3. The 
solutions were stored at -20 C under dry argon and used within 3 months. A 4 mg/mL solution 
of ergosterol in CHCl3 was prepared monthly and stored at -20 C under dry argon. Lipid films 
were prepared by charging a 12 x 75 mm test tube with 40 L porcine brain phosphatidylcholine, 
20 L porcine brain phosphatidylethanolamine and 3.8 L ergosterol. The solvent was removed 
with a gentle stream of nitrogen. The lipid film was then dissolved in 30 L n-decane to give the 
20 mg/ml solution of lipids used for the electrophysiology experiments. The decane solutions 
were used within 3 hours of preparation.  
 
Formation of planar lipid bilayers  
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Teflon® sheets were cut to approximately 1 cm2 and adhered to a home fabricated delrin 
cell37 using Dow Corning (Midland, MI) high vacuum grease. The area around the hole was then 
primed with the decane lipid solution. The primed sheet was left to stand for approximately 10 
minutes such that some of the decane evaporated. Then 3.5 mL of 2 M KCl, 10 mM potassium 
phosphate pH 7.0 buffer was added to each chamber. The membrane was formed by sequential 
vertical swabs across the hole using a flame polished glass applicator that had been previously 
dipped into the lipid solution. The formation of a membrane was detected by a reduction in the 
current to 0 pA. The integrity of this membrane was confirmed by applying a potential of 150 
mV for approximately one minute. If the current increased by >1 pA upon voltage introduction, 
the membrane was rejected. Membranes were between 20 and 45 pF in size.  
 
Interrogating Channel Formation  
If the membrane was acceptable, 3.5 μL of a compound in DMSO was added to both 
chambers and the solutions were stirred with zero applied potential for 10 minutes. After 10 
minutes the stirring was stopped, and 150 mV of potential was applied across the membrane. The 
formation of single AmB channels under similar conditions has been well documented.38-45 The 
concentration of AmB and MeAmB required to observe channel activity varied based upon the 
lot number and age of the lipids used to make the membrane. For AmB, single channel formation 
was observed at concentrations between 0.5 and 5 nM while MeAmB displayed single channel 
activity between 30 and 80 nM. The concentration of MeAmdeB was raised to 1000 nM without 
observing any channel activity. At concentrations greater than 100 nM MeAmdeB and AmdeB 
tended to grossly destroy the membrane, as evidenced by an abrupt change from zero current to 
an offscale reading. To verify the inability of MeAmdeB and AmdeB to form channels, 5 
independent experiments were performed at concentrations ranging from 50 to 100 nM, each 
with 15 minutes of applied potential. In every case, AmdeB and MeAmdeB failed to produce 
channel activity. These same conditions consistently led to channel formation with AmB and 
MeAmB.  
 
Yeast Binding Assay 
Determination of Binding 
The yeast binding assay was adapted from the report by Kobayashi and coworkers that 
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demonstrated binding of AmB to intact S. cerevisiae cells.46 10 mL of an overnight culture of S. 
cerevisiae in YPD was centrifuged at 1200 g for 5 min at 4 °C. The supernatant was decanted, 
and the cells were washed twice with sterile water using the same centrifuge conditions. The 
washed cells were then suspended in sterile water to an OD600 of 0.10 (5x106 CFU/mL), and 
990 μl of this suspension was added to a 1.5 mL microcentrifuge tube. 10 μL of a 200 M 
solution of compound in DMSO was added to the suspension, which was vortexed for 
approximately 10 seconds and then incubated at 30 °C for 15 minutes. The samples were 
subsequently centrifuged at 5000 RPM with a Savant HSC10K Speedfuge for 5 min to pellet the 
cells. The concentration of AmB in such aqueous solutions cannot be accurately determined 
because of aggregate formation.47,48 Thus, 950 μL of the supernatant was removed and incubated 
at -20 °C for approximately 20 minutes before being lyophilized overnight. The lyophilized 
sample was dissolved in 400 μL of MeOH and the concentration of compound in solution was 
determined by UV/Vis analysis using the known extinction coefficent of each compound. This 
analysis gives the percent recovery, the percent incorporation being equal to 1-(percent recovery). 
The samples were prepared in triplicate and the entire experiment was duplicated. The values 
represent the average of 5 or 6 trials plus or minus the standard deviation. 
 
Recovery Control 
To ensure that the compounds were not binding to the walls of the microcentrifuge tube 
or decomposing during the course of the experiment, a control was run using the experimental 
protocol outlined above but substituting pure water for the S. cerevisiae suspension. Greater than 
90% recovery was achieved with all four compounds.  
 
LUV Binding Assay 
Preparation of LUVs  
LUVs were prepared as described in Section III except dialysis was not performed and 
the newly extruded vesicles were purified via size exclusion chromatography using Sephadex 
G50-150 resin as the stationary phase and K buffer as the mobile phase. The concentration of 
phosphorus and the sterol content of the LUVs were determined as described in Section III.  
 
LUV Binding 
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The partitioning of AmB into both sterol-containing49-51 and sterol-free52-54 LUVs has 
been previously demonstrated. While many prior methods relied upon a measureable change of a 
physical property (such as electronic absorption spectra) upon the interaction of AmB with a 
phospholipid bilayer, the SEC based method is advantageous because it physically separates 
bound from unbound compound, and thereby avoids assumptions regarding the underpinnings of 
the observed spectral changes.55 A LUV solution of known phosphorus concentration was 
diluted to a concentration of 2.05 mM using K buffer, and the solution was gently vortexed. 
Then, a 975 μL sample of the LUV suspension was added to a 7 mL screw cap vial. 
Subsequently, 25 μL of a 0.8 mM DMSO solution of the compound under investigation was 
added and the sample was gently vortexed. The sample was then incubated at 30 °C for one hour. 
The sample was then purified via size exclusion chromatography using a 1.5 x 30 cm Sephadex 
G50-150 column, with K buffer as the mobile phase (LUVs typically eluted from the column 
between 9 and 11 ml of eluent). After the LUVs eluted from the column, the column was flushed 
with 100 mL of K buffer to remove any small molecules left on the resin. 
The concentration of the purified LUVs was then determined through analysis of 
phosphorus content, as described above. The concentration of compound within the lipid bilayer 
was determined by dissolving triplicate 50 μL samples of the LUV solution in 450 μL of 2:18:9 
hexane:isopropanol:water (v/v/v) and analyzing the sample by UV/Vis spectroscopy. The 
amount of compound incorporation was determined by comparing the final ratio of lipid to 
compound to the theoretical max of 100:1. The experiments were performed in quadruplicate for 
each compound; thus, the reported values represent the average of four runs plus or minus the 
standard deviation. The binding to sterol-free vesicles was determined in similar fashion except 
no ergosterol was added to the initial lipid film. AmB, MeAmB, AmdeB and MeAmdeB readily 
partition into sterol-free vesicles. 
 
LUV-free Control Studies 
As a control, the same procedure described above was repeated without LUVs to 
determine the amount of compound that elutes from the column at the approximate elution 
volume of the LUVs (the LUVs typically eluted between 9 and 11 mL). Five fractions of 5 mL 
elution volume were collected, frozen and lyophilized overnight. Then, the resulting solid was 
suspended in 1 mL of MeOH and vortexed vigorously for approximately two minutes. The 
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samples were then centrifuged at 4000 rpm with a Savant HSC10K Speedfuge for approximately 
30 minutes to pellet the inorganic salts. The supernatant was removed and analyzed by UV/vis 
spectroscopy to determine the amount of compound in solution. For all compounds, less than 
10% of the compound loaded onto the column eluted at the retention time of the LUVs. The 
measurement was performed in duplicate. 
 
Isothermal Titration Calorimetry 
General Information 
Experiments were performed using a VP-ITC isothermal titration calorimeter (MicroCal 
Inc., Piscataway, NJ).  Solutions of the compounds to be tested were prepared by diluting a 5.0 
mM stock solution of the compound in DMSO to 50 M with K buffer. The final DMSO 
concentration in the solution was 1% v/v. LUVs were prepared and phosphorus and ergosterol 
content was quantified as described in above. Ergosterol and lanosterol were also incorporated 
into POPC LUVs. The LUV solutions were diluted with buffer and DMSO to give a final 
phospholipid concentration of 8.0 mM in a 1% DMSO/K buffer solution. Immediately prior to 
use, all solutions were degassed under vacuum at 17 °C for 10 minutes. The reference cell of the 
instrument was filled with a solution of 1% v/v DMSO/K buffer. 
 
Titration Experiment 
Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 1.4399 mL or 1.4495 mL) which contained the 50 M solution of the 
compound in question at 25 °C. The volume of the first injection was 1 μL. Consistent with 
standard procedure,56 due to the large error commonly associated with the first injection of ITC 
experiments, the heat of this injection was not included in the analysis of the data. Next, forty 5 
L injections of the LUV suspension were performed. The injection duration was 2.1 seconds 
and 10.3 seconds for the 1 μL and 5 μL injections, respectively. The spacing between each 
injection varied between 240 seconds and 480 seconds and was adjusted to allow the instrument 
to return to baseline before the next injection was made. The rate of stirring for each experiment 
was 300 or 310 rpm.  
 
Data Analysis 
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ORIGIN software (MicroCal, Inc.) was used for baseline determination and integration of 
the injection heats, and Microsoft Excel was used for subtraction of dilution heats and the 
calculation of overall heat evolved. To approximate the dilution heats, the final integrated heat 
from each run was subtracted from all the data for that particular experiment.57 The overall heat 
evolved during the experiment was calculated using the following formula: 
)(μcal
1



n
i
n
injection
i
injectionoverall hh  
Where i = injection number, n = total number of injections, hinjectioni = heat of the ith injection, 
hinjectionn = the heat of the final injection of the experiment.  
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Chapter 3 
Elucidation of Ergosterol Binding as the Primary Mechanism of Amphotericin B 
 
 This chapter describes the synthesis and biophysical evaluation of C35-
deoxyamphotericin B. This derivative retains the ability to bind ergosterol but lacks the capacity 
to form ion channels. Separation of these two functions of amphotericin B resulted in the 
discovery that amphotericin B primarily kills yeast cells by binding ergosterol, and channel 
formation is a complimentary second mechanism that enhances the antifungal potency. C35-
deoxyamphotericin B was produced by Kaitlyn Gray, Dan Palacios, Ian Dailey, Matt Endo, 
Brice Uno, and Brandon Wilcock. Natamycin aglycone was prepared by Kaitlyn Gray. Dan 
Palacios and Matt Endo performed the potassium efflux assays. Dan Palacios, Matt Endo and 
Kaitlyn Gray conducted MIC experiments. Quantification of amphotericin B and ergosterol at 
the MIC concentration was done by Dan Palacios and Matt Endo. Portions of this chapter were 
adapted from Gray, K. C.; Palacios, D. S.; Dailey, I.; Endo, M. M.; Uno, B. E.; Wilcock, B. C.; 
Burke, M. D. Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 2234-2239. 
 
3-1 The Role of the C35 Hydroxyl 
 The hydroxyl group at 
C35 on AmB has been 
hypothesized to perform an 
essential function in the 
formation of the ion channel. 
There are two main proposed 
structures for the ion complex,1 
the double barrel model and the 
single barrel model (Figure 
3.1). The length of AmB is 
roughly one half the thickness 
of the phospholipid bilayer 
membrane. In the double barrel model, two AmB complexes align in a tail to tail fashion to span 
the entire bilayer membrane. The two barrels are proposed to be held together through hydrogen 
Figure 3.1. Single and double barrel models of the AmB ion 
channel. The C35 hydroxyl (red) is proposed to stabilize the 
complex through hydrogen bonding interactions between to barrels 
in the double barrel model and to the phospholipid head groups in 
the single barrel model.  
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bonding of the C35 hydroxyl groups on the AmBs. In the single barrel model, the membrane is 
pinched in, and the polar phospholipid head groups interact with the C35 hydroxyl to create a 
stable pore. In both cases, the C35 hydroxyl is predicted to be important for channel formation. If 
the predictions are correct, removal of this group would lead to diminished channel forming 
ability. 
 The methyl ester of a C35-deoxyAmB derivative was synthesized by the Carreira group 
and showed impaired ability to cause potassium efflux in liposomes and reduced antifungal 
activity in comparison to AmB methyl ester (AmE).2 We hypothesized that LUVs might be more 
sensitive than yeast membranes to permeabilization. Also, the AmE (a derivative with net 
positive charge) might have different membrane permeabilization capabilities than AmB. 
Matthew Endo investigated this and found that, at the elevated concentrations of 30 μM, AmE 
was able to permeablize LUVs containing no sterol while AmB was unable to permeablize the 
LUVs.3 This shows that AmE has different membrane permeabilization capacities than AmB and 
caution should be taken interpreting Carreira’s results. We also found that AmdeB, which 
doesn’t bind sterol or have antifungal activity, also permeablized the LUVs, but was incapable of 
permeablizing yeast membranes. This demonstrates that LUVs are more sensitive than the yeast 
membranes towards permeabilization. Given these results and the fact that no sterol binding 
studies were performed, we undertook the synthesis of C35-deoxyAmB (C35deOAmB) to test its 
sterol binding properties and channel forming capacity in yeast. 
 
3-2 The Synthesis of C35-deoxyAmB 
 The strategy for the synthesis of C35-deoxyAmB was based upon a hybrid approach 
utilizing new iterative cross-coupling methodology4,5 being developed in our group (Figure 3.2).  
Iterative cross coupling (ICC) relies on the ligand N-methyliminodiacetic acid (MIDA) 
attenuating the reactivity of boronic acids. MIDA imparts stability to the building blocks and is 
mildly deprotected with aqueous base. This allows a bifunctional MIDA-protected haloboronic 
acid to be coupled via a Suzuki-Miyaura reaction and subsequently deprotected to undergo an 
additional coupling. To employ this strategy, a hybrid synthesis with three building blocks was 
envisioned (Figure 3.2). The main building block comprising over half of the AmB skeleton was 
to be obtained from the degradation of AmB; the synthesis of this building block was based on 
previous degradative studies by Murata and Nicolaou.6,7 This building block was coupled to a 
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polyene building block developed in our group.8 The final building block consisted of the 
remaining fragment of the AmB skeleton with a methylene at the C35 position.3 
 The hybrid synthesis of C35-deoxyAmB (Scheme 3.1) was pioneered by Kaitlyn Gray 
and Dan Palacios with support from Brice Uno, Matt Endo, Ian Dailey and I. First, AmB was 
globally protected. The amine was protected as the phenylacetyl amide, and the hemi ketal was 
converted to the methyl ketal. Para-methoxybenzylidene acetals were installed on the polyol 
portion of AmB, and the acid was transformed into the TMSE ester after silylation of the 
remaining hydroxyl groups. The polyene portion of this protected intermediate was removed by 
ozonolysis. Takai olefination and cleavage of the ester at C1 completed the removal of half of 
the AmB skeleton. The resulting iodide from the Takai olefination was coupled to generate the 
AmB-derived, MIDA-protected building block. ICC with the remaining two building blocks 
created the linear C35-deoxyAmB skeleton. Macrolactonization followed by global deprotection 
generated the final C35-deoxyAmB compound.3 
Figure 3.2. Iterative-cross-coupling based hybrid strategy for the synthesis of C35-deoxyAmB. AmB is 
protected and degraded to form the main building block. Iterative cross coupling with a polyene and a 
deoxy building block followed by macrocyclization and global deprotection gives C35-deoxyAmB. 
Figure was adapted from ref. 3. 
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 One of the important aspects in the synthesis of AmB derivatives is the protecting group 
selection. The protecting groups must be orthogonal and/or robust enough to survive the 
chemistry conditions in the route yet be able to be mildly removed from the sensitive AmB 
framework. Finding an amine protecting group that meets these requirements was a challenge in 
this setting. AmB is sensitive to strong acid and hydrogenation conditions, and the group needed 
to be orthogonal to the nucleophilic/basic conditions of the ester cleavage and 
palladium/phosphines of the cross-coupling. These restrictions eliminated most of the 
Scheme 3.1. The synthesis of C35-deoxyAmB. Scheme adapted from ref. 3. 
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conventional choices for amine protecting groups. I envisioned utilizing a robust and stable acyl 
group to protect the amine as an amide. The deprotection of amides generally requires conditions 
that would be incompatible with AmB such as refluxing strong acid or base. However, amide 
bonds are commonly cleaved in nature by enzymes. For example, the phenylacetyl amide of 
penicillin G is transformed to the amine by the enzyme penicillin G amidase (PGA). In fact, this 
reaction is performed on large scale in industry to generate semi-synthetic penicillins.9 I 
therefore decided to investigate the prospect of protecting the amine on AmB as the phenylacyl 
amide. The phenylacetyl protecting group would be robust enough to survive the synthetic route 
and potentially be removed under mild conditions with PGA (Scheme 3.2). 
 I was able to successfully install the phenylacyl group selectively on the amine by 
generating the mixed anhydride and acylating at 0 °C. For removal of the phenylacyl group, I 
initially screened immobilized PGA sources on a variety of polymer backbones. I found these 
immobilized PGA reagents to be highly problematic. AmB had very poor solubility in the 
aqueous solutions the reaction requires and tended to aggregate and bind to the polymer supports. 
This complication made purification attempts to isolate clean product in good yields 
unsuccessful. However, crude PGA solution was obtained commercially, and I was able to adapt 
a PGA purification protocol10 to arrive at pure PGA solutions for the deprotection. The best 
results were obtained in the pH range of 7.2-7.4 with very low buffer concentrations and a high 
concentration of PGA. I eventually obtained up to 60% conversion to the desired product, AmB. 
The conversion was hindered by the poor solubility of the AmB substrate and product; however, 
the remaining N-phenylacetyl AmB could be isolated and resubmitted to the reaction conditions. 
These results suggested that the phenylacetyl group was viable for the synthetic route.  
 
Scheme 3.2. Installation and removal of the phenylacetyl protecting group on the C3’ amine of AmB. 
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 3-3 Biophysical Evaluation of C35-deoxyAmB 
 Kaitlyn Gray, Daniel Palacios, Ian Dailey, Matthew Endo, Brice Uno and I were able to 
produce milligram quantities of C35-dexoyAmB for biophysical testing conducted by my 
colleagues. In addition to AmB and C35-deoxyAmB, we also included AmdeB as a control and 
another antifungal polyene macrolide, natamycin, as well as the natamycin aglycone (Figure 3.3). 
Natamycin displays antifungal activity but is incapable of forming membrane permeablizing 
channels and has been shown to directly bind sterol.11 
 To evaluate whether C35-
deoxyAmB bound ergosterol or 
not, ITC was performed.3 A 
significant net exotherm from 
sterol-free vs. ergosterol-
containing liposomes revealed 
that the direct binding event still 
occurs (Figure 3.4). When 
potassium efflux experiments 
were conducted in yeast cells, it 
 
Figure 3.3. Polyene macrolide probes for the investigation of the contributions of ergosterol binding and 
membrane permeabilization to the mechanism of antifungal activity. Figure adapted from ref. 3. 
Figure 3.4. ITC exotherms with polyene macrolides and 
sterol-free and 10% ergosterol LUVs. Figure adapted from ref. 3. 
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was found that C35-deoxyAmB did not permeablize the membranes (Figure 3.5).3 
 Potassium efflux was also done with LUVs to ensure that the lack of efflux from yeast 
membranes was not due to an inability of C35-deoxyAmB to pass the cell wall. The antifungal 
activity of C35-deoxyAmB was compared to AmB in a MIC assay, and C35-deoxyAmB was 
determined to be only six times less active against S. cerevisiae despite its inability to permeablize 
membranes (Table 3.1). It is also notable that C35-deoxyAmB has a very similar MIC to 
natamycin, suggesting that sterol binding is the operative mechanism of antifungal activity. 
 The data gathered from these experiments supports the conclusion that a dual mechanism 
is operative in the case of AmB. The primary mechanism is ergosterol sequestration, and a 
secondary mechanism of membrane permeabilization gives a moderate boost in antifungal 
activity. To further add support to this conclusion, the ratio of AmB to ergosterol at the MIC 
concentrations was determined (Figure 3.6). For sterol sequestration to be the primary 
mechanism, a significant amount of the ergosterol must be bound by the AmB in order to disrupt 
cell function. At the MIC, we found that there is approximately a ten-fold excess of AmB over 
ergosterol to accomplish the sequestration.3 It is also conceivable that ergosterol sequestration 
A B 
Figure 3.5. Membrane permeabilization with polyene macrolides. A. LUVs containing 10% ergosterol. B. 
S. cerevisiae yeast cells. Figure adapted from ref. 3. 
 
Table 3.1. MIC for polyene macrolides against S. cerevisiae and C. albicans. Table adapted from ref. 3. 
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 could be a cause of cell death. 
Ergosterol plays important roles in 
the cell including membrane 
compartmentalization, endocytosis, 
vacuole fusion, and the function of 
membrane proteins.12-15 
 
3-4 Summary 
The discovery that ergosterol 
binding is the primary mechanism by 
which AmB kills yeast cells 
overturns the leading line of thought 
on the antifungal mechanism of AmB 
that has been in place for fifty years. 
If the toxicity to humans is caused by an analogous binding of cholesterol, research towards 
improving AmB as a therapeutic can now be focused on modulating its sterol binding properties 
instead of its channel forming properties. Since the ergosterol binding event is mediated by the 
mycosamine subunit, AmB derivatives lacking functional groups on the mycosamine are needed 
to further study the mechanism in order to provide insight for the design of better therapeutics. 
 
3-5 Experimental 
The experimental section is adapted from ref. 3. 
 
General Methods 
 
Materials  
 Commercially available materials were purchased from Sigma-Aldrich, Alfa Aesar, 
Strem, Avanti Polar Lipids, Fisher Scientific or Julich, and were used without further purification 
unless stated otherwise. Amphotericin B was a generous gift from Bristol-Myers Squibb 
Company.  Iodoform (methanol), camphorsulfonic acid (ethyl acetate), and triphenylphosphine 
(hexanes) were recrystallized from the indicated solvents prior to use.  All solvents were 
dispensed from a solvent purification system that passes solvents through packed columns 
Figure 3.6. Comparison of the number of molecules of 
AmB to ergosterol at the MIC concentration against 
S. cerevisiae and C. albicans. Figure adapted from ref. 3. 
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according to the method of Pangborn and coworkers16 (THF, Et2O, CH2Cl2, toluene, dioxane, 
hexanes : dry neutral alumina; DMSO, DMF, CH3OH : activated molecular sieves).  2,6-Lutidine 
and pyridine were freshly distilled under nitrogen from CaH2. EtOAc and EtOH were freshly 
distilled under nitrogen from activated molecular sieves. Water was doubly distilled or obtained 
from a Millipore MilliQ water purification system. Ozone was generated using an ozone 
solutions ozone generator. 
 
Reactions  
 Due to the light and air sensitivity of polyenes, all manipulations of polyenes were 
carried out under low light conditions and compounds were stored under an argon atmosphere. 
All reactions were performed in oven- or flame-dried glassware under an atmosphere of argon 
unless otherwise indicated.  Reactions were monitored by analytical thin layer chromatography 
performed using the indicated solvent on E. Merck silica gel 60 F254 plates (0.25mm).  
Compounds were visualized using a UV (λ254) lamp or stained by an acidic solution of p-
anisaldehyde or KMnO4.  Alternatively, reactions were monitored by RP-HPLC using an Agilent 
1100 series HPLC system equipped with a Symmetry® C18 5 micron 4.6 x 150 mm column 
(Waters Corp. Milford, MA) with UV detection at 406 nm and the indicated eluent and flow rate. 
 
Purification and Analysis   
 Flash chromatography was performed as described by Still and coworkers17 using the 
indicated solvent on E. Merck silica gel 60 230-400 mesh.  1H NMR spectra were recorded at 
23 °C on one of the following instruments: Varian Unity 400, Varian Unity 500, Varian Unity 
Inova 500NB.  Chemical shifts (δ) are reported in parts per million (ppm) downfield from 
tetramethylsilane and referenced internally to the residual protium in the NMR solvent (CHCl3, δ 
= 7.26, CD3C(O)CHD2, δ = 2.04, center line) or to added tetramethylsilane.  Data are reported as 
follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, p = pentet, 
sext = sextet, sept = septet, dd = doublet of doublets, ddd = doublet of doublet of doublets, td = 
triplet of doublets, m = multiplet, b = broad, app. = apparent), coupling constant (J) in hertz (Hz) 
and integration. 13C spectra were recorded at 23 °C with a Varian Unity 500. Chemical shifts (δ) 
are reported downfield of tetramethylsilane and are referenced to the carbon resonances in the 
NMR solvent (CDCl3, δ = 77.0, center line, CD3C(O)CD3, δ = 29.8, center line) or to added 
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tetramethylsilane. Carbons bearing boron substituents were not reported (quadrapolar relaxation). 
11B NMR were recorded using a General Electric GN300WB instrument and referenced to an 
external standard of BF3·Et2O. High resolution mass spectra (HRMS) were obtained at the 
University of Illinois mass spectrometry facility. All synthesized compounds gave HRMS within 
5 ppm of calculated values. Infrared spectra were collected from a thin film on NaCl plates or as 
a KBr pellet on a Mattson Galaxy Series FTIR 5000 spectrometer with internal referencing. 
Absorption maxima (νmax) are reported in wavenumbers (cm-1). 
 
Extinction Coefficient Determination 
General procedure 
 A sample of dried compound was massed in a tared vial using a Mettler Toledo MT5 
microbalance. This sample was then dissolved in DMSO to create a concentrated stock solution. 
A portion of this concentrated stock solution was diluted by a factor of five with DMSO to create 
a dilute stock solution. To achieve the final concentration for UV/Vis experiments, 5 µL of the 
dilute stock solution was diluted with 450 µL MeOH. For each compound, UV/vis experiments 
were performed using five different final concentrations and each concentration was prepared 
three times to obtain an average absorbance. The average absorbance was plotted against the 
concentration. The data was fitted with a linear least squares fit using Excel and the slope of the 
fitted line was used as the extinction coefficient. The extinction coefficients were as follows: 
AmB (ε406 = 164,000), AmdeB (ε406 = 102,000), C35deOAmB (ε404 = 78,000), natamycin (ε317 = 
76,000), and natamycin aglycone (ε303 = 38,000). 
 
Isothermal Titration Calorimetry 
General Information 
 Experiments were performed using a NanoITC isothermal titration calorimeter (TA 
Instruments, Wilmington, DE).  Solutions of the compounds to be tested were prepared by 
diluting a 15.0 mM stock solution of the compound in DMSO to 150 M with K buffer (5.0 mM 
HEPES/KHEPES, pH = 7.4). The final DMSO concentration in the solution was 1% v/v. POPC 
LUVs were prepared and phosphorus and ergosterol content was quantified as described below. 
The LUV solutions were diluted with buffer and DMSO to give a final phospholipid 
concentration of 8.0 mM in a 1% DMSO/K buffer solution. Immediately prior to use, all 
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solutions were degassed under vacuum at 20 °C for 10 minutes. The reference cell of the 
instrument (volume = 0.190 mL) was filled with a solution of 1% v/v DMSO/K buffer. 
 
LUV Preparation  
 Palmitoyl oleoyl phosphatidylcholine (POPC) was obtained as a 20 mg/mL solution in 
CHCl3 from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 C under an atmosphere 
of dry argon and used within 1 month. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at 4 C under an atmosphere of dry argon. Prior to preparing a lipid film, the 
solutions were warmed to ambient temperature to prevent condensation from contaminating the 
solutions. A 13 x 100 mm test tube was charged with 1.2 mL POPC and 350 L of the ergosterol 
solution. For sterol-free liposomes, a 13 x 100 mm test tube was charged with 1.2 mL POPC. 
The solvent was removed with a gentle stream of nitrogen and the resulting lipid film was stored 
under high vacuum for a minimum of eight hours prior to use. The film was then hydrated with 1 
mL of 5 mM HEPES pH 7.4 (K buffer) and vortexed vigorously for approximately 3 minutes to 
form a suspension of multilamellar vesicles (MLVs). The resulting lipid suspension was pulled 
into a Hamilton (Reno, NV) 1 mL gastight syringe and the syringe was placed in an Avanti Polar 
Lipids Mini-Extruder. The lipid solution was then passed through a 0.20 μm Millipore (Billerica, 
MA) polycarbonate filter 21 times, the newly formed large unilamellar vesicle (LUV) suspension 
being collected in the syringe that did not contain the original suspension of MLVs to prevent the 
carryover of MLVs into the LUV solution.  
 
Determination of Phosphorus Content  
 Determination of total phosphorus was adapted from the report of Chen and coworkers.18 
Three 10 μL samples of the LUV suspension were added to three separate 7 mL vials. 
Subsequently, the solvent was removed with a stream of N2. To each dried LUV film, and a 
fourth vial containing no lipids that was used as a blank, was added 450 μL of 8.9 M H2SO4. The 
four samples were incubated open to ambient atmosphere in a 225 °C aluminum heating block 
for 25 min and then removed to 23 °C and cooled for 5 minutes. After cooling, 150 μL of 30% 
w/v aqueous hydrogen peroxide was added to each sample, and the vials were returned to the 
225 °C heating block for 30 minutes. The samples were then removed to 23 °C and cooled for 5 
minutes before the addition of 3.9 mL water. Then 500 μL of 2.5% w/v ammonium molybdate 
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was added to each vial and the resulting mixtures were then vortexed briefly and vigorously five 
times. Subsequently, 500 μL of 10% w/v ascorbic acid was added to each vial and the resulting 
mixtures were then vortexed briefly and vigorously five times. The vials were enclosed with a 
PTFE lined cap and then placed in a 100 °C aluminum heating block for 7 minutes. The samples 
were removed to 23 °C and cooled for approximately 15 minutes prior to analysis by UV/Vis 
spectroscopy. Total phosphorus was determined by observing the absorbance at 820 nm and 
comparing this value to a standard curve obtained through this method and a standard 
phosphorus solution of known concentration. 
 
Determination of Ergosterol Content  
 Ergosterol content was determined spectrophotometrically. A 50 μL portion of the LUV 
suspension was added to 450 μL 2:18:9 hexane:isopropanol:water (v/v/v). Three independent 
samples were prepared and then vortexed vigorously for approximately one minute. The 
solutions were then analyzed by UV/Vis spectroscopy and the concentration of ergosterol in 
solution was determined by the extinction coefficient of 10400 L mol-1 cm-1 at the UVmax of 282 
nm and was compared to the concentration of phosphorus to determine the percent sterol content. 
The extinction coefficient was determined independently in the above ternary solvent system. 
LUVs prepared by this method contained between 7 and 14% ergosterol.  
 
Titration Experiment 
 Titrations were performed by injecting the LUV suspension at ambient temperature into 
the sample cell (volume = 0.191 mL) which contained the 150 M solution of the compound in 
question at 25 °C. The volume of the first injection was 0.23 μL. Consistent with standard 
procedure,19 due to the large error commonly associated with the first injection of ITC 
experiments, the heat of this injection was not included in the analysis of the data. Next, nineteen 
2.52 L injections of the LUV suspension were performed. The spacing between each injection 
was 240 seconds to ensure that the instrument would return to a stable baseline before the next 
injection was made. The rate of stirring for each experiment was 300 rpm.  
 
Data Analysis 
 NanoAnalyze software (TA Instruments) was used for baseline determination and 
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integration of the injection heats, and Microsoft Excel was used for subtraction of dilution heats 
and the calculation of overall heat evolved. To correct for dilution and mixing heats, the heat of 
the final injection from each run was subtracted from all the injection heats for that particular 
experiment.20 By this method, the overall heat evolved during the experiment was calculated 
using the following formula: 
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Where i = injection number, n = total number of injections, hinjectioni = heat of the ith injection, 
hinjectionn = the heat of the final injection of the experiment. Values represent the mean ± SD of at 
least three experiments. 
 
Potassium Efflux Assays 
General Information 
 Ion selective measurements were obtained using a Denver Instruments (Denver, CO) 
Model 225 pH meter equipped with a World Precision Instruments (Sarasota, FL) potassium 
selective electrode inside a Faraday cage. The electrode filled with 1000 ppm KCl standard 
solution and conditioned in a 1000 ppm KCl standard solution for 30 minutes prior to ion 
selective measurements. Measurements were made on 3 mL solutions that were magnetically 
stirred in 7 mL Wheaton vials incubated in a 30 °C aluminum block (S. cerevisiae) or at 23 °C 
(LUVs). The instrument was calibrated daily with KCl standard solutions to 10, 100, and 1000 
ppm potassium. The potassium concentration was sampled every 30 seconds throughout the 
course of the efflux experiments.  
 
Growth Conditions for S. cerevisiae  
 S. cerevisiae was maintained with yeast peptone dextrose (YPD) growth media consisting 
of 10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose, and 20 g/L agar for solid media. The 
media was sterilized by autoclaving at 250 °F for 30 min.  Dextrose was subsequently added as a 
sterile 40% w/v solution in water (dextrose solutions were filter sterilized). Solid media was 
prepared by pouring sterile media containing agar (20 g/L) onto Corning (Corning, NY) 100 x 20 
mm polystyrene plates. Liquid cultures were incubated at 30 °C on a rotary shaker and solid 
cultures were maintained at 30 °C in an incubator.  
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 Potassium Efflux from S. cerevisiae 
 The protocol to determine potassium efflux from S. cerevisiae was adapted from a similar 
experiment utilizing C. albicans.21 An overnight culture of S. cerevisiae in YPD was centrifuged 
at 300 g for 5 minutes at 23 C. The supernatant was decanted and the cells were washed twice 
with sterile water. After the second wash step, the cells were suspended in 150 mM NaCl, 5 mM 
HEPES pH 7.4 (Na buffer) to an OD600 of 1.5 (~1x109 CFU/mL) as measured by a Shimadzu 
(Kyoto, Japan) PharmaSpec UV-1700 UV/Vis spectrophotometer. A 3 mL sample of the cell 
suspension was then incubated in a 30 °C aluminum block with stirring for approximately 10 
minutes before data collection. The probe was then inserted and data was collected for 5 minutes 
before adding 30 μL of the compound in question as a 0.3 mM or 3.0 mM solution in DMSO. 
The cell suspension was stirred and data were collected for 30 minutes and then 30 μL of a 1% 
aqueous solution of digitonin was added to effect complete potassium release and data were 
collected for an additional 15 minutes. The experiment was performed independently three times 
for each small molecule.  
 
Data Analysis 
 The data from each run was normalized to the percent of total potassium release, from 0 
to 100%. Thus for each experiment a scaling factor S was calculated using the following 
relationship: 
K  final
K  initial 1







 S 100 
Each concentration data point was then multiplied by S before plotting as a function of time. 
 
Efflux from 10% ergosterol LUVs 
LUV Preparation  
 Palmitoyl oleoyl phosphatidylcholine (POPC) was obtained as a 25 mg/mL solution in 
CHCl3 from Avanti Polar Lipids (Alabaster, AL) and was stored at -20 C under an atmosphere 
of dry argon and used within 3 months. A 4 mg/mL solution of ergosterol in CHCl3 was prepared 
monthly and stored at 4 C under an atmosphere of dry argon. Prior to preparing a lipid film, the 
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solutions were warmed to ambient temperature to prevent condensation from contaminating the 
solutions. A 13 x 100 mm test tube was charged with 640 L POPC and 230 L of the ergosterol 
solution. The solvent was removed with a gentle stream of nitrogen and the resulting lipid film 
was stored under high vacuum for a minimum of eight hours prior to use. The film was then 
hydrated with 1 mL of 150 mM KCl, 5 mM HEPES pH 7.4 (K buffer) and vortexed vigorously 
for approximately 3 minutes to form a suspension of multilamellar vesicles (MLVs). The 
resulting lipid suspension was pulled into a Hamilton (Reno, NV) 1 mL gastight syringe and the 
syringe was placed in an Avanti Polar Lipids Mini-Extruder. The lipid solution was then passed 
through a 0.20 μm Millipore (Billerica, MA) polycarbonate filter 21 times, the newly formed 
large unilamellar vesicle (LUV) suspension being collected in the syringe that did not contain the 
original suspension of MLVs to prevent the carryover of MLVs into the LUV solution. To obtain 
a sufficient quantity of LUVs, three independent 1 mL preparations were pooled together for the 
dialysis and subsequent potassium efflux experiments. The newly formed LUVs were dialyzed 
using Pierce (Rockford, IL) Slide-A-Lyzer MWCO 3,500 dialysis cassettes. The samples were 
dialyzed three times against 600 mL of Na buffer. The first two dialyses were two hours long, 
while the final dialysis was performed overnight.  
 
Determination of Phosphorus Content  
 Determination of total phosphorus was adapted from the report of Chen and coworkers.18 
The LUV solution was diluted tenfold with Na buffer and three 10 μL samples of the diluted 
LUV suspension were added to three separate 7 mL vials. Subsequently, the solvent was 
removed with a stream of N2. To each dried LUV film, and a fourth vial containing no lipids that 
was used as a blank, was added 450 μL of 8.9 M H2SO4. The four samples were incubated open 
to ambient atmosphere in a 225 °C aluminum heating block for 25 min and then removed to 
23 °C and cooled for 5 minutes. After cooling, 150 μL of 30% w/v aqueous hydrogen peroxide 
was added to each sample, and the vials were returned to the 225 °C heating block for 30 
minutes. The samples were then removed to 23 °C and cooled for 5 minutes before the addition 
of 3.9 mL water. Then 500 μL of 2.5% w/v ammonium molybdate was added to each vial and 
the resulting mixtures were then vortexed briefly and vigorously five times. Subsequently, 500 
μL of 10% w/v ascorbic acid was added to each vial and the resulting mixtures were then 
vortexed briefly and vigorously five times. The vials were enclosed with a PTFE lined cap and 
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then placed in a 100 °C aluminum heating block for 7 minutes. The samples were removed to 
23 °C and cooled for approximately 15 minutes prior to analysis by UV/Vis spectroscopy. Total 
phosphorus was determined by observing the absorbance at 820 nm and comparing this value to 
a standard curve obtained through this method and a standard phosphorus solution of known 
concentration. 
 
Determination of Ergosterol Content  
 Ergosterol content was determined spectrophotometrically. The LUV solution was 
diluted tenfold with Na buffer, and 50 μL of the dilute LUV suspension was added to 450 μL 
2:18:9 hexane:isopropanol:water (v/v/v). Three independent samples were prepared and then 
vortexed vigorously for approximately one minute. The solutions were then analyzed by UV/Vis 
spectroscopy and the concentration of ergosterol in solution was determined by the extinction 
coefficient of 10400 L mol-1 cm-1 at the UVmax of 282 nm and was compared to the concentration 
of phosphorus to determine the percent sterol content. The extinction coefficient was determined 
independently in the above ternary solvent system. LUVs prepared by this method contained 
between 7 and 14% ergosterol.  
 
Efflux from LUVs  
 The LUV solutions were adjusted to 1 mM in phosphorus using Na buffer. 3 mL of the 1 
mM LUV suspension was added to a 7 mL vial and the solution was gently stirred. The 
potassium ISE probe was inserted and data were collected for one minute prior to the addition of 
the compound. Then, 30 μL of a 0.1 mM, 1.0 mM, or 3.0 mM DMSO solution of the compound 
in question was added and data were collected for five minutes. Then to effect complete 
potassium release, 30 μL of a 10% v/v solution of triton X-100 was added and data were 
collected for an additional five minutes. The experiment was duplicated with similar results. 
 
Data Analysis 
The data from each run were analyzed in the same manner as the efflux data from S. cerevisiae. 
 
Antifungal Assays 
Growth Conditions for S. cerevisiae  
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 S. cerevisiae was maintained with yeast peptone dextrose (YPD) growth media consisting 
of 10 g/L yeast extract, 20 g/L peptone, 20 g/L dextrose, and 20 g/L agar for solid media. The 
media was sterilized by autoclaving at 250 °F for 30 min.  Dextrose was subsequently added as a 
sterile 40% w/v solution in water (dextrose solutions were filter sterilized). Solid media was 
prepared by pouring sterile media containing agar (20 g/L) onto Corning (Corning, NY) 100 x 20 
mm polystyrene plates. Liquid cultures were incubated at 30 °C on a rotary shaker and solid 
cultures were maintained at 30 °C in an incubator.  
 
Growth Conditions for C. albicans 
 C. albicans was cultured in a similar manner to S. cerevisiae except both liquid and solid 
cultures were incubated at 37 °C. 
 
Broth Microdilution Minimum Inhibitory Concentration (MIC) Assay  
 The protocol for the broth microdilution assay was adapted from the Clinical and 
Laboratory Standards Institute document M27-A2.22 50 mL of YPD media was inoculated and 
incubated overnight at either 30 °C (S. cerevisiae) or 37 °C (C. albicans) in a shaker incubator. 
The cell suspension was then diluted with YPD to an OD600 of 0.10 (~5 x 105 cfu/mL) as 
measured by a Shimadzu (Kyoto, Japan) PharmaSpec UV-1700 UV/Vis spectrophotometer. The 
solution was diluted 10-fold with YPD, and 195 μL aliquots of the dilute cell suspension were 
added to sterile Falcon (Franklin Lakes, NJ) Microtest 96 well plates in triplicate. Compounds 
were prepared either as 400 μM (AmB, MeAmB) or 2 mM (AmdeB, MeAmdeB) stock solutions 
in DMSO and serially diluted to the following concentrations with DMSO: 1600, 1200, 800, 400, 
320, 240, 200, 160, 120, 80, 40, 20, 10 and 5 μM. 5 μL aliquots of each solution were added to 
the 96 well plate in triplicate, with each column representing a different concentration of the test 
compound. The concentration of DMSO in each well was 2.5% and a control well to confirm 
viability using only 2.5% DMSO was also performed in triplicate. This 40-fold dilution gave the 
following final concentrations: 50, 40, 30, 20, 10, 8, 6, 4, 1, 0.5, 0.25 and 0.125 μM. The plates 
were covered and incubated at 30 °C (S. cerevisiae) or 37 °C (C. albicans) for 24 hours prior to 
analysis. The MIC was determined to be the concentration of compound that resulted in no 
visible growth of the yeast. The experiments were performed in duplicate and the reported MIC 
represents an average of two experiments.   
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 Ergosterol Content Determination 
Determination of Ergosterol Standard Curve 
 Ergosterol was prepared as a 0.1 mg/mL stock solution in CHCl3 and serially diluted to 
the following concentrations with CHCl3: 0.1, 0.08, 0.06, 0.03, 0.01 and 0.005 mg/mL. 10 μL 
aliquots of each solution were analyzed by analytical RP-HPLC (Waters Sunfire C18, ODB 5 
micron, 4.6 x 150 mm, 2 mL/min flow rate, MeCN:ethanol (200 proof) 80:20 isocratic over 10 
minutes) in triplicate. Ergosterol was detected at 280 nm. Ergosterol concentration was plotted 
against the integration of the ergosterol peak (tr = 5.1 min) the data was fitted with a linear least 
squares fit using Excel giving a standard curve. 
 
Determination of Stigmasterol Standard Curve 
 Stigmasterol was prepared as a 4 mg/mL stock solution in toluene and serially diluted to 
the following concentrations with CHCl3: 4, 2, 1, 0.5, 0.25 and 0.125 mg/mL. 10 μL aliquots of 
each solution were analyzed by analytical RP-HPLC (Waters Sunfire C18, ODB 5 micron, 4.6 x 
150 mm, 2 mL/min flow rate, MeCN:ethanol (200 proof) 80:20 isocratic over 10 minutes) in 
triplicate. Stigmasterol was detected at 210 nm. Stigmasterol concentration was plotted against 
the integration of the ergosterol peak (tr = 7.8 min) the data was fitted with a linear least squares 
fit using Excel giving a standard curve. 
 
Ergosterol Determination  
 Determination of total ergosterol was adapted from the report of Arnezeder and 
coworkers.23 The starting yeast cultures were prepared identical to the yeast used in the MIC 
assays. 50 mL of YPD media was inoculated and incubated overnight at either 30 °C (S. 
cerevisiae) or 37 °C (C. albicans) in a shaker incubator. 15 mL of the overnight culture was 
centrifuged (300 g, 23 oC) for 5 minutes. The supernatant was decanted and the cells were 
resuspended in 15 mL of Na buffer (150 mM NaCl, 5 mM HEPES, pH 7.4) and centrifuged (300 
g, 23 oC) for 5 minutes. This process was repeated two additional times and after the third wash, 
the cells were suspended in Na buffer to an OD600 of 1.3 as measured by a Shimadzu (Kyoto, 
Japan) PharmaSpec UV-1700 UV/Vis spectrophotometer. 40 mL of the OD600 = 1.3 yeast 
suspension were centrifuged (600 g, 23 oC) for 10 minutes. The supernatant was decanted and 
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the cells were resuspended in 50 mL sterile water and centrifuged (300 g, 23 oC) for 5 minutes. 
The supernatant was decanted and the resulting yeast pellet was suspended in 10 mL of 0.1 M 
aqueous HCl and transferred to 40 mL I-Chem vial. 0.9 mL of a 4 mg/mL standard solution of 
stigmasterol in toluene was added to the sample as an internal standard. The sample was 
incubated at 90 C for 20 minutes and transferred to a 300 mL round bottom flask equipped with 
a stir bar. The I-Chem vial was washed with 50 mL of ethanol and 50 mL of 50% aqueous KOH 
and the washings were added to the 300 mL round bottom flask. The 300 mL round bottom flask 
was stirred at reflux for 30 minutes and then allowed to cool to room temperature. The solution 
was extracted three times with 30 mL of petroleum ether.  The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. The resulting solid was dissolved in 3 mL of 3:1 
isopropanol:acetone and filtered through a 0.22 μm low protein binding Durapore (PVDF) 
membrane. 10 µL aliquots of the filtered solution were analyzed by analytical RP-HPLC (Waters 
Sunfire C18, ODB 5 micron, 4.6 x 150 mm, 2 mL/min flow rate, MeCN:ethanol (200 proof) 
80:20 isocratic over 10 minutes) in triplicate. Ergosterol was detected at 280 nm and stigmasterol 
was detected at 210 nm. Ergosterol and stigmasterol concentrations were determined by 
comparing the integration of the ergosterol peak to the standard curves described above. The 
stigmasterol internal standard was used to adjust the ergosterol concentration for any loss of 
material during the extraction process. The experiment described above was repeated in triplicate 
for both S. cerevisiae and C. albicans. 
 
Determination of Cell Concentration at OD600 = 1.3 
 10 μL of the OD600 = 1.3 yeast suspension described above was diluted tenfold with Na 
buffer. 10 μL of the diluted suspension was injected into the INCYTO Neubauer Improved 
Disposable Hemocytometer. Yeast cells were counted with an AMG EVOS fl Microscope. The 
cell concentration determination was repeated in triplicate. 
 
Determination of Cell Concentration in the MIC Assay 
 The overnight cultures S. cerevisiae and C. albicans in YPD that were used in the 
ergosterol determination above were diluted with YPD to an OD600 of 0.10. This was done at the 
same time as the sterol determination experiment above to ensure that the sterol content directly 
related to the cell count. 10 μL of the suspension was injected into the INCYTO Neubauer 
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Improved Disposable Hemocytometer. Yeast cells were counted with an AMG EVOS fl 
Microscope. In the MIC assay, an OD600 = 0.10 yeast suspension was diluted 10-fold prior to 
running the assay so all cell counts were divided by 10 to get the cell concentration in the MIC 
assay. The cell concentration determination was repeated in triplicate. 
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Chapter 4 
Electronic Tuning of Site-Selective Acylation on Amphotericin B 
 
 This chapter describes the investigation of site-selective acylation of hydroxyl groups on 
amphotericin B towards the goal of efficiently accessing derivatives. Several strategies were 
explored using both enzymatic and small molecule catalysts with a variety of acyl donors. 
Ultimately, the strategy of electronically tuning the acyl donor achieved high selectivity for the 
C2’ hydroxyl. Selective acylation studies were performed by Brandon Wilcock. Production of 
intermediates was done by Brandon Wilcock, Brice Uno, Gretchen Bromann, Matt Clark, and 
Tom Anderson. Portions of this chapter were adapted from Wilcock, B. C.; Uno, B. E.; Bromann, 
G. L.; Clark, M. J.; Anderson, T. M.: Burke, M. D. Nature Chemistry 2012, 4, 996-1003. 
 
4-1 Site-Selective Reactions for Efficient Access to Derivatives of Natural Products 
 Natural products and complex small molecules can have the capacity to perform a variety 
of useful functions, and many display important biological activity or medicinal properties. 
Structural derivatives of these compounds are useful tools for the study of their function and/or 
the development of therapeutics and pharmaceuticals. Often, access to derivatives of natural 
products and complex small molecules can be limited by time, labor, and cost intensive synthesis. 
Sometimes the natural product can be readily obtained from nature or through production by an 
organism. In these cases, site-selective functionalization is an attractive frontier synthesis 
strategy1-7 that can have exceptional step efficiency compared to total synthesis for the 
generation of derivatives. However, this strategy can be challenging in complex small molecules 
that contain the same functional group at multiple sites. Thus, generalized approaches for 
maximizing site selectivity or enabling the development of reagents with the ability to override 
substrate bias to achieve site-divergent functionalizations would be highly useful in small 
molecule science. 
 Polyols are a common type of natural product where site-selective functionalization is 
especially sought after. For instance, sugars are commonly present in biomolecules and natural 
products and selective protection and derivatization of these sugar units is a major area of 
scientific research.8 AmB is an excellent example of a polyol natural product that would greatly 
benefit from site-selective deoxygenation to efficiently access deoxyAmB derivatives to 
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elucidate the roles of the ten hydroxyl groups appended to this vital antifungal agent. Towards 
this end, site-selective acylation is a promising method for isolating single hydroxyl groups on 
polyol substrates.1,9-19 Application of this method leads to the following strategy for the creation 
of deoxyAmB derivatives. First, site-selective acylation of a hydroxyl group followed by 
orthogonal protection of the remaining hydroxyls and subsequent deacylation isolates the 
hydroxyl. Second, the exposed hydroxyl is deoxygenated generating the desired derivative after 
global deprotection (Figure 4.1). 
In order to achieve site-selective acylation on a polyol substrate under irreversible kinetic 
control, there must be a significant difference in the activation energies of the transition states for 
the rate-determining acyl transfer step. The transition state energies will be dependent upon the 
interactions between the acylating complex, generated from an acyl donor and a catalyst, and the 
polyol substrate. Thus, selective acylation can be achieved by finding a combination of acyl 
donor and catalyst that interacts with the polyol substrate in a fashion that results in a lower 
activation energy for the transition state of one of the hydroxyls in comparison to the other 
hydroxyls (Figure 4.2). 
 
Figure 4.1. Strategy for generating deoxygenated amphotericin B derivatives using site selective 
acylation. 
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Methods for achieving site-selective acylation have mostly focused on stereochemical 
modification of the acylation catalyst1,9-17 and the use of enzymes.18,19 The Miller group has had 
success employing this approach through the use of small peptide based catalyst libraries.1,6,9-12 
For example, erythromycin A is primarily acylated at the C4” position with N-methyl imidazole 
as the catalyst, but the C11 hydroxyl is the major site of acylation with a peptide catalyst (Figure 
4.3 A).1 In addition, enzymes have also been employed for selective acylation of natural products 
and sugars.18,19 For instance, Gu and coworkers were able to selectively acylate rapamycin using 
a lipase from Candida antartica B. (Figure 4.3 B).18 Other developments in this area include 
Figure 4.2. Basis for achieving site-selective acylation on a polyol substrate using a combination of acyl 
donor and catalyst to lower the activation energy of the transition state of one of the hydroxyls in 
comparison to the others.  
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chiral small molecule catalysts such as functionalized 4-N,N-dimethylaminopyridine (DMAP) 
derivatives.13,14 For instance, Kawabata and coworkers were able to selectively acylate the C4 
position of octyl β-D-glucopyranoside (Figure 4.3 C).14 Another common approach is increasing 
the steric bulk of the acyl donor to gain bias towards the less sterically hindered site.20,21 There 
are a couple of reports where the counterion of the acylating complex was able to significantly 
influence the site of acylation.17,22 
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Figure 4.3. Examples of site-selective acylation. A. Peptide catalyzed acylation of erythromycin A by 
Lewis and Miller. B. Enzymatic acylation of rapamycin by Gu and coworkers. C. Selective acylation with 
functionalized DMAP by Kawabata and Furata. 
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 4-2 Enzyme-Mediated Acylation of Amphotericin B Substrates 
In order to generate a workable substrate for acylation, the more reactive carboxylic acid, 
amine, and hemiketal functionality present on AmB needed to be protected. These protections 
were also necessary to impart a reasonable level of solubility to perform the reactions, 
purification, and analysis. Substrate 4.1 was therefore synthesized according to Scheme 4.1.23  
First, the amine was protected as the phenylacetyl amide. Next, the hemiketal was 
transformed to a methyl ketal, and then the carboxylic acid was methylated to generate a methyl 
ester. These series of protections gives a substrate containing nine free hydroxyls. Selectively 
acylating one out of nine hydroxyls is a significant synthetic challenge. I noticed, however, that 
this challenge could be significantly reduced if the desired target hydroxyl was not at C3, C5, C9, 
or C11. This is accomplished by installing 1,3 ketals or acetals on the C3/C5 and C9/C11 
hydroxyl groups to give substrates 4.2 and 4.3. This protection reduces the number of available 
Scheme 4.1. Synthesis of AmB substrates for selective acylation experiments.  
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hydroxyl sites by four and also provides some steric discrimination against the adjacent C8 
hydroxyl group thereby strategically targeting the hydroxyls at C35, C15, C4’, and C2’. 
I obtained a collection of 42 commercially available lipases and amidases and performed 
an initial screen of solvents utilizing the simple acyl donor vinyl acetate and 4.1. Most of the 
enzymes failed to give any reactivity with AmB; however, a few enzymes did show reactivity in 
polar solvents such as DMF. The greater solubility of 4.1 in these more polar solvents 
significantly aided the reaction. Halogenated and protic solvents were not tolerated, and mixtures 
of DMF and nonpolar solvents had no observable affect on selectivity and reduced the rate of the 
 
Figure 4.4. HPLC traces of lipase mediated acylation reactions on substrate 4.1.  
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reaction. While some lipases accepted 4.1 as a substrate, very poor selectivity was observed by 
high-performance liquid chromatography (HPLC) and mass spectrometry (MS) analysis when 
simple acyl donors such as vinyl acetate were used (Figure 4.4). I observed unresolved mixtures 
of mono and polyacylated compounds. I therefore investigated a variety of acyl donors including 
substituted aromatic vinyl esters as well as straight chain and branched aliphatic vinyl esters. The 
selectivity increased for some donors, but useful levels of selectivity were still unobtainable with 
substrate 4.1 (Figure 4.4). 
To address the selectivity issue, I screened the collection of lipases with substrate 4.2. 
The increased steric demand of 4.2 greatly reduced reactions rates or resulted in complete 
inactivity with the enzymes that were active with 4.1. However, I found that one lipase, AS1, 
was still significantly active with this substrate and benzoic vinyl ester. Aliphatic vinyl esters 
reacted at a much slower rate. The reaction with benzoic vinyl ester produced a major product 
and two minor products. After HPLC isolation of the products and 2-D nuclear magnetic 
resonance (NMR) analysis, I found the major product to be acylation at C2’ and acylation at C4’ 
and bisacylation (C2’ and C4’) were minor products (Figure 4.5). 
 
Figure 4.5. HPLC trace of the site-selective acylation of the C2’ hydroxyl by lipase AS1. 
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 I focused on substituted aromatic vinyl esters varying the position (para, ortho, and meta) 
as well as the steric bulk of the substitution (methyl, phenyl, tertbutyl). I found that in all cases 
acylation at the C2’ hydroxyl was the major product; however, the reaction rate and ratio to the 
minor products varied (Table 4.1).  
I found p-tertbutylbenzoic vinyl ester gave an optimum balance of selectivity, 88% of the 
products were monoacylated at C2’, and resolution for chromatographic purification (Scheme 
4.2). The reaction was stopped at 50% conversion to prevent excessive generation of the 
bisacylated product via acylation of the product 4.4 at the C4’ position. The starting material, 4.2, 
was recovered and resubmitted. 
Unfortunately, I found this reaction to be irreproducible between different batches of 
lipase powder. While the selectivity remained high when the lipase was active, many batches 
failed to react with 4.2 even though the lipase was active with smaller substrates. I suspected 
 
Table 4.1. Site-selective acylation of substrate 4.2 by lipase AS1 and some selected vinyl esters. 
Scheme 4.2. Site-selective acylation of the C2’ hydroxyl by lipase AS1. 
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small differences in the hydration state from the lyophilization process affected the flexibility of 
the lipase in the dry organic solvent used to run the reactions.24 Increasing the temperature of the 
reaction to 70 oC increased reactivity in some batches. Relyophilization also activated some 
batches; however, I was unable to develop a reliable lyophilization process that would produce 
lipase powder with consistent activity. Thus, emphasis was placed on small-molecule catalyzed 
acylation to obtain a consistent and reliable acylation reaction. 
 
4-3 DMAP Catalyzed Acylation on Amphotericin B Substrates 
A common method to try to achieve site-selective acylation is modifying the catalyst’s 
steric and stereochemical properties. Instead of employing this approach, I focused on changing 
the properties of the acyl donor; I could access a large variety of anhydrides and acid chlorides 
either commercially or synthetically significantly faster than modification of catalysts such as 
DMAP. I briefly investigated DMAP-catalyzed acylation on substrate 4.1. I observed many 
Figure 4.6. HPLC traces of acylation reactions with substrate 4.1 and DMAP.  
57
mono and poly acylated products when these reactions were analyzed by HPLC and MS. 
Employing more sterically demanding acyl donors failed to produce a viable selective reaction 
(Figure 4.6). Therefore, I focused on site-selective acylation of substrate 4.3. Specifically, I 
targeted the C2’ hydroxyl on the mycosamine. The C2’ hydroxyl is a high priority target since 
the mycosamine is essential for sterol binding and the antifungal activity of AmB (see Chapter 1), 
and it has been implicated in a possible hydrogen bond with the sterol (see Chapter 3).  
I started with standard acylating conditions commonly found in the literature utilizing 
acetic anhydride and DMAP. HPLC and MS analysis of the reaction mixture showed a mixture 
of mono, bis, and tris acylated products (Figure 4.7, entry 1).23 Characterization of preparative 
HPLC isolated peaks showed that monoacylated C2’ product was only 2% of the total products. I 
systematically investigated increasing the steric bulk of the acyl donor by employing the 
anhydride series: propionic, isobutyric, and pivalic. I found the extremely sterically demanding 
pivalic anhydride to be unreactive under the reaction conditions. Propionic and isobutyric 
anhydride had little effect on the percentage of the products that was monoacylated at C2’; 
 
 
Figure 4.7. HPLC traces and C2’ selectivity for acylation reactions. Increasing the steric bulk of the acyl 
donor had little effect on the C2’ selectivity. C2’ selectivity is defined as the percent of the products 
monoacylated at C2’. Figure adapted from ref. 23. 
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however, there was an impact on the ratio of C4’ to C15 acylation. With acetic anhydride, C4’ 
acylation is the major product, but with isobutyric anhydride, monoacylated C15 was produced 
in a nearly equal amount to C4’ (Figure 4.7, entry 2). 
There have been a few reports of site selectivity being influenced by switching the 
counterion of the acylating complex.17,22 I explored this possibility by replacing the anhydride 
acyl donors, that produce a carboxylate counterion in the DMAP complex, with acyl chlorides 
which produce a chloride counterion. A significant increase in the amount of monoacylated C2’ 
product was observed when the counterion was chloride. Acylation with acetyl chloride resulted 
in 26% selectivity compared to the 2% generated by utilizing the corresponding acetic anhydride 
(Figure 4.8, entry 1). I evaluated the same steric series used in the anhydride acyl donor studies 
and found that the C2’ selectivity increased as the steric bulk of the acyl donor increased. While 
there was a significant increase in C2’ selectivity, isobutyric chloride was only able to produce 
moderate selectivity of 48% (Figure 4.8, entry 2). This became problematic upon scale-up due to 
purification limitations separating out the other isomers found in significant quantities. The C2’ 
selectivity needed to be increased to achieve a useful preparative process that could produce a 
large enough quantity of acylated C2’ intermediate to make derivatives for biophysical 
evaluation. 
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Inspiration was found in a strategy employed by Jacobsen and coworkers to improve the 
enantioselectivities of manganese-based epoxidations. Jacobsen found that utilizing more 
electron-rich salen ligands translated into higher enantioselectivities.25 This phenomenon was 
linked to the Hammond postulate.26 The electron-rich ligands engender milder manganese-based 
oxidants that react via a more product-like transition state. This results in higher 
enantioselectivity by presumably amplifying the enantiotopic face-discriminating interactions 
between the prochiral olefin and the chiral oxidant. These underlying principles should translate 
to site selectivity in acylation reactions. According to the Hammond postulate,27 the transition 
state of the acylation reaction will become more product-like as the reaction becomes less 
exothermic. In a more product-like transition state, the site-discriminating interactions between 
the acylating complex and substrate will be magnified leading to increased site selectivity. Thus, 
using electron-rich acyl donors would create a milder reagent resulting in a less exothermic 
reaction with, presumably, greater site selectivity (Figure 4.9). 
Figure 4.8. HPLC traces and C2’ selectivity for acylation reactions. Acyl chloride donors produce higher 
C2’ selectivity than anhydride donors (Figure 4.7) via a counterion effect. Selectivity is also enhanced by 
increased steric bulk with the acyl chloride donors. C2’ selectivity is the percent of the products 
monoacylated at C2’. Figure adapted from ref. 23. 
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To test this electronic tuning strategy hypothesis, I decided to use para-substituted 
benzoyl chlorides. Electron-poor donors gave low to moderate selectivities for C2’ while high 
selectivities were observed with electron-rich donors. For example, employing p-nitrobenzoyl 
chloride resulted in 39% C2’ selectivity in comparison to 72% with p-N,N-
dimethylaminobenzoyl chloride (Figure 4.10).23  
Figure 4.9. The Hammond postulate applied to site-selective acylation. More electron-rich acyl donors 
are predicted to react via a later, more product-like transition state magnifying the site-discriminating 
interactions between the substrate and the acylating reagent. The magnified interactions increase the 
difference between activation energies generating greater selectivity. Figure adapted from ref. 23. 
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 I performed a Hammett study28 with five para-substituted benzoyl chlorides to see if the 
observed selectivities were consistent with the Hammond postulate.23 I found as the electron-
withdrawing capacity of the substituent increased, the site-selectivity decreased (Figure 4.11 A). 
A linear correlation was obtained when the log of the ratio of site isomers C2’/other was plotted 
against the σpara values of the substituent of the corresponding acyl donors (Figure 4.11 B). If the 
observed selectivity trend was indeed the result of the Hammond postulate, there would also be a 
linear correlation with the rate of the reaction. I therefore determined the initial rates of these 
reactions and found that as the electron-donating capacity of the substituent increased, the rate 
decreased (Figure 4.11 A). A plot of the log of the initial rates against the σpara values revealed a 
linear correlation (Figure 4.11 C). Combining these two experiments in a plot of selectivity 
against the initial rate also generated a linear correlation (Figure 4.11 D). This supports the 
Hammond postulate as the basis of the electronic tuning phenomenon. 
Figure 4.10. HPLC traces and C2’ selectivity for acylation reactions. More electron-rich acyl donors 
produce higher C2’ selectivity. C2’ selectivity is defined as the percent of the products monoacylated at 
C2’. Figure adapted from ref. 23. 
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Having achieved success with electronic tuning and the acylation of the C2’ site, I 
wondered whether electronic tuning could also promote site divergency. When the counterion of 
the acylating complex is a carboxylate ion, the major products are C4’and C15 (Figure 4.7, entry 
2). If symmetrical substituted-benzoic anhydrides were used, both the acyl donor and the 
counterion of the acylating complex would be electronically tuned. This could create competing 
or synergistic effects making predictions about the outcome difficult. I tested the electron-poor p-
nitrobenzoic anhydride and the electron-rich p-tertbutylbenzoic anhydride and found that site 
divergency could be achieved.23 In the case of the electron-poor p-nitrobenzoic anhydride, 
Figure 4.11. Hammett analysis of site-selective acylation reactions. A. Table of the σpara value, C2’ 
selectivity, and initial rate for the acyl donors. B. A Hammett plot of the log of the ratio of the C2’ 
product to all other products vs. σpara. C. Hammett plot of the log of the initial rate vs. σpara. D. Plot of the 
C2’ selectivity vs. the initial rate. Figure adapted from ref. 23. 
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acylation at C15 was favored over C4’ with a selectivity ratio of 3:1 C15:C4’ (Figure 4.12, entry 
1). In contrast, the electron-rich p-tertbutylbenzoic anhydride favored acylation at C4’ over C15 
with a selectivity ratio of 2:1 C4’:C15 (Figure 4.12, entry 2). 
 I also investigated how the position of the substituent on the aromatic ring influenced the 
selectivity of the selective acylation. Specifically, I employed para, ortho, and meta phenyl-
substituted benzoyl chlorides and found that the reaction remained C2’ selective. However, I did 
observe a significant decrease in selectivity as the phenyl group approached the carbonyl, C2’ 
selectivity: para>meta>ortho (Figure 4.13). 
Figure 4.12. HPLC traces and product ratios for acylation reactions.  Electronic tuning of symmetrical 
anhydrides results in site-divergent acylations. Figure adapted from ref. 23. 
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  Additional screening of electron-rich acyl chloride donors lead to the selection of p-
tertbutylbenzoyl chloride as the acyl donor for the large scale production of an acylated C2’ 
intermediate. The p-tertbutylbenzoyl chloride acyl donor provided an optimized combination of 
C2’ site selectivity (66%), conversion (68%), and ease of purification by standard silica gel 
chromatography resulting in 45% isolated yield (Scheme 4.3).23 It is noteworthy to mention that 
this result is comparable to the lipase mediated acylation (Scheme 4.2) showing that small 
molecules can sometimes have the potential to perform higher order functions displayed by 
proteins. 
Figure 4.13. HPLC traces and C2’ selectivity for acylation reactions. The C2’ selectivity as a function of 
the position of the sterically bulky phenyl substituent on the benzoyl chloride. 
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Scheme 4.3. DMAP-mediated site-selective acylation of the C2’ hydroxyl group. Figure adapted from 
ref. 23. 
 
4-4 Summary 
Electronic tuning of the acyl donor has proven to be an effective means for increasing the 
selectivity of acylation reactions on amphotericin. It is important to note that the reactions 
performed utilized only achiral reagents. This suggests that physical or mechanistic features 
other than stereochemistry can impact site-divergent functionalization in ways that exceed 
current understanding and utilization. In addition, since electronic tuning operates by magnifying 
the interactions between reagent and substrate, electronic tuning can be utilized to enhance 
selectivity for a particular reagent-substrate pair even if the site-discriminating interactions are 
unknown. Importantly, electronic tuning is a complementary method to the stereochemical 
approach. There are many chiral small-molecule catalysts employed for acyl transfer. Electronic 
tuning can be combined with stereochemical approaches with catalysts and donors. Thus 
electronic tuning has the potential to have a significant impact on site-selective acylations and 
the development of site-divergent acylations of complex small molecules and natural products.  
 
4-5 Experimental 
The experimental section is adapted from ref. 23. 
 
General Methods 
Materials 
Amphotericin B was a gift from the Bristol-Myers Squibb Company. All other commercially 
available reagents were obtained from Sigma-Aldrich, TCI America, Fischer Scientific, Combi-
Blocks Inc., and Oakwood Products. Chemicals were used without further purification unless 
otherwise specified. Camphorsulfonic acid was purified before use by recrystallization with ethyl 
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acetate. Triethyl amine, diisopropylethyl amine, pyridine, and 2,6-lutidine were freshly distilled 
over calcium hydride under nitrogen atmosphere. All solvents were obtained from a solvent 
purification system utilizing packed columns as described by Pangborn and coworkers.29 
 
Reactions 
All reactions were performed under argon atmosphere in low light conditions with flame 
dried glassware unless otherwise indicated. All compounds were stored in the dark under argon 
atmosphere. Thin layer chromatography or reverse phase HPLC was used to monitor reaction 
progress. Thin layer chromatography was performed on silica gel 60 F254 plates from Merck with 
the indicated solvent. Visualization of the compounds was accomplished with a UV lamp (λ254) 
and ceric ammonium molybdate (CAM) stain. Analytical HPLC was done on an Agilent 1100 
Series HPLC with a C18 5 μm, 4.6 x 150 mm, Symmetry® column from Waters Corp at a flow 
rate of 1 mL/min with the indicated solvent and gradient. The detection wavelength was set to 
383 nm.  
 
Purification and Analysis 
 Merck silica gel 60 230-400 mesh and SiliCycle reverse phase C18 (17%) 40-63 μm 60 
angstrom silica gel was used for flash chromatography with the indicated solvent. HPLC reverse 
phase purification was done on a waters C18 5 μm, 30 x 150 mm Sunfire column at a flow rate 
of 25 mL/min with the indicated solvent and gradient. The detection wavelength was set to 383 
nm. 1H NMR spectra were taken at 23 °C on a Varian Unity Inova Narrow Bore spectrometer at 
a 1H frequency of 500 MHz with a Varian 5 mm 1H{13C/15N}pulsed-field gradient Z probe. 
Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane and 
referenced internally to the residual protium in the NMR solvent (CHD2OD, δ = 3.30, center 
line; CD3C(O)CHD2, δ = 2.04, center line; CD3S(O)CHD2, δ = 2.50, center line; CCl3H, δ = 7.26, 
center line). Data is reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, m = multiplet, b = broad, app = apparent), coupling constant (J) in Hertz (Hz) and 
integration. 13C spectra were obtained at 23 °C with a Varian Unity Inova spectrometer at a 13C 
frequency of 125 MHz with a 5 mm Nalorac gradient {13C/15N}1H quad probe. Chemical shifts 
(δ) are reported downfield of tetramethylsilane and are referenced to the carbon resonances in the 
NMR solvent (CD3OD, δ = 49.0, center line; CD3C(O)CD3, δ = 29.8, center line; CD3S(O)CD3, 
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δ = 39.5, center line; CDCl3, δ = 77.0, center line). ESI high resolution mass spectra (HRMS), 
ESI low resolution mass spectra (LRMS) and matrix-assisted laser desorption/ionization 
(MALDI) spectra were obtained at the University of Illinois mass spectrometry facility. 
 
Synthesis of AmB derivatives 
 
 
N-phenylacetyl, methyl ketal, methyl ester 4.1 
Phenyl acetic acid (662 mg, 1.62 mmol, 3 eq) was dissolved in THF (30 mL). Trimethyl 
acetyl chloride (400 μL, 3.25 mmol, 2 eq) was added followed by triethyl amine (900 μL, 6.46 
mmol, 4 eq). The reaction was allowed to stir for 8 hours at room temperature. The reaction was 
placed in an ice bath, and DMSO (30 mL) was added over 2 minutes as it cooled. Once the 
reaction reached 0 °C, AmB (1.5 g, 1.62 mmol, 1 eq) was added. The yellow-tan suspension 
slowly became soluble over 90 minutes stirring at 0 °C. The reaction was poured slowly into 
rapidly stirring diethyl ether (1.8 L) at 0 °C. After 15 minutes of stirring, the resulting yellow 
precipitate was vacuum filtered with a Buchner funnel equipped with Whatman 50 filter paper 
and washed 3 times with diethyl ether (200 mL). The yellow powder was dried under vacuum for 
8 hours. 
The powder was then suspended in THF:MeOH 1:1 (60 mL) and cooled to 0 °C. 
Camphorsulfonic acid (94 mg, 405 μmol, 0.25 eq) was added, and the yellow-tan suspension 
slowly became soluble over 45 minutes of stirring at 0 °C. The reaction was quenched by triethyl 
amine (57 μL, 405 μmol, 0.25 eq) at 0 °C. The reaction solution was concentrated by 
approximately 2/5 by rotary evaporation and poured into diethyl ether:hexane 1:1 (1.2 L) while 
stirring rapidly. After stirring 15 minutes, the yellow precipitate was collected in a Buchner 
funnel equipped with Whatman 50 filter paper by vacuum filtration. The precipitate was washed 
3 times with diethyl ether (200 mL). The powder was dried under vacuum for 8 hours. 
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The powder was suspended in THF (60 mL) and cooled to 0 °C. Freshly distilled 
diazomethane (8.10 mmol, 5 eq) was added dropwise to the suspension over 20 minutes at 0 °C. 
The reaction was allowed to stir for 30 additional minutes at 0 °C. After quenching with acetic 
acid (8.10 mmol, 5 eq) at 0 °C, the solution was then concentrated under reduced pressure and 
purified by flash chromatography (SiO2; DCM:MeOH 9:1) to give 4.1 as a yellow solid (971 mg, 
907 μmol, 56 %). 
 
 
 
TLC (DCM:MeOH 9:1) 
Rf = 0.2, stained by CAM 
 
HPLC 
tR = 18.1 min; flow rate = 1mL/min, gradient = 5 → 95 % MeCN in water over 30 min. 
  
1HNMR (500 MHz, pyridine d-5:CD3OD 10:1) 
δ 9.01 (d, J = 8.5 Hz, 1H), 7.53 (m, 2H), 7.25 (m, 3H), 6.58-6.32 (m, 12H), 6.23 (m, 1H), 
5.69 (m, 2H), 4.95 (m, 1H), 4.90 (s, 1H), 4.83 (m, 1H), 4.67 (m, 2H), 4.46 (m, 2H), 4.38 (app 
d, J = 3 Hz, 1H), 4.17 (m, 1H), 4.01 (m, 2H), 3.86 (m, 2H), 3.74 (m, 5H), 3.56 (m, 1H), 3.26 
(s, 3H), 2.94 (m, 1H), 2.84 (t, J = 10.5 Hz, 1H), 2.69 (m, 2H), 2.54 (m, 1H), 2.31-1.81 (m, 13 
H), 1.72 (m, 1H), 1.57 (d, J = 6 Hz, 3H), 1.44 (d, J = 6 Hz, 3H), 1.32 (d, J = 6.5 Hz, 3H), 
1.24 (d, J = 7 Hz, 3H) 
 
13CNMR (125 MHz, pyridine d-5:CD3OD 10:1) 
δ 174.4, 174.2, 172.3, 171.9, 137.9, 137.5, 134.8, 134.7, 134.3, 134.2, 133.8, 133.7, 133.6, 
133.5, 133.1, 132.9, 132.4, 130.5, 130.1, 129.1, 127.3, 102.3, 99.4, 78.2, 75.8, 75.7, 75.4, 
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75.0, 72.1, 71.4, 71.0, 68.5, 67.8, 67.7, 67.1, 57.8, 56.8, 52.2, 45.2, 44.1, 43.8, 43.6, 42.1, 
36.6, 31.0, 19.2, 18.9, 18.0, 12.8. 
 
HRMS (ESI) 
Calculated for C57H83NO18 (M + Na)+:   1092.5508 
Found:     1092.5515 
 
 
 
 
Cyclopentylidene ketals 4.2 and SI1 
 To a suspension of 4.1 (1.54 g, 1.44 mmol, 1 eq) in methanol (24 mL) was added 1,1-
dimethoxy cyclopentane (7.2 mL) followed by camphorsulfonic acid (84 mg, 360 μmol, 0.25 eq). 
The solution was stirred for 1 hour. The reaction was quenched with saturated sodium 
bicarbonate (900 mL) and extracted 3 times with ethyl acetate (900 mL). The organic layers were 
washed with water (900 mL) and then with saturated sodium chloride (900 mL). The organic 
layers were combined and dried over magnesium sulfate and concentrated in vacuo after 
filtration. The reaction resulted in 4.2 and SI1 as a 1:1 mixture. Flash chromatography (SiO2; 
DCM:MeOH 97:3→19:1) purification yielded a yellow-orange solid (1.04 g, 864 mmol, 60 %). 
The two isomers were separated by preparative HPLC (C18 SiO2, water:MeCN, 95:5 → 5:95 
over 30 minutes) for acylation experiments 
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TLC (DCM:MeOH 9:1) 
 Rf = 0.38, stained by CAM 
 
HPLC 
 4.2 tR = 27.1 min; SI1 tR = 27.9 min; flow rate = 1mL/min, gradient = 30 → 95% MeCN 
 in water over 30 min. 
  
1HNMR (500 MHz, acetone d-6) 
δ 7.35 (m, 4H), 7.29 (m, 4H), 7.24-7.18 (m, 4H), 6.40-6.18 (m, 24H), 5.90 (m, 2H), 5.56 
(m, 2H), 5.24 (m, 1H), 5.18 (m, 1H), 4.65 (app t, J = 5 Hz, 2H), 4.58 (bs, 2H), 4.20 (m, 
2H), 4.17-4.06 (m, 4H), 4.01 (m, 2H), 3.94 (m, 3H), 3.87 (m, 3H), 3.65-3.60 (m, 11H), 
3.49 (m, 2H), 3.37-3.27 (m, 4H), 3.09 (s, 3H), 3.03 (s, 3H), 2.42-2.11 (m, 12H), 2.00-
1.74 (m, 22H) 1.71-1.51 (m, 27H), 1.43-1.25 (m, 9H), 1.20 (m, 6H), 1.18 (m, 6H), 1.10 
(d, J = 7 Hz, 6H), 1.01 (d, J = 7 Hz, 6H) 
 
13CNMR (125 MHz, acetone d-6) 
δ 173.6, 173.5, 172.7, 169.8, 169.7, 137.4, 137.0, 136.7 136.1, 134.4, 134.3, 134.1, 133.9, 
133.7, 133.6, 133.4, 133.3, 133.1, 132.8, 132.5, 132.3, 132.1, 130.0, 129.5, 129.1, 129.0, 
127.2, 118.6, 110.6, 101.8, 101.0, 98.2, 81.6, 79.9, 78.0, 75.6, 74.6, 74.4, 73.4, 72.9, 70.8, 
70.5, 70.4, 69.9, 69.8, 67.7, 67.4, 67.0, 66.9, 66.2, 57.5, 57.4, 56.4, 54.8, 51.9, 48.5, 48.4, 
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43.4, 43.3, 42.8, 42.0, 41.7, 41.5, 40.9, 40.8, 40.7, 38.1, 38.0, 37.8, 37.7, 37.2, 36.9, 33.9, 
33.8, 33.3, 31.7, 31.6, 24.9, 24.8, 24.0, 23.9, 18.7, 18.6, 18.0, 17.6, 17.4, 11.8, 11.7. 
 
HRMS (ESI) 
Calculated for C67H95NO18 (M + Na)+:   1224.6447 
Found:      1224.6410 
 
 
 
4-t-Butyl benzoate ester 6 
 To a non-flame dried flask was added 4.2 (600 mg, 499 μmol, 1 eq) and lipase AS1 
powder (150 mg, 0.25 mass eq). DMF (25 mL), exposed to the air for 5 minutes to provide 
residual water, was added followed by 4-t-butyl benzoate vinyl ester (306 μL, 1.50 mmol, 3 eq). 
The reaction was placed under argon and heated to 70 °C over 15 minutes. The reaction was 
stirred at 70 °C for 24 hours where the yellow solution turned dark brown. The reaction was 
vacuum filtered by Buchner funnel equipped with Whatman 50 filter paper. The enzyme powder 
was washed with ethylacetate:acetone 1:2 (100 mL). The combined filtrates were concentrated in 
vacuo followed by purification by flash chromatography (SiO2; DCM:MeOH 49:1→19:1) to 
remove the vinyl ester and other acylated compounds. The resulting mixture of starting material 
and product, a yellow-orange powder, was subjected to reverse phase chromatography (C18; 
water:acetonitrile 3:2 → 1:19) resulting in 4.4 and SI2 (270 mg, 225 μmol, 45 %). 
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TLC (DCM:MeOH 9:1) 
 Rf = 0.33, stained by CAM 
 
HPLC 
 4.4 tR = 34.3 min; SI2 tR = 35.0 min; flow rate = 1ml/min, gradient = 5 → 50 % MeCN        
 in water over 10 min followed by 50 → 95 % MeCN in water over 25 min. 
 
1HNMR (500 MHz, acetone d-6) 
δ 8.00 (m, 4H), 7.60 (m, 4H), 7.41 (m, 2H), 7.23-7.11 (m, 10H), 6.36-6.11 (m, 22H), 6.05 
(m, 2H), 5.93-5.76 (m, 2H), 5.68 (m, 2H), 3.56 (m, 2H), 5.14 (m, 1H), 5.06 (m, 1H), 4.87 
(s, 2H), 4.65 (bs, 2H), 4.25-4.01 (m, 8H), 4.00-3.76 (m, 8H), 3.68-3.37 (m, 14H), 3.25 (m, 
2H), 2.86 (s, 3H), 2.81 (s, 3H), 2.41-2.32 (m, 5H), 2.27-2.19 (m, 2H), 2.17-2.11 (m, 5H), 
1.99-1.49 (m, 40H), 1.44-1.21 (m, 42H), 1.18 (m, 6H), 1.10 (m, 6H) 1.00 (m, 6H) 
 
13CNMR (125 MHz, acetone d-6) 
δ 173.2, 171.6, 169.8, 169.7, 165.8, 157.1, 137.5, 136.8, 134.2, 134.1, 134.0, 133.8, 133.8, 
133.7, 133.6, 133.5, 133.1, 132.8, 132.5, 132.4, 131.8, 131.6, 131.3, 131.1, 130.5, 129.9, 
128.8, 127.8, 127.7, 127.0, 126.0, 118.5, 110.6, 110.5, 101.5, 100.7, 96.5, 81.6, 79.9, 77.7, 
75.5, 74.5, 743.4, 73.3, 73.2, 72.1, 70.8, 69.8, 67.5, 67.3, 66.9, 66.5, 66.3, 57.9, 57.8, 54.6, 
51.8, 48.3, 48.2, 43.6, 43.2, 43.1, 42.8, 42.6, 41.9, 41.6, 41.5, 40.8, 40.7, 38.0, 37.9, 37.8, 
37.6, 36.9, 36.8, 35.5, 33.9, 33.8, 33.2, 31.6, 31.3, 31.2, 28.5, 28.2, 24.9, 24.8, 24.7, 23.9, 
22.9, 22.8, 18.3, 18.0, 17.8, 11.8, 11.7  
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HRMS (ESI) 
Calculated for C78H107NO19 (M + Na)+:   1384.7335 
Found:      1384.7300 
 
 
 
 
 
p-methoxybenzylidene acetal 4.3 
To a suspension of 4.1 (1.50 g, 1.40 mmol, 1 eq) in MeOH:THF 2:1 (17 mL) was added 
anisaldehyde dimethyl acetal (2 mL) followed by camphorsulfonic acid (81 mg, 0.35 mmol, 0.25 
eq). The solution was stirred for 20 min. The reaction was quenched with triethylamine dropwise 
until the dark tan solution underwent a color change to light tan. The reaction was poured into 
saturated sodium bicarbonate and extracted 3 times with ethyl acetate. The organic layers were 
washed with water followed by a wash with saturated sodium chloride. The organic layers were 
combined and dried over sodium sulfate, filtered, and concentrated under reduced pressure. Flash 
chromatography (SiO2; EtOAc:Hexane:MeOH 77:20:3) purification yielded 4.3 as a yellow-
orange solid (1.10 g, 0.84 mmol, 60 %). 
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TLC (EtOAc:Hexane:MeOH 77:20:3) 
Rf = 0.25, stained by CAM 
 
HPLC 
tR = 15.4 min; flow rate = 1mL/min, gradient = 5% MeCN in water for 2 min then 5 → 54% 
MeCN in water over 3 min then 54 → 95% MeCN in water over 13 min. 
  
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.42 (m, 2H), 7.35 (m, 4H), 7.29 (m, 2H), 7.21 (m, 2H), 6.86 (m, 4H), 6.43-6.20 (m, 12H), 
5.88 (m, 1H), 5.58 (m, 1H), 5.51 (s, 1H), 5.46 (s, 1H), 5.26 (m, 1H), 4.64 (m, 1H), 4.58 (app 
s, 1H), 4.20-4.10 (m, 2H), 4.02 (m, 1H), 3.95-3.86 (m, 3H), 3.78 (m, 6H), 3.75 (m, 2H), 3.66 
(s, 3H), 3.63 (m, 1H), 3.45 (m, 2H), 3.36 (m, 1H), 3.30 (m, 2H), 3.05 (s, 3H), 2.57 (m, 1H), 
2.40 (m, 1H), 2.31-2.24 (m, 3H), 1.96 (m, 1H), 1.89-1.45 (m, 9H), 1.37 (m, 2H), 1.22 (m, 
4H), 1.19 (d, J = 6 Hz, 3H), 1.17 (m, 1H), 1.11 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 7.5 Hz, 3H) 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 173.6, 172.7, 169.7, 160.6, 160.5, 137.5, 136.9, 136.2, 134.1, 134.0, 133.9, 133.7, 133.6, 
133.5, 132.9, 132.6, 132.5, 132.2, 129.9, 129.8, 128.9, 128.3, 128.2, 127.2, 120.9, 117.6, 
113.8, 101.0, 100.7, 100.6, 98.1, 81.1, 77.9, 76.2, 74.7, 74.4, 73.2, 73.1, 72.9, 72.8, 70.7, 70.5, 
67.2, 66.9, 57.3, 56.4, 55.4, 51.8, 48.6, 43.4, 43.3, 42.6, 41.8, 41.5, 37.8, 36.8, 33.8, 33.2, 
28.7, 18.7, 18.0, 17.4, 11.8. 
 
HRMS (ESI) 
Calculated for C73H95NO20 (M + Na)+:   1328.6369 
Found:     1328.6388 
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C2’-p-tertbutylbenzoic ester 4.6e 
THF (160 mL) was added to a flask containing 4.3 (6.16 g, 4.72 mmol, 1 eq). DMAP (922 
mg) was added to a separate flask and dissolved in THF (100 mL). 4-tertbutylbenzoyl chloride 
(1.29 mL, 6.60 mmol, 1.4 eq) was added dropwise to the DMAP solution creating a white 
suspension. DIPEA (1.31 mL, 7.54 mmol, 1.6 eq) was added to the solution of 4.3. A portion of 
the white suspension was then transferred dropwise to the solution of 4.3 and DIPEA (over 
approximately 1 hr) until the majority of 4.3 had been consumed as evidenced by TLC. The 
reaction was pored into EtOAc and washed with water followed by saturated sodium bicarbonate. 
Two more washes with water were performed followed by a wash with saturated sodium 
chloride. The organic layer was then dried over sodium sulfate and filtered. The solvent was 
removed under reduced pressure and column chromatography (SiO2; EtOAc:Hexane:MeOH 
60:37:3) purification yielded 4.6e as a yellow-orange solid (3.11 g, 2.12 mmol, 45 %) as well as 
unreacted 4.3. 
  
 
 
TLC (EtOAc:Hexane:MeOH 60:37:3) 
Rf = 0.22, stained by CAM 
 
HPLC 
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tR = 19.4 min; flow rate = 1mL/min, gradient = 5% MeCN in water for 2 min then 5 → 54% 
MeCN in water over 3 min then 54 → 95% MeCN in water over 13 min. 
  
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.99 (d, J = 8.5 Hz, 2H), 7.59 (d, J = 8.5 Hz, 2H), 7.39 (m, 3H), 7.34 (m, 2H), 7.23 (m, 2H), 
7.17 (m, 2H), 7.12 (m, 1H), 6.85 (m, 4H), 6.39-6.13 (m, 10H), 6.07 (m, 1H), 5.92 (m, 1H), 
5.76 (m, 1H), 5.68 (m, 1H), 5.56 (m, 1H), 5.48 (s, 1H), 5.43 (s, 1H), 5.14 (m, 1H), 4.88 (app 
s, 1H), 4.65 (m, 1H), 4.24 (m, 1H), 4.15 (m, 2H), 3.97 (m, 1H), 3.91-3.82 (m, 2H), 3.77 (s, 
6H), 3.68 (m, 5H), 3.51 (m, 2H), 3.47 (m, 1H), 3.40 (m, 2H), 2.84 (s, 3H), 2.54 (m, 1H), 2.41 
(m, 1H), 2.27 (m, 1H), 2.13 (m, 1H), 1.95 (m, 1H), 1.86 (m, 1H), 1.78-1.42 (m, 10H), 1.40-
1.31 (m, 13H), 1.30-1.19 (m, 2H), 1.18 (d, J = 6.5 Hz, 3H), 1.11 (d, J = 6.5 Hz, 3H), 1.01 (d, 
J = 7.0 Hz, 3H) 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 172.7, 171.1, 169.2, 165.3, 160.1, 160.0, 156.7, 137.1, 136.4, 136.3, 133.6, 133.5, 133.4, 
133.3, 133.2, 133.1, 132.5, 132.1, 132.0, 131.2, 131.1, 130.0, 129.4, 128.3, 127.7, 126.5, 
125.6, 120.7, 113.3, 100.5, 96.1, 80.5, 77.2, 75.7, 74.1, 73.1, 72.6, 72.4, 71.7, 70.6, 66.4, 66.2, 
57.2, 54.8, 54.1, 51.3, 47.9, 43.0, 42.7, 41.9, 40.9, 37.2, 36.3, 35.1, 33.4, 32.6, 30.8, 17.8, 
17.4, 11.3. 
 
HRMS (ESI) 
Calculated for C84H107NO21 (M + Na)+:   1488.7233 
Found:     1488.7212 
 
DMAP-mediated Acylation Studies 
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 General Procedure for Acylation Reactions 
4.3 (5 mg, 3.83 μmol, 1 eq) was added to a vial and dissolved in THF (450 μL). DIPEA (0.8 
μL, 4.60 μmol, 1.2 eq) and DMAP (0.515 mg, 4.21 μmol, 1.1 eq) were added to the solution. The 
acyl chloride or anhydride (1 eq) in THF (50 μL) was added to the reaction. The reaction was 
allowed to stir at room temperature for 15 hrs. The reaction was filtered and analyzed by 
reversed-phase HPLC (C18, MeCN/H2O). 
 
HPLC gradient 
flow rate = 1mL/min, gradient = 5% MeCN in water for 2 min then 5 → 54% MeCN in 
water over 3 min then 54 → 95% MeCN in water over 13 min., hold 95% MeCN in water for 7 
min. followed by gradient to 5% water, 75% MeCN, 20% THF over 3 min. then increasing to 
5% water, 95% THF in one minute and holding 95% THF in water for 3 min. 
 
Determination of Selectivity 
The conversion and ratio of products were determined by integration of the HPLC trace to 
get the area under the peaks. The identification of major peaks is covered in section IV. 
Conversion was calculated as the sum of the product peak areas over the total area. % C2’ 
selectivity was calculated as the area for the C2’ mono-acylated product over the total product 
area. The ratio of site isomers used in the Hammett analysis is the C2’ mono-acylated product 
over the sum of the other product areas. 
 
Major Product Characterization  
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C2’-p-nitrobenzoic ester 4.6c 
 
HPLC 
tR = 17.0 min 
  
1HNMR (500 MHz, CD3C(O)CD3) 
δ 8.40 (d, J = 8.5 Hz, 2H), 8.29 (d, J = 8.5 Hz, 2H), 7.44 (m, 1H), 7.39 (d, J = 9.0 Hz, 2H) 
7.34 (d, J = 8.5 Hz, 2H), 7.21 (m, 2H), 7.16 (m, 2H), 7.11 (m, 1H), 6.85 (m, 4H), 6.39-6.12 
(m, 10H), 6.01 (m, 2H), 5.79 (m, 1H), 5.65 (m, 1H), 5.61 (m, 1H), 5.48 (s, 1H), 5.43 (s, 1H), 
5.18 (m, 1H), 4.92 (app s, 1H), 4.65 (m, 1H), 4.27 (m, 1H), 4.14 (m, 2H), 3.98 (m, 1H), 3.88 
(m, 2H), 3.77 (m, 6H), 3.69 (m, 5H), 3.65-3.38 (m, 5H), 2.86 (s, 3H), 2.55 (m, 1H), 2.40 (m, 
1H), 2.28 (m, 2H), 2.17 (m, 1H), 1.94 (m, 1H), 1.85 (m, 1H), 1.80-1.40 (m, 10H), 1.34 (d, J 
= 5.0 Hz, 3H), 1.27 (m, 2H), 1.18 (d, J = 6.5 Hz, 3H), 1.11 (d, J = 6.5 Hz, 3H), 1.00 (d, J = 
7.0 Hz, 3H) 
 
HRMS (ESI) 
Calculated for C80H98N2O23 (M + Na)+:     1477.6458 
Found:       1477.6404 
 
 
 
 
C2’-p-dimethylaminobenzoic ester 4.6d 
 
HPLC 
tR = 17.3 min 
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1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.89 (d, J = 9.0 Hz, 2H), 7.36 (m, 6H), 7.18 (m, 4H), 6.82 (m, 6H), 6.40-6.04 (m, 11H), 
5.82 (m, 1H), 5.73 (m, 2H), 5.52 (m, 1H), 5.48 (s, 1H), 5.43 (s, 1H), 5.11 (m, 1H), 4.84 (app 
s, 1H), 4.65 (m, 1H), 4.16 (m, 3H), 3.87 (m, 3H), 3.77 (s, 6H), 3.68 (m, 5H), 3.51-3.38 (m, 
5H), 3.09 (s, 6H), 2.85 (s, 3H), 2.53 (m, 1H), 2.40 (m, 1H), 2.27 (m, 2H), 2.14 (m, 1H), 1.93 
(m, 1H), 1.87 (m, 1H), 1.78-1.40 (m, 10H), 1.32 (d, J = 5.5 Hz, 3H), 1.26 (m, 2H), 1.18 (d, J 
= 6.5 Hz, 3H), 1.10 (d, J = 6.5 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H) 
 
HRMS (ESI) 
Calculated for C82H104N2O21 (M + Na)+:    1475.7029 
Found:        1475.6982 
 
 
 
C2’-isobutyric ester 4.6b 
 
HPLC 
tR = 17.3 min 
  
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.45 (app d, J = 8.5 Hz, 2H), 7.37 (app d, J = 8.5 Hz, 2H), 7.29 (m, 3H), 7.24 (m, 1H), 7.09 
(app d, J = 7.5 Hz, 1H), 6.90 (app d, J = 7.5 Hz, 4H), 6.46-6.21 (m, 12H), 5.90 (m, 1H), 5.66 
(m, 1H), 5.54 (s, 1H), 5.48 (s, 1H), 5.36 (m, 1H), 5.24 (m, 1H), 4.77 (app s, 1H), 4.65 (m, 
1H), 4.19 (m, 2H), 4.11 (m, 1H), 3.96 (m, 3H), 3.81 (s, 6H), 3.74 (m, 5H), 3.52-3.36 (m, 5H), 
3.05 (s, 3H), 2.60 (m, 2H), 2.43 (m, 1H), 2.32 (m, 2H), 2.23 (m, 1H), 1.99-1.86 (m, 2H), 
1.79-1.66 (m, 4H), 1.61-1.48 (m, 4H), 1.36 (m, 2H), 1.30 (d, J = 6.0 Hz, 3H), 1.21 (m, 5H), 
1.18-1.13 (m, 9H), 1.04 (d, J = 7.0 Hz, 3H) 
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 HRMS (ESI) 
Calculated for C77H101NO21 (M + Na)+:     1398.6764 
Found:       1398.6758 
 
 
 
C4’-isobutyric ester 4.7b 
 
HPLC 
tR = 18.7 min 
  
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.41 (app d, J = 8.5 Hz, 2H), 7.35-7.26 (m, 5H), 7.21 (m, 1H), 6.87 (m, 5H), 6.42-6.18 (m, 
12H), 5.88 (m, 1H), 5.57 (m, 1H), 5.51 (s, 1H), 5.45 (s, 1H), 5.25 (m, 1H), 4.79 (t, J=10.0, 
1H), 4.65 (m, 2H), 4.21-4.10 (m, 3H), 4.01-3.91 (m, 3H), 3.77 (s, 6H), 3.71 (m, 3H), 3.65 (s, 
3H), 3.54 (m, 2H), 3.44-3.35 (m, 2H), 3.05 (s, 3H), 2.56 (m, 1H), 2.41-2.22 (m, 5H), 1.99-
1.45 (m, 10H), 1.31 (m, 2H), 1.18 (m,4H), 1.10 (m, 7H), 1.02-0.98 (m, 9H) 
 
HRMS (ESI) 
Calculated for C77H101NO21 (M + Na)+:   1398.6764 
Found:     1398.6740 
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C15-isobutyric ester 4.8b 
 
HPLC 
tR = 19.1 min 
  
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.38-7.18 (m, 9H), 6.85 (m, 4H), 6.43-6.18 (m, 12H), 5.88 (m, 1H), 5.58 (m, 1H), 5.51 (s, 
1H), 5.45 (s, 1H), 5.29 (m, 2H), 4.67 (m, 1H), 4.59 (app s, 1H), 4.18 (m, 1H), 4.04 (m, 1H), 
3.93 (m, 2H), 3.86 (m, 1H), 3.77 (m, 6H), 3.71 (m, 2H), 3.64 (m, 4H), 3.50 (m, 1H), 3.45 (m, 
1H), 3.34 (m, 1H), 3.29 (m, 2H), 3.09 (s, 3H), 2.61-2.28 (m, 5H), 2.00 (m, 1H), 1.93-1.25 (m, 
12H), 1.19 (m, 6H), 1.12 (m,5H), 1.05 (m, 6H), 1.01 (d, J = 7.0 Hz, 3H) 
 
HRMS (ESI) 
Calculated for C77H101NO21 (M + Na)+:   1398.6764 
Found:     1398.6755 
 
 
 
C4’-p-tertbutylbenzoic ester 4.7c 
  
HPLC 
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tR = 21.4 min 
  
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.84 (d, J = 8.0 Hz, 2H), 7.49 (d, J = 8.5 Hz, 2H), 7.42 (d, J = 8.5 Hz, 2H), 7.35 (d, J = 8.5 
Hz, 2H), 7.04 (m, 6H), 6.86 (m, 4H), 6.43-6.19 (m, 12H), 5.90 (m, 1H), 5.57 (m, 1H), 5.52 (s, 
1H), 5.46 (s, 1H), 5.26 (m, 1H), 5.06 (t, J = 10 Hz, 1H) 4.76 (app s, 1H), 4.69 (m, 1H), 4.40 
(m, 1H), 4.16 (m, 2H), 4.04 (m, 1H), 3.95 (m, 2H), 3.85 (m, 1H), 3.79 (s, 6H), 3.72 (m, 3H), 
3.69 (s, 3H), 3.52-3.34 (m, 3H), 3.08 (s, 3H), 2.59 (m, 1H), 2.40 (m, 1H), 2.29 (m, 3H), 2.00 
(m, 1H), 1.92-1.83 (m, 3H), 1.77-1.62 (m, 3H), 1.58-1.46 (m, 4H), 1.36 (s, 9H), 1.33(m, 1H), 
1.20-1.16 (m, 8H), 1.11 (d, J = 6.0 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H) 
 
HRMS (ESI) 
Calculated for C84H107NO21 (M + Na)+:   1488.7233 
Found:     1488.7230 
 
 
 
C15-p-tertbutylbenzoic ester 4.8c 
  
HPLC 
tR = 21.7 min 
  
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.91 (d, J = 8.5 Hz, 2H), 7.56 (d, J = 8.5 Hz, 2H), 7.32 (m, 8H), 7.19 (m, 2H), 6.86 (d, J = 
8.5 Hz, 2H), 6.65 (d, J = 8.5 Hz, 2H), 6.41-6.18 (m, 12H), 5.91 (m, 1H), 5.55 (m, 2H), 5.50 
(s, 1H), 5.45 (s, 1H), 5.27 (m, 1H), 4.69 (m, 1H), 4.62 (app s, 1H), 4.17 (m, 1H), 4.12 (m, 
1H), 3.95 (m, 2H), 3.87 (m, 1H), 3.80 (m, 1H), 3.78 (s, 3H), 3.71 (m, 2H), 3.64 (m, 6H), 
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3.52-3.43 (m, 2H), 3.35-3.28 (m, 3H), 3.14 (s, 3H), 2.71 (m, 2H), 2.58 (m, 1H), 2.39 (m, 1H), 
2.30 (m, 1H), 1.97-1.84 (m, 3H), 1.74-1.38 (m, 9H), 1.34 (s, 9H), 1.22-1.16 (m, 8H), 1.10 (d, 
J = 6.5 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H) 
 
HRMS (ESI) 
Calculated for C84H107NO21 (M + Na)+:   1488.7233 
Found:     1488.7214 
 
 
Determination of the Site of Acylation 
The major products of the acylation reaction were purified by HPLC. Mass spectrometry was 
utilized to determine if the products were mono- or bis-acylated. 1H and gradient COSY NMR 
analysis was performed on the starting material (4.3) and the products, and the proton signals 
were assigned. Upon acylation, the signal of the proton on the carbon bearing the acylated 
hydroxyl was found to move significantly downfield (approximately 1.5 ppm). 
 
Determination of the Initial Rates 
Acylation reactions were set up according to the general procedure described in section III. 
Aliquots were taken and quenched in a solution of piperidine in DMF over the course of the 
reaction. The aliquots were filtered and analyzed by HPLC as described in the general procedure. 
The conversion was determined and plotted against time. The initial rate was then determined 
from the slope of a linear line fitted to the earliest time points.  
 
Control Experiments 
 
Determining the reversibility of acylation. 
Acylation reactions were setup according to the general procedure described in section III. 
The mono-acylated products of the acylation reactions were purified by preparative HPLC. Each 
product was then resubmitted to acylating conditions: 
Acylated product (1 eq) was added to a vial and dissolved in THF (450 μL). DIPEA (0.8 μL, 
4.60 μmol, 1.2 eq) and DMAP (0.515 mg, 4.21 μmol, 1.1 eq) were added to the solution. The 
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solution was allowed to stir at room temperature for 15 hrs. The reaction was then analyzed by 
reversed-phase HPLC (C18, MeCN/H2O). 
In all cases there was no acyl transfer to other hydroxyl groups confirming the reaction is 
irreversible. 
 
Assessing the Extent of Background Acylation.   
Acylation reactions for the para-substituted benzoyl chloride reagents were setup according 
to the general procedure described in section III excluding the DMAP reagent: 
4.3 (5 mg, 3.83 μmol, 1 eq) was added to a vial and dissolved in THF (450 μL). DIPEA (0.8 
μL, 4.60 μmol, 1.2 eq) was added to the solution. The acyl chloride (1 eq) in THF (50 μL) was 
added to the reaction. The reaction was allowed to stir at room temperature for 15 hrs. The 
reaction was quenched in a solution of piperidine in DMF and filtered. The reactions were then 
analyzed by reversed-phase HPLC (C18, MeCN/H2O). 
In all cases the conversion was less than 10%. This shows the reaction rate for the DMAP 
catalyzed acylation is sufficiently faster than the uncatalyzed reaction. The small differences in 
the rates of background acylation do not account for the 33% difference in C2’ selectivity 
between the nitro and dimethylamino substituted donors. To further suppress any background 
acylation, all acylation reactions were run with 1.1 eq of DMAP. The equilibrium between free 
DMAP/acyl chloride and Acyl-DMAP ion/chloride ion is known to favor the ion complex,2 and 
salt formation is immediately observed after addition of the acyl chloride to DMAP. 
Using a full equivalent of DMAP ensures that the vast majority of the acyl chloride is 
associated with DMAP during the reaction thus further reducing the rate of background acylation 
to a negligible amount. 
(2) Lutz, V.; Glatthaar, J.; Wurtele, C.; Seratin, M.; Hausmann, H. Chem. Eur. J. 2009, 15, 8548-8557. 
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Chapter 5 
Semisynthesis of C2’-deoxyAmphotericin B 
 
This chapter details the development of a degradative synthetic route to C2’-deoxyAmB 
including the isolation and deoxygenation of the C2’ hydroxyl and protecting group scheme 
optimization. Additionally, the development of a hybrid based synthetic route is described. The 
deoxygenation and deprotection studies were performed by Brandon Wilcock. Large scale 
production of intermediates was done by Brandon Wilcock, Brice Uno, Gretchen Bromann, Matt 
Clark, and Tom Anderson. Brice Uno prepared the C2’-epi-AmB, AmB-ergosterol conjugate, 
amine protecting groups, and the sugar donor for the hybrid route. Portions of this chapter were 
adapted from Wilcock, B. C.; Uno, B. E.; Bromann, G. L.; Clark, M. J.; Anderson, T. M.: Burke, 
M. D. Nature Chemistry 2012, 4, 996-1003. 
 
5-1 Importance and Predicted Roles of the C2’ Hydroxyl 
Having established mycosamine-mediated ergosterol binding as the primary mechanism 
of the antifungal activity of AmB (Chapter 3), further research involving the mycosamine 
subunit is needed to acquire a better understanding of the mechanism on a molecular level. The 
mycosamine has three protic functional groups that could play essential roles in the sterol 
binding process. This is critical as the high toxicity of AmB is proposed to arise from the 
difference in the main sterol in the membrane, cholesterol in human cells versus ergosterol in 
yeast. Figuring out important interactions in the binding of ergosterol and cholesterol by AmB 
could lead to the design of AmB derivatives with improved therapeutic indexes. Thus, AmB 
derivatives that lack one of the protic groups on the mycosamine, the C2’ hydroxyl, the C3’ 
amine, or the C4’ hydroxyl group are useful probes. 
Recent reports in the literature have made the C2’ hydroxyl an interesting target for 
deoxygenation. Computer molecular modeling studies have predicted a hydrogen bonding 
interaction between the C2’ hydroxyl and the 3-β hydroxyl of the sterol.1-3 In addition to our 
studies showing the mycosamine is essential for sterol binding, Murata reports restricting the 
mycosamine orientation with a tether from the C3’ amine to the C41 acid has an effect on the 
selectivity for sterol-containing membranes over sterol-free membranes.4  
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Carreira has reported the synthesis of an AmB derivative with the C2’ hydroxyl in the 
equatorial position instead of the native axial position and the C41 acid protected as the methyl 
ester (C2’-epi-AmE).5 No loss of activity was observed with this derivative compared to the 
corresponding amphotericin B methyl ester; however, methylation of the C2’-epi hydroxyl 
drastically reduced the antifungal activity. No sterol binding studies were performed, and the 
conclusions that can be drawn from these derivatives are limited. The effects of having the acid 
protected as the methyl ester are unknown. If there is a hydrogen bond between the C2’ hydroxyl 
and the 3-β hydroxyl of the sterol, the C2’-epi hydroxyl might still be able to interact via rotation 
of the mycosamine unit. While methylation reduces the ability to hydrogen bond, it does not 
completely eliminate the ability. Also, methylation introduces steric effects that could be behind 
the loss of activity. Thus, sterol binding experiments with a C2’-deoxyAmB derivative are 
needed to further elucidate the role of the C2’ hydroxyl. 
To efficiently generate the C2’-deoxyAmB derivative, a top-down degradative synthesis 
would be more efficient, step and material wise, than a hybrid or total synthesis route. Utilizing 
the selective acylation chemistry I have developed (see Chapter 4), the C2’ hydroxyl group can 
be successfully isolated. Deoxygenation of the C2’ hydroxyl on the sensitive AmB framework is 
a very challenging problem. Many of the reagents usually employed in common deoxygenation 
reactions are incompatible with one or more of the functional groups on AmB. For instance, the 
polyene motif is highly sensitive to radical conditions in Barton-McCombie6 type 
deoxygenations. AmB also contains functional groups sensitive to some metal reagents and 
strong hydride reducing agents. 
 
5-2 Isolation and Deoxygenation of the C2’ Hydroxyl 
In order to deoxygenate the C2’ hydroxyl, it must be isolated and unprotected. To 
accomplish this, I selectively installed a temporary acyl protecting group on the C2’ hydroxyl 
generating intermediate 4.4 (see Chapter 4). Orthogonal protection of the remaining hydroxyl 
groups was readily achieved with tertbutyldimethylsilyl (TBS) groups (Scheme 5.1). Next, the 
C2’ ester was cleaved with either sodium methoxide or potassium cyanide in methanol. The C2’ 
hydroxyl was now isolated and exposed for further functionalization such as deoxygenation. 
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 I first attempted activation of the hydroxyl through mesylation followed by direct 
displacement by hydride sources, but I found this sequence unproductive due difficulty installing 
the mesyl group as well as inactivity with mild hydride reagents and elimination side products in 
the subsequent reduction reaction. Stronger aluminum based hydride reagents caused 
decomposition. I therefore decided to explore if there was a window of reactivity with radical 
based conditions where deoxygenation at C2’ might be faster than destruction of the polyene unit 
of AmB. Model studies showed that a significant amount of AmB could survive under some mild 
radical deoxygenation conditions utilized on a model sugar substrate. However, attempts to 
install thiocarbonyl functionality on the C2’ hydroxyl to attempt a Barton-McCombie 
deoxygenation6 failed. The major product isolated was a bicycle generated by attack from the 
C3’ nitrogen to form thiocarbamate (Scheme 5.2). 
To avoid this problem, I pursued the possibility of transforming the C2’ hydroxyl group 
into an iodide which could undergo radical deoxygenation or reductive displacement with a 
hydride. I found the standard conditions of iodine and triphenylphosphine unreactive at low 
temperatures. Upon heating these conditions resulted in decomposition. However, I found a 
report of an alcohol to iodide transformation for sugars using the alternative reagent 
triiodoimidazole.7 I was able to employ this alternative method on AmB successfully generating 
the C2’ iodide in 80% yield (Scheme 5.3). With this new substrate 5.2, I attempted radical based 
Scheme 5.1. Isolation of the C2’ hydroxyl group. 
 
Scheme 5.2. Initial attempts at deoxygenation of the C2’ hydroxyl group. 
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conditions using tributyltin hydride and various initiators such as azobisisobutyronitrile (AIBN) 
and peroxides. I found the rate of deiodination to be uncompetitive with the decomposition of the 
polyene on AmB. 
 In light of the radical sensitivity of AmB, I turned to hydride reagents to reduce the 
iodide at C2’. The AmB framework is sensitive to strong hydride reagents such as lithium 
aluminum hydride commonly used to reduce halides. AmB, however, is compatible with milder 
hydrides such as sodium borohydride. The reduction of secondary iodides with sodium 
borohydride can be problematic and usually requires harsh conditions; high temperature and 
polar aprotic solvents are often needed to affect this transformation.8 If the iodide is sterically 
hindered, the problem of elimination instead of substitution can be significant. I observed no 
reductive deiodination with sodium borohydride in DMPU up to 65 °C, and at higher 
temperatures significant decomposition and elimination occurred (Scheme 5.4). 
I explored the possibility of activating the iodide through the addition of a halophilic salt 
in a similar fashion to the way that a Lewis acid may activate a carbonyl towards nucleophilic 
attack by associating with the oxygen.  I tried several silver and mercury salts and discovered 
that addition of silver acetate facilitated the deiodination to give a useful 61% yield (Scheme 5.4). 
Having developed a working deoxygenation, synthetic efforts were directed at the protecting 
group strategy in order to generate the final C2’-deoxyAmB compound. 
Scheme 5.3. Formation of the C2’ iodide and radical deoxygenation attempt. 
Scheme 5.4. Silver assisted reductive deiodination at C2’. 
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 5-3 Deprotection and the Protecting Group Strategy 
 Having achieved site-selective acylation and deoxygenation of the C2’ hydroxyl group, 
all that remained was global deprotection to generate C2’-deoxyAmB. Model studies I conducted 
on AmB and previous synthetic work on AmB from Nicolaou,9,10 and Murata,11 suggested that 
the robust protecting groups (phenylacetyl amide for the amine, methyl ester for the acid, TBS 
ethers and cyclopentylidene ketals for the hydroxyls, and methyl ketal for the hemiketal) could 
be deprotected in synthetically useful yields. Thus, I used these groups in the development of the 
selective acylation and deoxygenation chemistry previously described in Chapters 4 and 5. 
Unfortunately, I found that the protected C2’-deoxyAmB substrate is far more sensitive to the 
deprotection conditions than protected AmB; this was especially true for the acidic reaction steps. 
As a result, I encountered large amount of side products and decomposition resulting in low 
yields (Scheme 5.5).  
 I began by investigating several sources of fluoride for the silyl ether removal. Conditions 
utilizing Tetra-n-butylammonium fluoride (TBAF) resulted in incomplete conversions and 
tris(dimethylamino)sulfonium difluorotrimethylsilicate (TASF) caused complete decomposition. 
HF-pyridine was more successful at removing the TBS groups; however, the TBS group at C35 
required heating to remove resulting in less than 10% yield. 
 I also observed greater sensitivity to acidic conditions used to remove the 
cyclopentylidene ketals on the polyol motif of the protected C2’-deoxyAmB substrate. I screened 
various types of acids, temperatures, concentrations, and solvents to find the mildest conditions 
that would remove the cyclopentylidene ketal groups. I determined that the most compatible acid 
was camphorsulfonic acid (CSA). Dry HCl, generated from the addition of acetyl chloride to 
MeOH, was also tolerated, but other inorganic acids performed poorly. Significant side products 
and decomposition limited the yield to less than 10% in all cases. Thus, I decided to replace the 
Scheme 5.5. Attempted deprotections on C2’-deoxyAmB intermediate 5.3. 
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TBS and cyclopentylidene groups with more labile groups. I determined that triethylsilyl (TES) 
groups were not stable enough to survive the deacylation step in the route. However, 
diethylisopropylsilyl (DEIPS) groups were stable enough if sodium methoxide was replaced with 
potassium cyanide in the C2’ ester deacylation step. The cyclopentylidene ketals were replaced 
with p-methoxybenzylidene acetals. I found that the p-methoxybenzylidene acetals were able to 
be deprotected with less acid and in less time resulting in decreased decomposition and higher 
yields. 
 With these optimized protecting groups in place, I was able to follow the synthetic route 
in Scheme 5.6 utilizing the selective acylation and reductive deiodination chemistry previously 
described to arrive at the C2’-deoxyAmB intermediate 5.6.12 Optimization of the protecting 
groups and attempts at producing C2’-deoxyAmB were greatly facilitated by the production of 
intermediates on large scale in collaboration with my colleagues Gretchen Broman, Brice Uno, 
Matt Clark, and Thomas Anderson.  
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 The yields for the C2’ ester cleavage and C2’ iodide reduction steps were lower, but the 
rest of the chemistry translated well from the previous protecting group scheme route with 
comparable yields. The versatility of intermediate 5.5, containing the free hydroxyl at C2’, was 
further investigated by colleague Brice Uno. He found that a variety of other C2’ derivatives 
could be generated besides the methylene.12 For instance, the C2’ hydroxyl was able to be 
inverted via standard Mitsunobu13 conditions. Also, a molecule of ergosterol was successfully 
Scheme 5.6. Synthesis of C2’-deoxyAmB intermediate 5.6 utilizing optimized protecting groups. Scheme 
adapted from ref. 12. 
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tethered to the C2’ hydroxyl,12 making an AmB small-molecule conjugate reminiscent of the 
proposed AmB-ergosterol complex (Scheme 5.7).14 
 With C2’-deoxyAmB intermediate 5.6 in hand, I began global deprotection to see if the 
more liable DEIPS and p-methoxybenzylidene acetals utilized in this route could be removed in 
synthetically useful yields (Scheme 5.8). After extensive optimization, I was able to improve the 
yield for the HF-pyridine deprotection of the silyl groups to 38%. As with the cyclopentylidene 
ketals, I screened a variety of acids, solvent mixtures, and concentrations to find conditions to 
remove the p-methoxybenzylidene acetals and/or methyl ketal. While the p-methoxybenzylidene 
acetals were removed under more mild conditions with methanol and CSA, I found the methyl 
Scheme 5.7. Functionalization of the free C2’ hydroxyl group. Scheme adapted from ref. 12. 
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ketal deprotection to the hemiketal required forcing conditions with aqueous acid that resulted in 
less than 10% yield as before.  
 I therefore hypothesized if cleaving the methyl ester first might impact the reactivity of 
the C13 methyl ketal center. This became problematic due to some base sensitivity of the p-
methoxybenzylidene acetal at C3/C5. Strong bases will cause elimination at C2-C3 expelling the 
p-methoxybenzylidene acetal. However, I was able to find a window of reactivity with potassium 
hydroxide that gave a moderate yield for the methyl ester deprotection. Fortunately, the methyl 
ketal exchange to the hemi ketal was more facile with the free acid at C41. After optimization, I 
was able to remove both p-methoxybenzylidene acetals and the methyl ketal in one step thereby 
removing an acidic deprotection step. I determined it was critical to keep the amount of water co-
solvent to a minimum, and acetonitrile was essential to accelerate the reaction rate. While the 
yields for the removal of the silyl ethers, methyl ketal, and p-methoxybenzylidene acetals were 
improved, they were still low. The final step of removing the phenylacetyl group on the C3’ 
amine with PGA proceeded with very low conversion and produced an unresolved and 
inseparable mixture of products. MS analysis of the mixture showed a mass peak consistent with 
 
Scheme 5.8. Global deprotection of C2’-deoxyAmB intermediate 5.6. 
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the desired C2-deoxyAmB product; however, even after attempts at optimization, I was unable to 
isolate any product from the decomposition mixture (Scheme 5.8). 
 An alternative C3’ amine protecting group was needed if the route was going to be 
synthetically viable. The selective acylation chemistry readily transferred to AmB substrates 
containing alternative amine protecting groups such as Fluorenylmethyloxycarbonyl (Fmoc), 
allyloxycarbonyl (alloc), and various other amides and carbamates. Fmoc was unstable to the 
deacylation conditions, and the C2’ acyl group transferred to the neighboring C3’ amine. Alloc 
was a suitable substitution except for the reductive deiodination step which failed. The reduction 
of the iodide was highly dependent upon the identity of the protecting group on the C3’ amine. 
Alloc was exchanged for various other protecting groups, many synthesized by colleague Brice 
Uno, shown in Scheme 5.9. 
  I found that they caused the elimination side product to become dominate or inactivity 
under the reaction conditions. Interestingly enough, elimination was also a common product 
when alloc was removed from the C2’-iodoAmB derivative with palladium or nickel conditions. 
Attempts at selectively reducing the elimination products with borohydride based hydride 
reagents were unsuccessful. In light of the low yielding deprotection steps and the need to 
develop a new method for deoxygenation of the C2’ hydroxyl, an alternative route to C2’-
deoxyAmB was considered. 
 
5-4 The Hybrid Route to C2’-deoxyAmB 
 A hybrid approach to C2’-deoxyAmB and other AmB derivatives that are functional-
group deficient on the mycosamine can be summed up as follows: global protection and removal 
of the mycosamine, synthesis of the functional-group deficient sugar, and glycosidation followed 
by deprotection (Figure 5.1). 
Scheme 5.9. Examples of alternative C3’ amine protecting groups investigated for the reductive 
deiodination at C2’. Reactions with these groups resulted in large amounts of the competitive elimination 
reaction product, decomposition, or inactivity.  
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 Even though the synthetic route requires the synthesis of the sugar donor, it does a have 
the significant advantage of less demanding chemistry being performed on the AmB framework. 
This is extremely beneficial for the protecting group strategy and overall yield. I was able to 
eliminate the acetals on the polyol by globally silylating with the easily removed TES groups. In 
addition, the methyl ester was replaced with a triisopropylsilyl (TIPS) ester which is deprotected 
in good yield in the same step as the TES ethers thus saving a step. 
The protected amphoteronolide substrate was generated according to Scheme 5.10. Fmoc 
protection of the amine followed by hemiketal protection as the methyl ketal and global 
silylation of the hydroxyl groups lead to intermediate 5.10.15 Protection of the acid as the TIPS 
ester, oxidative cleavage of the mycosamine, and reduction of the conjugated ketone completes 
the synthesis of the protected amphoteronolide acceptor. 
 
Figure 5.1. Hybrid strategy to access mycosamine derivatives of amphotericin B. 
 
Scheme 5.10. Synthesis of protected amphoteronolide B. 
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 Synthesis of the C2’-deoxysugar donor was done by colleague Brice Uno. Sugar 
intermediate 5.13 (Scheme 5.11) is known in the literature reached in 6 steps from 2-furyl methyl 
ketone.5,16,17 The hydroxyl of 5.13 was protected as the TBS ether,19 and then the epoxide was 
opened with lithium triethylborohydride. The resulting hydroxyl was mesylated to create 
intermediate 5.14. Subsequent nucleophilic displacement of the mesylated hydroxyl by sodium 
azide completes the installation of all the functional groups. Removal of the para-methoxybenzyl 
(PMB) group on the hydroxyl at C1’ generates the deoxysugar donor 5.15 (Scheme 5.10). With 
the acosamine sugar donor and protected amphoteronolide acceptor synthesized, focus turned to 
achieving glycosidation. 
  The mycosamine on AmB is attached via a β-1,2-cis linkage. This can be a difficult 
linkage to form as the alpha linkage is favored with direct attack onto the oxocarbenium sugar 
intermediate due to the anomeric effect and steric hindrance from the axial substituent at the C2 
position (Figure 5.2A). Normally glycosidations to obtain these types of linkages are done with 
participating groups located at the C2 position of the sugar donor. For instance, Nicolaou18 and 
Carreira19 have attached sugars to protected amphoteronolide B substrates using anchimeric 
assistance from the neighboring equatorial group at the C2 position followed by inversion at the 
C2 position (Figure 5.2B). In the case of a C2-deoxysugar this method is not an option to achieve 
β selective glycosidation. 
 
Scheme 5.11. Synthesis of the C2-deoxysugar donor. Synthesis of the intermediate 5.13 has been 
previously reported in refs. 5, 16, and 17. 
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  Methods to achieve β-selective direct glycosidation of C2-deoxysugars are rare.20-23 
Selectivity is often highly influenced by the stereochemistry and protecting groups of the 
substituents on the sugar. There are many options for anomeric activating groups and reagents 
for direct glycosidation. I investigated preparing the trichloroacetimidate donor and found this 
donor to be unstable, and it gave poor results under a variety of glycosidation conditions. I found 
that conditions involving oxidative reagents such as I2 or N-iodosuccinimide also did poorly 
causing decomposition as well as reoxidation of the C19 hydroxyl on AmB. Thus, I turned to 
using a one pot procedure where a more stable donor could be generated and attached under 
buffered conditions with diphenyl sulfoxide, triflic anhydride, and 2,6-lutidine.24,25 Both the 
donor and the protected amphoteronolide substrate were stable and glycosidation proceeded in an 
efficient fashion under these conditions (Scheme 5.12). Due to the lack of an participating group 
at the C2 position of the sugar, the ratio of α to β linkage varied in the range of 2:1 to 1:1 α:β.  
The isomers were inseparable at this stage, but after removal of the silyl groups with HF-
pyridine, the two isomers could be purified by preparative HPLC. I found the C2’-deoxyAmB 
intermediates containing the azide protecting group were sensitive to base if water was present. 
In addition, having a free amine at C3’ greatly accelerated the rate of methyl ketal conversion to 
the hemiketal under aqueous CSA conditions in comparison to the C3’ azide intermediate. This 
A 
B 
 
Figure 5.2. Glycosidation linkage of AmB. A. Factors disfavoring the formation of the β-1,2-cis linkage 
on AmB via direct glycosidation. B. Anchimeric assistance traditionally used to achieve β selective 
glycosidation of the protected AmB aglycone. 
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acceleration provided a significant increase in the yield and cleanliness of the reaction; thus, it 
was critical that the azide was deprotected before the methyl ketal. Mild deprotection of the azide 
was achieved with trimethylphosphine and water in good yield, and subsequent methyl ketal 
exchange to the hemi ketal generated C2’-deoxyAmB (Scheme 5.12). 
 
5-5 Summary 
With the completion of the hybrid route, C2’-deoxyAmB can now be generated in large 
quantities for biophysical experiments. Evaluation of this derivative with the same biophysical 
studies that have proven successful with the derivatives discussed in Chapters 2 and 3 will 
further elucidate the sterol-AmB interaction by determining the role the C2’ hydroxyl plays. The 
hybrid strategy can also be adapted to create a synthetic route to C4’-deoxyAmB and C3’-
deaminoAmB. Since the primary antifungal mechanism of AmB is ergosterol binding (Chapter 
3), and it is likely that cholesterol binding underlies human toxicity, a better understanding of the 
sterol binding events enabled by all of these functional-group deficient derivatives will provide 
insight in the development of AmB derivatives with improved therapeutic index. 
 
Scheme 5.12. Glycosidation and global deprotection of protected amphoteronolide B to generate C2’-
deoxyAmB. 
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 5-6 Experimental 
Portions of the experimental section are adapted from ref. 12. 
 
General Methods 
Materials 
Amphotericin B was a gift from the Bristol-Myers Squibb Company. All other commercially 
available reagents were obtained from Sigma-Aldrich, TCI America, Fischer Scientific, Combi-
Blocks Inc., and Oakwood Products. Chemicals were used without further purification unless 
otherwise specified. Camphorsulfonic acid was purified before use by recrystallization with ethyl 
acetate. Triethyl amine, diisopropylethyl amine, pyridine, and 2,6-lutidine were freshly distilled 
over calcium hydride under nitrogen atmosphere. All solvents were obtained from a solvent 
purification system utilizing packed columns as described by Pangborn and coworkers.26  
 
Reactions 
All reactions were performed under argon atmosphere in low light conditions with flame 
dried glassware unless otherwise indicated. All compounds were stored in the dark under argon 
atmosphere. Thin layer chromatography or reverse phase HPLC was used to monitor reaction 
progress. Thin layer chromatography was performed on silica gel 60 F254 plates from Merck with 
the indicated solvent. Visualization of the compounds was accomplished with a UV lamp (λ254) 
and ceric ammonium molybdate (CAM) stain. Analytical HPLC was done on an Agilent 1100 
Series HPLC with a C18 5 μm, 4.6 x 150 mm, Symmetry® column from Waters Corp at a flow 
rate of 1 mL/min with the indicated solvent and gradient. The detection wavelength was set to 
383 nm.  
 
Purification and Analysis 
 Merck silica gel 60 230-400 mesh and SiliCycle reverse phase C18 (17%) 40-63 μm 60 
angstrom silica gel was used for flash chromatography with the indicated solvent. HPLC reverse 
phase purification was done on a waters C18 5 μm, 30 x 150 mm Sunfire column at a flow rate 
of 25 mL/min with the indicated solvent and gradient. The detection wavelength was set to 383 
nm. 1H NMR spectra were taken at 23 °C on a Varian Unity Inova Narrow Bore spectrometer at 
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a 1H frequency of 500 MHz with a Varian 5 mm 1H{13C/15N}pulsed-field gradient Z probe. 
Chemical shifts (δ) are reported in parts per million (ppm) downfield from tetramethylsilane and 
referenced internally to the residual protium in the NMR solvent (CHD2OD, δ = 3.30, center 
line; CD3C(O)CHD2, δ = 2.04, center line; CD3S(O)CHD2, δ = 2.50, center line; CCl3H, δ = 7.26, 
center line). Data is reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = 
triplet, dd = doublet of doublets, td = triplet of doublets, m = multiplet, b = broad, app = 
apparent), coupling constant (J) in Hertz (Hz) and integration. 13C spectra were obtained at 23 °C 
with a Varian Unity Inova spectrometer at a 13C frequency of 125 MHz with a 5 mm Nalorac 
gradient {13C/15N}1H quad probe. Chemical shifts (δ) are reported downfield of tetramethylsilane 
and are referenced to the carbon resonances in the NMR solvent (CD3OD, δ = 49.0, center line; 
CD3C(O)CD3, δ = 29.8, center line; CD3S(O)CD3, δ = 39.5, center line; CDCl3, δ = 77.0, center 
line). ESI high resolution mass spectra (HRMS), ESI low resolution mass spectra (LRMS) and 
matrix-assisted laser desorption/ionization (MALDI) spectra were obtained at the University of 
Illinois mass spectrometry facility. 
 
Synthesis of Compounds 
 
 
 
TBS Ether SI3 and SI4 
 Prior to the reaction, 4.4/SI2 (300 mg, 220 μmol, 1 eq) was azeotropically dried with 
acetonitrile followed by DCM and placed under vacuum for 8 hours. The orange powder was 
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dissolved in DCM (7.3 mL), and 2,6-lutidine (282 μL, 2.42 mmol, 11 eq) was added. The 
solution was cooled to 0 °C, and then TBS triflate (455 μL, 1.98 mmol, 9 eq) was added 
dropwise over 10 minutes. The reaction was allowed to stir at 0 °C for 90 minutes where the 
solution turned from orange to blackish color. The reaction was diluted with diethyl ether (500 
mL) at 0 °C followed by quenching with saturated sodium bicarbonate (500 mL). The ether 
extract was washed twice with cupric sulfate (400 mL), water (400 mL), and saturated sodium 
chloride (400 mL). Each of the washes was back extracted with diethyl ether (300 mL). The 
combined ether layers were then dried over magnesium sulfate, filtered, and concentrated in 
vacuo. Flash chromatography (SiO2; hexane:ethyl acetate 19:1 → 4:1) purification yielded a 
yellow-orange solid (294 mg, 162 μmol, 73 %). 
 
TLC (hexane:ethyl acetate 4:1) 
 Rf = 0.38, stained by CAM 
 
1HNMR (500 MHz, acetone d-6)  
δ 8.03 (m, 4H), 7.64 (m, 4H), 7.32-7.13 (m, 12H), 6.35-6.15 (m, 22H), 6.02 (m, 2H), 5.88 
(m, 2H), 5.50 (m, 2H), 4.92 (m, 2H), 4.75 (m, 2H), 4.65 (m, 2H), 4.35 (m, 3H), 4.25 (m, 
2H), 4.03 (m, 3H), 3.88-3.66 (m, 15H), 3.58-3.40 (m, 9H), 2.84 (s, 3H), 2.73 (s, 3H), 
2.43 (m, 3H), 2.37-2.19 (m, 3H), 2.15 (m, 6H), 1.96-1.48 (m, 42H), 1.47-0.96 (m, 58H), 
0.95-0.80 (m, 72H), 0.11-(-0.01) (m, 48H) 
 
13CNMR (125 MHz, acetone d-6)  
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δ 173.1, 170.9, 169.9, 169.8, 166.0, 157.3, 138.1, 136.7, 135.0, 134.8, 134.7, 134.4, 134.4, 
134.1, 133.9, 133.7, 133.5, 133.2, 132.5, 132.3, 132.1, 131.9, 127.2, 127.1, 126.1, 118.5, 
110.6, 110.5, 101.1, 100.6, 96.4, 96.2, 80.7, 77.7, 75.1, 74.7, 73.7, 73.0, 72.7, 69.8, 68.7, 
67.4, 66.8, 66.6, 66.4, 66.2, 58.1, 54.2, 51.8, 48.5, 48.3, 43.8, 43.5, 43.0, 41.3, 41.0, 40.7, 
38.3, 38.1, 37.6, 36.7, 35.7, 33.8, 33.7, 32.0, 31.6, 31.4, 26.5, 26.3, 26.2, 26.0, 25.9, 25.3, 
24.9, 24.3, 23.9, 23.3, 22.8, 19.2, 18.9, 18.6, 18.4, 18.3, 18.2, -3.2, -3.3, -3.5, -3.6, -4.0, -
4.1, -4.3, -4.9. 
 
HRMS (ESI) 
Calculated for C102H163NO19Si4 (M + Na)+:   1841.0794 
Found:      1841.0776 
 
 
 
 
 
Alcohol 5.1 
 Prior to the reaction, SI3/SI4 was azeotropically dried with acetonitrile followed by 
DCM and placed under vacuum for 8 hours. To a solution of SI3/SI4 (130 mg, 71.4 μmol, 1 eq) 
in THF:MeOH 1:1 (1.8 mL) was added a solution of sodium methoxide (38.6 mg, 714 μmol, 10 
eq) in MeOH (0.6 mL) dropwise. The reaction was allowed to stir at room temperature for 3 
hours. The reaction was recharged with sodium methoxide (38.6 mg, 714 μmol, 10 eq) in MeOH 
(0.6 mL) dropwise. After stirring for 2 hours, the reaction solution was diluted with ethyl acetate 
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(200 mL) and washed twice with water (200 mL) followed by a wash with saturated sodium 
chloride (200 mL). The organic layer was dried over magnesium sulfate, filtered and 
concentrated in vacuo. 5.1 and SI5 were separable by flash chromatography (SiO2; hexane:ethyl 
acetate 4:1) purification yielded yellow-orange solids (104 mg, 62.8 μmol, 88 %). 
 
 
TLC (hexane:ethyl acetate 3:1) 
 Rf = SI5 0.18, 5.1 0.25, stained by CAM 
 
1HNMR (500 MHz, acetone d-6)  
δ 7.35 (m, 2H), 7.28 (m, 2H), 7.21 (m, 1H), 6.99 (d, J = 10 Hz, 1H), 6.39-6.15 (m, 11H) 
6.08 (m, 1H), 5.84 (m, 1H), 5.76 (m, 1H), 4.81 (m, 1H), 4.63 (m, 1H), 4.61 (s, 1H), 4.22 
(m, 1H), 4.04 (m, 2H), 3.85 (app t, J = 10 Hz, 2H), 3.75 (m, 1H), 3.71-3.52 (m, 9H), 3.48 
(m, 1H), 3.32 (m, 1H), 3.00 (s, 3H), 2.41 (m, 1H), 2.31 (m, 1H), 2.23 (m, 2H), 2.16 (m, 
1H), 1.97-1.71 (m, 9H), 1.70-1.38 (m, 12H), 1.34-1.24 (m, 8H), 1.22 (d, J = 6.5 Hz, 3H), 
1.17 (d, J = 6.0 Hz, 3H), 1.10 (m, 1H), 1.02 (d, J = 7.0 Hz, 3H), 0.96 (d, J = 7.0 Hz, 3H), 
0.93 (s, 9H), 0.91 (s, 9H), 0.85 (s, 9H), 0.83 (s, 9H), 0.13-(-0.02) (m, 24H) 
 
13CNMR (125 MHz, acetone d-6) 
δ 173.4, 170.6, 169.9, 138.8, 137.1, 137.0, 134.5, 134.4, 134.3, 134.1, 133.9, 133.8, 133.6, 
133.1, 132.5, 132.1, 130.8, 130.2, 129.3, 129.0, 127.2, 110.6, 100.8, 98.4, 75.3, 75.2, 74.6, 
74.5, 73.2, 72.1, 71.6, 70.1, 68.9, 67.0, 66.7, 57.7, 55.5, 52.0, 48.4, 43.9, 43.8, 43.3, 41.5, 
41.1, 40.8, 37.6, 36.8, 33.7, 32.7, 32.1, 31.7, 27.9, 26.4, 26.3, 25.9, 25.4, 24.9, 24.9, 23.3, 
22.9, 19.1, 18.9, 18.7, 18.6, 18.3, 18.0, -3.3, -3.4, -4.0, -4.1, -4.2, -4.9.  
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HRMS (ESI) 
Calculated for C91H151NO18Si4 (M + Na)+:   1680.9906 
Found:      1680.9905 
 
 
 
 
 
Iodide 5.2 
 Prior to the reaction, 5.1/SI6 was azeotropically dried with acetonitrile followed by DCM 
and placed under vacuum for 8 hours. A flask was charged with alcohol 5.1/SI6 (50 mg, 30 μmol, 
1 eq), triiodoimidazole (13.4 mg, 30 μmol, 1 eq), imidazole (6.1 mg, 90 μmol, 3 eq), and 
triphenyl phosphine (15.7 mg, 60 μmol, 2 eq). The contents were dissolved in toluene (2 mL), 
and the reaction was allowed to stir at 70 oC for 6 hours. The reaction was then recharged with 
triiodoimidazole (13.4 mg, 30 μmol, 1 eq), imidazole (6.1 mg, 90 μmol, 3 eq), and triphenyl 
phosphine (15.7 mg, 60 μmol, 2 eq). After stirring for 2 hours at 70 oC, the reaction was diluted 
with ether (100 mL). The ether was washed twice with water (100 mL) followed by saturated 
sodium chloride (100 mL). The organic layer was dried over magnesium sulfate, filtered, and 
concentrated in vacuo. Flash chromatography (SiO2; hexane:ethyl acetate 9:1) purification 
yielded a yellow-orange solid (42.5 mg, 24 μmol, 80 %). 
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TLC (hexane:ethyl acetate 3:1) 
 Rf = 0.55, stained by CAM 
 
1HNMR (500 MHz, acetone d-6) 
δ 7.37 (m, 2H), 7.29 (m, 2H), 7.21 (m, 1H), 6.37-6.25 (m, 9H), 6.23-6.08 (m, 3H), 5.83 
(m, 2H), 4.79 (m, 1H), 4.71 (d, J = 8.5 Hz, 1H), 4.58 (m, 1H), 4.27 (m, 1H), 4.06 (m, 2H), 
3.85, (app t, J = 5.0 Hz, 1H), 3.74 (m, 1H), 3.66 (s, 3H), 3.64- 3.51 (m, 8H), 3.42 (m, 1H), 
3.03 (s, 3H), 4.2 (m, 1H), 2.28 (m, 3H), 2.15 (m, 1H), 2.02-1.92 (m, 3H), 1.87-1.73 (m, 
6H), 1.70-1.38 (m, 15H), 1.34-1.25 (m, 5H), 1.21 (d, J = 6.0 Hz, 3H), 1.17(d, J = 6.0 Hz, 
3H), 1.10 (m, 1H), 1.04(d, J = 7.0 Hz, 3H), 0.97 (d, J = 7.0 Hz, 3H), 0.93 (s, 9H), 0.91 (s, 
9H), 0.86 (s, 9H), 0.83 (s, 9H), 0.11-(-0.01) (m, 24H)   
 
13CNMR (125 MHz, acetone d-6) 
δ 173.0, 169.9, 138.5, 138.0, 136.4, 134.7, 134.6, 134.4, 134.3, 133.9, 133.8, 133.5, 133.0, 
132.3, 131.8, 130.8, 130.7, 128.9, 128.4, 127.3, 110.7, 110.6, 102.6, 100.7, 76.6, 75.3, 
75.2, 74.5, 72.1, 70.0, 68.9, 67.1, 67.0, 66.7, 57.6, 52.0, 48.5, 44.5, 44.1, 43.4, 41.4, 41.3, 
40.8, 37.7, 37.4, 33.6, 32.8, 32.1, 31.7, 27.9, 26.5, 26.3, 25.9, 25.4, 24.9, 23.4, 22.9, 18.9, 
18.7, 18.5, 18.3, 17.9, -3.6, -3.4, -3.9, -4.1, -4.2, -4.3, -4.9.  
 
HRMS (ESI) 
Calculated for C91H150NO17Si4I (M + Na)+:   1790.8923 
Found:      1790.8929 
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Methylene 5.3 
 To a solution of 5.2/SI6 (8 mg, 4.52 μmol, 1 eq) in DMPU (0.45 mL) was added sodium 
borohydride (1.4 mg, 36.2 μmol, 8 eq) and silver acetate (0.9 mg, 5.42 μmol, 1.2 eq). The 
reaction was heated to 60 oC for 3 hours. The reaction was diluted with ether (20 mL) and 
quenched with saturated sodium bicarbonate (20 mL). The ether layer was washed twice with 
water (20 mL) followed by a wash with saturated sodium chloride (20 mL). The combined 
aqueous layers were back extracted with ether (30 mL). The combined organic layers were dried 
over magnesium sulfate, filtered, and concentrated in vacuo. Flash chromatography (SiO2; 
hexane:ethyl acetate 4:1) purification yielded a yellow-orange solid (4.5 mg, 2.76 μmol, 61 %). 
 
 
 
TLC (hexane:ethyl acetate 3:1) 
 Rf = 0.45, stained by CAM 
 
1HNMR (500 MHz, acetone d-6) 
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δ 7.30 (m, 5H), 6.56 (m, 1H), 6.39-5.99 (m, 12H), 5.80 (m, 1H), 5.63 (m, 1H), 5.16 (d, J 
= 4 Hz, 1H), 4.99 (m, 1H), 4.26 (m, 3H), 4.12 (m, 1H), 3.88 (m, 1H), 3.80 (m, 1H), 3.72 
(m, 1H), 3.65 (m, 3H), 3.58 (m, 3H), 3.45 (m, 1H), 3.19 (m, 1H), 3.03 (s, 3H), 2.66 (m, 
1H), 2.48-2.10 (m, 12H), 1.97-1.76 (m, 6H), 1.71-1.48 (m, 12H), 1.45-1.25 (m, 6H), 
1.20-1.16 (m, 5H), 1.07-0.84 (m, 43H), 0.14-(-0.01) (m, 24H)  
 
HRMS (ESI) 
Calculated for C91H150NO17Si4I (M + Na)+:   1664.9957 
Found:      1664.9896 
 
 
 
 
 
diethylisopropyl silyl ether 5.4 
4.6e (2.30 g, 1.57 mmol, 1 eq) was azeotropically dried with acetonitrile and left under 
vacuum overnight.  DCM (40 mL) was added followed by hexane (40 mL) slowly while strirring 
to prevent 4.6e from crashing out of solution. 2,6-lutidine (2.4 mL, 20.4 mmol, 13 eq) was added 
and the solution was cooled to 0 °C. Diethylisopropylsilyl triflate (DEIPSOTf) (2.5 mL, 12.5 
mmol, 8 eq) was added dropwise at 0 °C over 20 min. The reaction was stirred for an additional 
30 min. The reaction was diluted with diethyl ether and quenched with saturated sodium 
bicarbonate at 0 °C. The reaction was extracted with diethyl ether and washed with 1 M copper 
sulfate until no white precipitate was observed. The organic layers were washed twice with water 
and then once with saturated sodium chloride. The organic layers were then dried over sodium 
sulfate and filtered. The solvent was removed under reduced pressure and column 
chromatography (SiO2; EtOAc:Hexane 1:9 → 1:4) purification yielded 5.4 as a yellow-orange 
solid (2.24 g, 1.13 mmol, 72 %). 
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TLC (EtOAc:Hexane 1:3) 
Rf = 0.25, stained by CAM 
 
1HNMR (500 MHz, CD3C(O)CD3) 
δ 8.01 (d, J = 8.5 Hz, 2H), 7.63 (d, J = 8.5 Hz, 2H), 7.34 (m, 4H), 7.22 (m, 3H), 7.17 (m, 3H), 
6.84 (m, 4H), 6.35-6.13 (m, 9H), 6.04 (m, 1H), 5.91 (m, 1H), 5.74 (m, 2H), 5.49 (m, 1H), 
5.41 (s, 1H), 5.39 (s, 1H), 4.92 (app s, 1H), 4.75 (m, 1H), 4.66 (m, 1H), 4.31 (m, 1H), 4.25 
(m, 1H), 4.12 (m, 1H), 3.84 (m, 1H),  3.81-3.77 (m, 9H), 3.68 (m, 4H), 3.64 (s, 3H), 3.57-
3.45 (m, 3H), 2.74 (s, 3H), 2.45 (m, 2H), 2.26 (m, 1H), 2.17 (m, 1H), 2.09 (m, 1H), 1.90 (m, 
2H), 1.73-1.59 (m, 4H), 1.51-1.34 (m, 18H), 1.26-1.11 (m, 6H), 1.08-0.76 (m, 54H), 0.73-
0.39 (m, 19H). 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 173.1, 171.1, 169.8, 165.9, 160.7, 157.4, 138.2, 136.5, 134.6, 134.4, 134.2, 133.9, 133.8, 
133.4, 132.8, 132.7, 132.5, 132.1, 131.1, 130.7, 130.6, 130.2, 129.0, 128.9, 128.8, 128.6, 
128.2, 127.1, 126.2, 121.3, 117.9, 115.1, 113.8, 113.7, 101.7, 100.9, 100.5, 96.6, 81.3, 75.6, 
74.7, 73.7, 73.2, 72.9, 72.7, 72.6, 68.6, 66.6, 58.1, 55.4, 54.5, 51.8, 48.3, 43.4, 41.0, 37.9, 
36.8, 35.7, 31.4, 19.0, 18.0, 17.9, 17.8, 17.7, 17.6, 17.4, 14.0, 13.8, 13.4, 7.7, 7.6, 7.5, 7.4, 7.1, 
5.1, 4.8, 4.7, 4.6, 4.4, 4.1. 
 
HRMS (ESI) 
Calculated for C112H171NO21Si4 (M + Na)+:   2001.1318 
Found:           2001.1221 
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hydroxyl 5.5 
5.4 (550 mg, 278 μmol, 1 eq) was dissolved in THF:MeOH 1:2 (13.5 mL), and KCN (27.0 
mg, 417 μmol, 1.5 eq) was added. The reaction was heated to 40 °C for 2 days. The reaction was 
diluted with diethyl ether and washed with water three times followed by a wash of saturated 
sodium chloride. The organic layers were dried over sodium sulfate and filtered. The solvent was 
removed under reduced pressure and column chromatography (SiO2; EtOAc:Hexane 1:4 → 3:7) 
purification yielded 5.5 as a yellow-orange solid (329 mg, 181 μmol, 65 %). 
 
 
  
TLC (EtOAc:Hexane 3:7) 
Rf = 0.22, stained by CAM 
 
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.35 (m, 6H), 7.29 (m, 2H), 7.22 (m, 1H), 6.93 (d, J = 9.5 Hz, 1H), 6.85 (m, 4H), 6.40-6.17 
(m, 11H), 6.09 (m, 1H), 5.82 (m, 1H), 5.77 (m, 1H), 5.43 (s, 1H), 5.42 (s, 1H), 4.80 (m, 1H), 
4.62 (m, 1H), 4.60 (app s, 1H), 4.23 (m, 1H), 4.15 (m, 1H), 3.98 (m, 1H), 3.85 (m, 3H),  3.78 
(m, 7H), 3.71 (m, 4H), 3.66 (m, 2H), 3.62 (s, 3H), 3.58-3.50 (m, 2H), 3.32 (m, 1H), 3.02 (s, 
3H), 2.48 (m, 1H), 2.42 (m, 1H), 2.29-2.19 (m, 3H), 1.95-1.87 (m, 3H), 1.74 (m, 2H), 1.62-
1.28 (m, 7H), 1.24-1.15 (m, 7H), 1.04-0.76 (m, 56H), 0.72-0.50 (m, 13H), 0.44-0.36 (m, 4H). 
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13CNMR (125 MHz, CD3C(O)CD3) 
δ 173.4, 170.8, 169.9, 160.8, 160.6, 137.2, 136.9, 134.6, 134.5, 134.1, 133.9, 133.8, 133.6, 
133.2, 132.7, 132.6, 132.2, 130.9, 130.3, 129.5, 129.1, 128.7, 128.3, 127.3, 121.3, 117.9, 
113.9, 113.8, 110.6, 101.8, 101.1, 100.8, 98.5, 81.4, 75.9, 75.0, 74.7, 74.6, 73.4, 73.0, 72.8, 
71.5, 68.8, 67.1, 57.7, 55.8, 55.5, 52.0, 48.5, 43.8, 43.0, 41.2, 37.9, 36.7, 33.5, 32.7, 28.1, 
18.9, 18.0, 17.9, 17.8, 17.4, 14.0, 13.9, 13.8, 13.5, 7.7, 7.6, 7.5, 7.2, 5.1, 4.9, 4.7, 4.6, 4.4, 4.1. 
 
HRMS (ESI) 
Calculated for C101H159NO20Si4 (M + Na)+:   1841.0430 
Found:           1841.0464 
 
 
 
 
iodide SI8 
5.5 (350 mg, 192 μmol, 1 eq), triiodoimidazole (130 mg, 288 μmol, 1.5 eq), triphenyl 
phosphine (152 mg, 378 μmol, 3 eq), and imidazole (60 mg, 866 μmol, 4.5 eq) were placed in a 
flask and dissolved in toluene (9.6 mL). The reaction was heated to 70 °C for 3 hrs. The reaction 
was diluted with diethyl ether and washed with saturated sodium bicarbonate followed by water 
four times. A final wash of saturated sodium chloride was performed, and the organic layers 
were dried over sodium sulfate and filtered. The solvent was removed under reduced pressure 
and column chromatography (SiO2; EtOAc:Hexane 3:17) purification yielded SI8 as a yellow-
orange solid (296 mg, 154 μmol, 80 %). 
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TLC (EtOAc:Hexane 3:7) 
Rf = 0.55, stained by CAM 
 
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.38-7.28 (m, 9H), 7.22 (m, 1H), 6.86 (m, 4H), 6.40-6.09 (m, 12H), 5.83 (m, 2H), 5.43 (s, 
1H), 5.41 (s, 1H), 4.79 (m, 1H), 4.69 (app d, J = 7.5 Hz, 1H), 4.57 (m, 1H), 4.28 (m, 1H), 
4.15 (m, 1H), 4.04 (m, 1H), 3.89 (m, 1H),  3.84 (m, 1H), 3.77 (m, 7H), 3.72 (m, 3H), 3.65 (s, 
3H), 3.57 (m, 2H), 3.40 (m, 1H), 3.05 (s, 3H), 2.51-2.40 (m, 2H), 2.25 (m, 3H), 2.00 (m, 1H), 
1.88 (m, 2H), 1.74 (m, 2H), 1.62-1.40 (m, 7H), 1.31-1.15 (m, 9H), 1.07-0.76 (m, 58H), 0.72-
0.50 (m, 13H), 0.44-0.36 (m, 4H). 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 172.5, 169.3, 160.6, 160.2, 160.0, 158.4, 137.5, 134.2, 134.1, 133.9, 133.6, 133.4, 133.2, 
132.9, 132.5, 132.1, 132.0, 131.9, 131.3, 130.2, 130.0, 128.3, 128.1, 127.7, 126.8, 113.3, 
113.2, 102.1, 101.3, 100.5, 100.1, 94.2, 80.8, 76.3, 75.4, 74.4, 74.0, 72.5, 72.2, 68.1, 66.7, 
57.0, 54.8, 51.4, 47.9, 43.8, 43.4, 42.5, 40.6, 37.3, 36.8, 32.9, 27.5, 18.1, 17.4, 17.3, 17.2, 
16.8, 13.4, 13.2, 12.9, 7.1, 7.0, 6.9, 6.6, 4.5, 4.3, 4.2, 4.1, 3.8, 3.6. 
 
HRMS (ESI) 
Calculated for C101H158NO19Si4I (M + Na)+:    1950.9448 
Found:              1950.9543 
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methylene 5.6 
SI8 (320 mg, 166 μmol, 1 eq) was placed in a vial and azeotropically dried with toluene and 
placed under vacuum overnight. The vial was backfilled with argon and DMPU (6.6 mL) was 
added. Sodium borohydride (50 mg, 1.33 mmol, 8 eq) and silver(I) acetate (42 mg, 249 μmol, 
1.5 eq) was added in a glovebox. The reaction was heated in the range of 50-55 °C for 3 hrs. 
After 3 hrs, an aliquot was removed in the glovebox every 30 min to monitor the reaction by 
TLC. The reaction was allowed to run to approximately 85 % conversion until the rate of 
decomposition exceeded conversion of the starting material. The reaction was cooled to room 
temperature and then diluted with dry diethyl ether that had been cooled to 0 °C. The reaction 
was quenched with saturated sodium bicarbonate cooled to 0 °C. Room temperature diethyl ether 
was used to extract the aqueous layer. The organic layer was then washed with water twice. A 
final wash of saturated sodium chloride was performed, and the organic layers were dried over 
sodium sulfate and filtered. The solvent was removed under reduced pressure and column 
chromatography (SiO2; EtOAc:Hexane 3:17) purification yielded 5.6 as a yellow-orange solid 
(89.8 mg, 49.8 μmol, 30 %). 
This reaction is quite sensitive to water and air. DMPU was obtained from Aldrich absolute 
over molecular sieves H2O ≤ 0.03%. The product is unstable to the reaction conditions and 
decomposes over time; the best yields are obtained by stopping the reaction before complete 
conversion and recovering the starting material and product.  
The reaction was found to be dependent upon the identity of the protecting group on the C3’ 
amine. Extensive elimination or inactivity was observed for other protecting groups. 
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TLC (EtOAc:Hexane 1:3) 
Rf = 0.47, stained by CAM 
 
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.40-7.33 (m, 9H), 7.26 (m, 1H), 6.87 (m, 4H), 6.42-6.06 (m, 12H), 5.70 (m, 2H), 5.46 (s, 
1H), 5.44 (s, 1H), 4.69 (app d, J = 5 Hz, 1H), 4.97 (m, 1H), 4.23 (m, 3H), 3.93 (m, 1H), 3.82-
3.70 (m, 10H), 3.66 (m, 4H), 3.58 (m, 2H),  3.39 (m, 1H), 3.17 (m, 1H), 3.04 (s, 3H), 2.63 (m, 
2H), 2.42 (m, 1H), 2.30 (m, 3H), 1.98 (m, 1H), 1.88 (m, 1H), 1.76-1.34 (m, 10H), 1.29-1.14 
(m, 8H), 1.05-0.76 (m, 59H), 0.72-0.50 (m, 13H), 0.44-0.36 (m, 4H). 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 173.6, 170.0, 160.8, 160.7, 136.9, 134.6, 134.3, 133.6, 136.4, 133.0, 132.6, 132.5, 130.0, 
129.4, 128.7, 128.4, 127.6, 113.9, 113.8, 102.0, 101.2, 81.7, 80.9, 76.5, 75.2, 73.4, 73.1, 55.5, 
51.7, 44.1, 43.8, 42.7, 41.5, 37.9, 33.6, 32.6, 28.5, 18.0, 17.9, 17.8, 17.6, 17.4, 13.9, 13.5, 7.7, 
7.6, 7.5, 7.4, 7.2, 4.8, 4.7, 4.4, 4.2. 
 
HRMS (ESI) 
Calculated for C101H159NO19Si4 (M + Na)+:   1825.0481 
Found:           1825.0496 
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epi-alcohol 5.7 
5.5 (18.2 mg, 10 μmol, 1 eq), triphenylphosphine (4.0 mg, 15 μmol, 1.5 eq), and p-
nitrobenzoic acid (2.0 mg, 12 μmol, 1.15 eq) were placed in a flask and azeotroped in toluene to 
dryness (3x 0.5 mL). The reaction was then dissolved in toluene (0.3 mL) and cooled to 0 oC for 
the dropwise addition of DIAD (3.0 μl, 15 μmol, 1.5 eq). The reaction was stirred for 20 min at 0 
oC then heated to 70 oC for 2 hrs. The reaction was diluted with diethyl ether (10 mL) and 
washed with saturated sodium bicarbonate (3.0 mL). The aqueous phase was extracted with 
diethyl ether (10 mL). A final wash of saturated sodium chloride was performed, and the organic 
layers were dried over sodium sulfate and filtered. The solvent was removed under reduced 
pressure and column chromatography (SiO2; EtOAc:Hexane 5:95 to 1:3) purification yielded the 
C2’ nitrobenzoate ester as a yellow-orange solid. Two reactions were run: (11.7 mg, 5.9 μmol, 
59 %) (13.5 mg, 6.8 μmol, 68%) 
The C2’ p-nitrobenzoate ester was combined (25.2 mg, 12.8 μmol, 1.0 eq) and taken up in 
MeOH:THF 2:1 (435 μl). Potassium cyanide (2.5 mg, 38 μmol, 3.0 eq) was then added and the 
reaction was stirred for 72 hrs at 30 oC. The reaction was then diluted with diethyl ether (10 mL) 
and washed with saturated sodium bicarbonate (3.0 mL). The aqueous phase was extracted with 
diethyl ether (2x 10 ml). A final wash of saturated sodium chloride was performed, and the 
organic layers were dried over sodium sulfate and filtered. The solvent was removed under 
reduced pressure and column chromatography (SiO2: EtOAc:Hexane 1:4 → 3:7) purification 
yielded 5.7 as a yellow-orange solid ( 15.8 mg, 8.7 μmol, 68 %). 
 
116
 
 
TLC (EtOAc:Hexane 3:7) 
Rf = 0.2, stained by CAM 
 
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.36 (m, 6H), 7.28 (m, 2H), 7.21 (m, 1H), 7.15 (m, 1H), 6.86 (m, 4H), 6.41-6.18 (m, 11H), 
6.10 (m, 1H), 5.86 (m, 1H), 5.77 (m, 1H), 5.44 (s, 1H), 5.43 (s, 1H), 4.81 (m, 1H), 4.56 (m, 
1H), 4.36 (app d, J = 7.5, 1H), 4.26 (m, 1H), 4.17 (m, 1H), 3.97-3.85 (m, 4H), 3.79 (m, 7H), 
3.73 (m, 4H), 3.66 (s, 3H), 3.61-3.48 (m, 3H), 3.43 (m, 1H), 3.33 (m, 1H), 3.04 (s, 3H), 2.49 
(m, 1H), 2.42 (m, 1H), 2.30-2.21 (m, 3H), 1.95-1.87 (m, 3H), 1.80-1.67 (m, 3H), 1.64-1.27 
(m, 6H), 1.24-1.16 (m, 7H), 1.04-0.76 (m, 56H), 0.73-0.51 (m, 13H), 0.46-0.37 (m, 4H). 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 173.9, 172.1, 170.1, 161.0, 137.9, 137.0, 134.8, 134.7, 134.3, 134.1, 133.9, 133.7, 133.3, 
132.9, 132.4, 131.1, 130.5, 129.7, 129.1, 128.9, 128.5, 127.3, 114.1, 114.0, 103.4, 102.0, 
101.3, 100.9, 81.6, 76.5, 76.1, 75.2, 74.7, 73.3, 73.0, 69.0, 67.6, 57.8, 55.6, 52.1, 48.6, 44.3, 
44.2, 38.1, 33.7, 32.9, 19.1, 18.2, 18.1, 18.0, 17.6, 14.3, 14.2, 14.1, 13.7, 7.8, 7.7, 7.6, 7.3, 5.4, 
5.1, 5.0, 4.9, 4.6, 4.4 
 
HRMS (ESI) 
Calculated for C101H159NO20Si4 (M + Na)+:    1841.0430 
Found:            1841.0464 
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conjugate 5.8 
Ergosterol (400 mg, 1.01 mmol, 1 eq) and succinic anhydride (1.01 g, 10.1 mmol, 10.0 eq) 
were azeotroped with toluene (3x 1.0 mL) in a 40 mL vial. Dry pyridine (20 mL 0.05 M) was 
then added followed by dimethylaminopyridine (DMAP) (154.2 mg, 1.26 mmol, 1.25 eq). The 
reaction was sealed with a teflon lined cap and heated to 140 oC for 16 hrs. The resulting black 
solution was extracted with HCl (10% v/v) and EtOAc. The organic phase was dried with 
sodium sulfate, filtered, and concentrated. Chromatography (SiO2; EtOAc:Hexane 1:5 with 1% 
AcOH) purification yielded A as a white solid (282 mg, 0.57 mol, 56%). 
A (12.5 mg, 25 μmol, 2.5 eq) was dissolved in toluene (0.3 mL) and oxalyl chloride (10.0 μL, 
118 μmol, 4.75 eq) was added and the reaction was heated to 50 oC and stirred for 15 min. The 
resulting yellow solution was azeotroped with toluene (3x 0.3 mL) to dryness. The resulting off-
white solid B was then dissolved in THF (0.3 mL) whereupon DMAP (3.1 mg, 25 μmol, 2.5 eq) 
was added to generate a cloudy white suspension. In a separate vial 5.5 (18.2 mg, 10 μmol, 1.0 
eq) was dissolved in THF (0.15 mL) and diethylisopropyl amine (10 μL, 57 μmol, 5.7 eq) was 
added. The resulting yellow/orange solution was added dropwise via cannula to the first 
suspension and stirred for 3 hrs at room temperature. The reaction was diluted with diethyl ether 
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(10 mL) and washed with saturated sodium bicarbonate (3.0 mL). The aqueous phase was 
extracted with diethyl ether (2x 10 mL). A final wash of saturated sodium chloride was 
performed, and the organic layers were dried over sodium sulfate and filtered. The solvent was 
removed under reduced pressure and column chromatography (SiO2; EtOAc:Hexane 5:95 → 
1:3) purification yielded the 5.8 as a yellow-orange solid (14.5 mg, 6.3 μmol, 63 %) 
 
 
 
TLC (EtOAc:Hexane 1:3) 
Rf = 0.76, stained by CAM 
 
1HNMR (500 MHz, CD3C(O)CD3) 
δ 7.36 (m, 4H), 7.28 (m, 4H), 7.23 (m, 1H), 6.93 (m, 1H), 6.86 (m, 4H), 6.39-6.12 (m, 12H), 
5.84(m, 2H), 5.61 (m, 1H), 5.41 (m, 3H), 5.26 (m, 3H), 5.83-4.61 (m, 4H), 4.29-4.13 (m, 3H), 
3.90-3.81 (m, 3H), 3.79 (s, 3H), 3.78 (s, 3H), 3.72 (m, 2H), 3.67 (s, 3H), 3.56 (m, 2H), 3.47 
(m, 2H),  3.00 (s, 3H), 2.71-2.34 (m, 9H), 2.31-2.08 (m, 5H), 2.00-1.45 (m, 30H), 1.41-0.38 
(m, 98H) 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 173.4, 173.2, 172.3, 171.2, 170.1, 160.8, 142.3, 139.6, 137.8, 136.8, 136.7, 134.8, 134.5, 
134.1, 133.7, 133.3, 132.9, 132.6, 132.1, 131.0, 130.5, 129.2, 128.9, 128.5, 127.5, 126.2, 
121.4, 117.5, 114.1, 114.0, 102.0, 101.3, 100.9, 81.6, 76.2, 75.2, 75.1, 74.1, 73.9, 73.3, 73.1, 
72.3, 68.9, 67.1, 58.1, 56.7, 55.7, 55.4, 54.6 52.1, 48.8, 47.1, 44.2, 43.9, 43.8, 43.7, 43.2, 41.4, 
39.9, 38.8, 38.0, 37.6, 34.0, 33.8, 30.9, 29.1, 29.0, 28.4, 23.9, 21.7, 20.5, 20.2, 19.2, 18.3, 
18.2, 18.1, 18.0, 17.9, 17.6, 16.6, 14.2, 14.1, 13.7, 12.6, 7.9, 7.8, 7.7, 7.6, 7.3, 5.4, 5.1, 5.0, 
4.9, 4.7, 4.4, 1.5 
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 MS (MALDI) 
Calculated for C133H205NO23Si4 (M + Na)+:    2319 
Found:            2319 
 
 
 
TIPS ester 5.11 
 Intermediate 5.10 (15.8 g, 7.20 mmol, 1 eq) was azeotropically dried with toluene and 
placed under vacuum overnight. Hexane (240 mL) and 2,6-lutidine (2.9 mL, 25.2 mmol, 3.5eq) 
were added. The resulting solution was cooled to 0 oC and triisopropylsilyl triflate (2.9 mL, 10.8 
mmol, 1.5eq) was added slowly over 15 min. The reaction was quenched after 1 hr with 
saturated aqueous sodium bicarbonate and extracted with ether. The organic layer was washed 
with copper sulfate, water, and finally saturated sodium chloride. The organic layer was dried 
with sodium sulfate and filtered. The solvent was removed under reduced pressure, and column 
chromatography (SiO2; Ether:Hexane 5:95 → 1:4) purification yielded the 5.11 as a yellow-
orange solid (15.2 g,  6.5 mmol, 90 %). 
 
 
 
TLC (Ether:Hexane 0.1% Et3N 3:7) 
Rf = 0.72, stained by CAM 
 
1HNMR (500 MHz, CD3C(O)CD3) 
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δ 7.86 (d, J = 7.5 Hz, 2H), 7.69 (d, J = 7.5 Hz, 2H), 7.41 (t, J = 7.5 Hz, 2H), 7.33 (t, J = 7.5 
Hz, 2H), 6.53-6.05 (m, 12H), 5.51 (m, 1H), 5.34 (m, 1H), 4.65 (m, 2H), 4.47 (m, 3H), 4.34 
(m, 2H), 4.24 (m, 2H), 4.13 (m, 1H), 3.98 (m, 2H), 3.90 (m, 1H), 3.83 (m, 1H),  3.66 (m, 2H), 
3.45 (m, 1H), 3.27 (m, 1H), 3.15 (s, 3H), 2.56 (m, 1H), 2.42 (m, 2H), 2.10-2.01 (m, 3H), 
1.94-1.59 (m, 12H), 1.50 (m, 1H), 1.38-1.30 (m, 4H), 1.23 (m, 4H), 1.16 (m, 20H), 1.07-0.89 
(m, 85H), 0.78-0.55 (m, 56H). 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 172.3, 170.5, 156.2, 145.0, 142.1, 139.0, 135.7, 135.3, 135.2, 134.7, 133.8, 132.9, 132.8, 
132.7, 132.5, 131.4, 130.7, 130.6, 128.4, 127.8, 125.8, 125.7, 120.7, 101.2, 99.5, 76.7, 74.6, 
74.0, 73.9, 73.2, 71.1, 69.4, 68.0, 67.5, 67.3, 67.2, 59.0, 58.2, 48.2,  48.0, 47.8, 44.3, 43.4, 
42.1, 41.2, 37.2, 35.6, 27.4, 19.9, 19.2, 19.0, 18.4, 18.2, 12.9, 11.3, 7.6, 7.5, 7.4, 7.3, 6.4, 6.2, 
6.1, 6.0, 5.9, 5.8. 
 
LRMS (ESI) 
Calculated for C126H231NO19Si10 (M + Na)+:   2365.5 
Found:            2365.1 
 
 
 
 
 
allylic alcohol 5.12 
 Intermediate 5.11 (12.5 g, 5.35 mmol, 1 eq) was azeotropically dried with toluene and 
placed under vacuum overnight. THF (100 mL) was added. The resulting solution was cooled to 
0 oC, and DDQ (1.82 g, 8.03 mmol, 1.5eq) and CaCO3 (5.3 g, 53.5 mmol, 10 eq) were added. 
The reaction was warmed to room temperature and quenched after 30 min with saturated 
aqueous sodium bicarbonate and extracted with ether. The organic layer was washed with water 
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and then saturated sodium chloride. The organic layer was dried with sodium sulfate and filtered. 
The solvent was removed under reduced pressure, and flash column chromatography (SiO2; 
Ether:Hexane 1:4) purification yielded the enone as a dark red solid. This intermediate is 
sensitive to silica gel and was immediately subjected to the next reaction conditions.  
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TLC (Ether:Hexane 3:17) 
Rf = 0.35, stained by CAM 
 
LRMS (ESI) 
Calculated for C93H180NO14Si8 (M + Na)+:   1768.1 
Found:          1768.0 
 
 The enone intermediate was azeotropically dried with toluene. THF (10 mL) and MeOH 
(20 mL) was added. The resulting solution was cooled to 0 oC, and NaBH4 (1.08 g, 28.6 mmol, 
5.3 eq) was added. The reaction was quenched after 30 min with 1M aqueous ammonium 
chloride and extracted with ether. The organic layer was washed with water and then saturated 
sodium chloride. The organic layer was dried with sodium sulfate and filtered. The solvent was 
removed under reduced pressure, and flash column chromatography (SiO2; Ether:Hexane 1:9 → 
1:4) purification yielded the 5.12 as a yellow-orange solid. This intermediate is not stable to long 
term storage and extended periods on silica gel. (4.5 g, 2.57 mmol, 48 % 2 steps). 
 
 
TLC (Ether:Hexane 1:4) 
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Rf = 0.44, stained by CAM 
 
1HNMR (500 MHz, CD3C(O)CD3) 
δ 6.49-6.10 (m, 13H), 5.53 (m, 1H), 4.68 (m, 1H), 4.50 (m, 2H), 4.22 (m, 1H), 4.15 (m, 1H), 
4.06 (m, 1H), 4.00 (m, 1H), 3.91 (d, J = 4 Hz, 1H), 3.83 (m, 1H), 3.68 (m, 1H), 3.63 (m, 1H),  
3.15 (s, 3H), 2.55 (m, 2H), 2.42 (m, 1H), 2.36 (m, 1H), 2.13 (m, 1H), 2.01 (m, 2H), 1.95-1.70 
(m, 8H), 1.63 (m, 3H), 1.49 (m, 1H), 1.31 (m, 3H), 1.18-1.14 (m, 20H), 1.07-0.96 (m, 69H), 
0.77-0.61 (m, 43H). 
 
13CNMR (125 MHz, CD3C(O)CD3) 
δ 172.2, 170.5, 139.6, 138.6, 134.8, 134.7, 134.0, 133.3, 133.1, 133.0, 132.8, 132.7, 131.7, 
131.6, 130.8, 127.9, 101.1, 76.7, 74.0, 73.2, 71.0, 69.3, 69.1, 67.4, 67.3, 59.2, 48.0, 47.8, 44.4, 
43.5, 41.8, 41.3, 40.6, 35.5, 27.4, 19.8, 19.2, 18.4, 18.3, 12.8, 11.2, 7.7, 7.6, 7.5, 7.4, 7.3, 6.4, 
6.2, 6.1, 5.9, 5.8. 
 
LRMS (ESI) 
Calculated for C93H182NO14Si8 (M + Na)+:   1770.2 
Found:          1770.2 
 
 
 
octaol SI10 
 Intermediate 5.12 (2.5 g, 1.29 mmol, 1 eq) was azeotropically dried with toluene and 
placed under vacuum overnight. Hexane (80 mL) was added followed by activated 4 angstrom 
molecular sieves. The resulting solution was allowed to stir at room temperature while the sugar 
donor was prepared. The sugar donor (739 mg, 2.57 mmol, 2.0 eq) was dissolved in DCM (26 
mL). Diphenyl sulfoxide (911 mg, 4.50 mmol, 3.5 eq) and activated 4 angstrom molecular sieves 
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were added. The reaction was stirred for 4 hours at room temperature. 2,6-lutidine (675 μL, 5.79 
mmol, 4.5 eq) was added, and the reaction was cooled to -60 °C. Triflic anhydride (1M in DCM) 
(2.57 mL, 2.57 mmol, 2 eq) was added slowly. The reaction was warmed to -20 °C and stirred 
for 1.5 hrs. 2,6-lutidine (600 μL, 5.15 mmol, 4.0 eq) was added to the solution of 5.12, and it was 
cooled to -30 °C. The sugar donor reaction was cannulated over to the solution of 5.12. The 
reaction was warmed to 0 °C for 1hr. The reaction was quenched with saturated aqueous sodium 
bicarbonate and extracted with ether. The organic layer was washed with copper sulfate, water, 
and saturated sodium chloride. The organic layer was dried with sodium sulfate and filtered. The 
solvent was removed under reduced pressure, and column chromatography (SiO2; Ether:Hexane 
3:47) purification yielded the glycosidated product as a mixture of isomers ranging from 1:1 to 
2:1 α:β (2.12 g, 1.06 mmol, 82 %). The isomers were inseparable at this stage and were taken 
directly on the next reaction.  
 
 
 
TLC (Ether:Hexane 1:19) 
Rf = 0.25, stained by CAM 
 
LRMS (ESI) 
Calculated for C105H205N3O16Si9 (M + Na)+:   2039.3 
Found:             2039.9 
 
 The glycosidated product SI9 (710 mg, 352 μmol, 1 eq) was azeotropically dried with 
toluene in a teflon vial. THF (3 mL) was added, and the solution was cooled to 0 °C. Pyridine (3 
mL) in a teflon vial was cooled to 0 °C, and MeOH (0.5 mL) was added. 70% HF-pyridine was 
added slowly to the pyridine-MeOH solution at 0 °C. This solution was transferred slowly to the 
THF solution of glycosylated intermediate. The reaction was allowed to stir for 12 hours at room 
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temperature. The reaction was quenched at 0 °C with excess MeOTMS and diluted with toluene. 
The solution was concentrated under reduced pressure and diluted again with toluene. This 
process was repeated 3 times to remove all of the pyridine. The product is base sensitive, 
especially if water is present, – care must be taken not to concentrate directly to solid with 
pyridine present. Reversed phase HPLC purification (C18 SiO2; MeCN:5 mM NH4OAc in H2O 
1:19 → 19:1 over 30 minutes) allowed the α and β isomers to be separated and yielded 260 mg, 
275 μmol, 78 %. 
 
 
 
HPLC (C18 SiO2; MeCN:5 mM NH4OAc in H2O 1:19 → 19:1 over 30 minutes) 
tr = 17.1 min, α 
tr = 16.2 min, β 
 
1HNMR (500 MHz, CD3S(O)CD3) 
δ 6.32-6.05 (m, 12H), 5.81 (m, 1H), 5.60 (m, 1H), 4.97 (m, 1H), 4.58 (m, 1H), 4.43 (m, 1H), 
3.99 (m, 1H), 3.84 (m, 1H), 3.73 (m, 2H), 3.52 (m, 2H), 3.32 (m, 1H), 3.21 (m, 1H), 3.10 (m, 
1H), 3.00 (s, 3H), 2.93 (m, 2H), 2.29 (m, 1H), 2.16 (m, 2H), 2.01 (m, 2H), 1.76 (m, 1H), 1.68 
(m, 1H), 1.52-1.23 (m, 14H), 1.15 (d, J = 5.5 Hz, 3H), 1.11 (d, J = 5.5 Hz, 3H), 1.03 (d, J = 6 
Hz, 3H), 0.89 (d, J = 7 Hz, 3H). 
 
HRMS (ESI) 
Calculated for C48H73N3O16 (M + Na)+:   970.4889 
Found:     970.4897 
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amine SI11 
 SI10 (19 mg, 20 μmol, 1 eq) was dissolved in DMSO (657 μL). Added water (36 μL, 200 
μmol, 100 eq) and trimethyl phosphine (1M) (60 μL, 60 μmol, 3 eq). The reaction was heated to 
55 °C for 3 hrs. Reversed phase HPLC purification (C18 SiO2; MeCN:5 mM NH4OAc in H2O 
1:19 → 19:1 over 30 minutes) yielded SI11 (10.5 mg, 11.4 μmol, 57 %). 
 
 
 
HPLC (C18 SiO2; MeCN:5 mM NH4OAc in H2O 1:19 → 19:1 over 30 minutes) 
tr = 14.3 min 
 
1HNMR (500 MHz, CD3S(O)CD3) 
δ 6.34-6.06 (m, 12H), 5.90 (m, 1H), 5.62 (m, 1H), 4.94 (m, 1H), 4.63 (m, 1H), 4.52 (m, 1H), 
3.97 (m, 1H), 3.90 (m, 1H), 3.73 (m, 2H), 3.56 (m, 1H), 3.38 (m, 1H), 3.30 (m, 1H), 3.25 (m, 
1H), 3.15 (m, 1H), 2.95 (m, 5H), 2.25 (m, 4H), 2.03 (m, 1H), 1.77 (m, 3H), 1.53-1.24 (m, 
13H), 1.17 (d, J = 5 Hz, 3H), 1.11 (d, J = 6 Hz, 3H), 1.03 (d, J = 6 Hz, 3H), 0.89 (d, J = 6.5 
Hz, 3H). 
 
HRMS (ESI) 
Calculated for C48H75NO16 (M + H)+:   922.5164 
Found:               922.5169 
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C2’-deoxyAmB 
 SI11 (5 mg, 5.42 μmol, 1 eq) was placed in a vial. 180 μL of a 180 mM solution of CSA 
in 2:1 THF:H2O was added. The reaction was stirred for 30 min. Reversed phase HPLC 
purification (C18 SiO2; MeCN:5 mM NH4OAc in H2O 1:19 → 19:1 over 30 minutes) yielded 
C2’-deoxyAmB (3.9 mg, 4.34 μmol, 80 %). 
 
 
 
HPLC (C18 SiO2; MeCN:5 mM NH4OAc in H2O 1:19 → 19:1 over 30 minutes) 
tr = 15.1 min 
 
1HNMR (500 MHz, CD3S(O)CD3) 
δ 6.47-5.94 (m, 11H), 5.73 (m, 1H), 5.42 (m, 2H), 5.23 (m, 1H), 4.77 (m, 1H), 4.61 (m, 1H), 
4.38 (m, 1H), 4.26 (m, 1H), 4.15 (m, 1H), 4.06 (m, 1H), 3.99 (m, 1H), 3.70-3.20 (m, 4H), 
3.09 (m, 1H), 2.92 (m, 1H), 2.36-2.16 (m, 5H), 1.99 (m, 1H), 1.83-1.72 (m, 4H), 1.56-1.51 
(m, 4H), 1.39-1.23 (m, 7H), 1.15 (d, J = 5.5 Hz, 3H), 1.11 (d, J = 6 Hz, 3H), 1.03 (d, J = 6 
Hz, 3H), 0.91 (d, J = 6.5 Hz, 3H). 
 
HRMS (ESI) 
Calculated for C47H73NO16 (M + H)+:   908.5008 
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Found:             908.5007 
 
 
 
 
alcohol SI12 
 Epoxide intermediate (8 g, 21 mmol, 1 eq) was dissolved in THF (263 mL). The resulting 
solution was cooled to 0 oC, and LiHBEt3 (1M in THF) (105 mL, 105 mmol, 5eq) was added 
slowly. The reaction heated to 60 oC for 2.5 hrs. The reaction was cooled to 0 oC and quenched 
with 1M ammonium chloride. The mixture was extracted with ether. The organic layer was 
washed with water and saturated sodium chloride. The organic layer was dried with sodium 
sulfate and filtered. The solvent was removed under reduced pressure, and column 
chromatography (SiO2; Ether:Hexane 1:4 → 1:3) purification yielded SI2 as an oil (5.47 g,  14.3 
mmol, 68 %). 
 
 
 
TLC (Ether:Hexane 3:7) 
Rf = 0.38, stained by CAM 
 
1HNMR (500 MHz, CDCl3) 
δ 7.27 (d, J = 8.5 Hz, 2H), 6.88 (d, J = 9 Hz, 2H), 4.87 (d, J = 4 Hz, 1H), 4.66 (d, J = 12 Hz, 
1H), 4.44 (d, J = 11.5 Hz, 1H), 4.04 (m, 1H), 3.92 (m, 1H), 3.81 (s, 3H), 3.32 (dd, J = 3 Hz, J 
= 9.5 Hz, 1H), 3.19 (m, 1H), 2.14 (dd, J = 3.5 Hz, J = 15 Hz, 1H), 1.89 (td, J = 3.5 Hz, J = 
14.5 Hz,  1H), 1.26 (d, J = 6.5 Hz, 3H), 0.93 (s, 9H), 0.12 (s, 6H). 
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13CNMR (125 MHz, CDCl3) 
δ 159.5, 129.9, 114.0, 95.7, 75.1, 68.9, 68.0, 63.7, 55.5, 35.7, 26.1, 18.4, -4.0, -4.4. 
 
HRMS (ESI) 
Calculated for C20H34O5Si (M + Na)+:   405.2073 
Found:              405.2078 
 
 
 
 
 
mesylate 5.14 
 SI12 (4.83 g, 12.6 mmol, 1 eq) was dissolved in THF (15 mL). Pyridine (10.2 mL, 126 
mmol, 10 eq) and MsCl (3.17 mL, 41 mmol, 3.25 eq) were added. The reaction was stirred 
overnight. The reaction was then quenched with saturated aqueous sodium bicarbonate and 
extracted with ether. The organic layer was washed with 1M ammonium chloride, water, and 
saturated sodium chloride. The organic layer was dried with sodium sulfate and filtered. The 
solvent was removed under reduced pressure, and column chromatography (SiO2; Ether:Hexane 
2:3) purification yielded 5.14 as a solid (4.24 g, 9.2 mmol, 73 %). 
 
 
 
TLC (Ether:Hexane 2:3) 
Rf = 0.27, stained by CAM 
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1HNMR (500 MHz, CDCl3) 
δ 7.27 (d, J = 9 Hz, 2H), 6.88 (d, J = 8.5 Hz, 2H), 4.90 (dd, J = 3 Hz, J = 8 Hz, 2H), 4.66 (d, 
J = 11.5 Hz, 1H), 4.35 (d, J = 11 Hz, 1H), 4.13 (m, 1H), 3.80 (s, 3H), 3.43 (dd, J = 3 Hz, J = 
9 Hz, 1H), 2.91 (s, 3H), 2.41 (dd, J = 3 Hz, J = 15 Hz, 1H), 1.96 (m, 1H), 1.23 (d, J = 6.5 Hz, 
3H), 0.93 (s, 9H), 0.14 (s, 3H), 0.11 (s, 3H). 
 
13CNMR (125 MHz, CDCl3) 
δ 159.4, 130.2, 129.6, 113.9, 94.8, 77.5, 72.7, 69.1, 64.3, 55.5, 39.9, 34.5, 26.0, 18.3, -3.9, -
4.6. 
 
HRMS (ESI) 
Calculated for C21H36O5SiS (M + Na)+:   483.1849 
Found:                483.1848 
 
 
 
 
azide SI13 
 5.14 (1.6 g, 3.47 mmol, 1 eq) was dissolved in DMF (15 mL). Sodium azide (1.6 g, 24.3 
mmol, 7 eq) was added. The reaction heated to 160 °C for 1.5 hrs. The reaction was cooled to 
room temperature. The reaction was quenched with saturated aqueous sodium bicarbonate and 
extracted with ether. The organic layer was washed with water, and saturated sodium chloride. 
The organic layer was dried with sodium sulfate and filtered. The solvent was removed under 
reduced pressure, and column chromatography (SiO2; Ether:Hexane 1:19) purification yielded 
SI13 as a solid (1.13 g, 2.78 mmol, 80 %). 
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TLC (Ether:Hexane 1:19) 
Rf = 0.30, stained by CAM 
 
1HNMR (500 MHz, CDCl3) 
δ 7.29 (d, J = 9 Hz, 2H), 6.91 (d, J = 8.5 Hz, 2H), 4.91 (d, J = 3 Hz, 2H), 4.61 (d, J = 11.5 Hz, 
1H), 4.39 (d, J = 11 Hz, 1H), 3.82 (s, 3H), 3.71 (m, 2H), 3.10 (t, J = 9 Hz, 1H), 2.19 (dd, J = 
5 Hz, J = 13.5 Hz, 1H), 1.73 (td, J = 4 Hz, J = 12.5 Hz, 1H), 1.27 (d, J = 6 Hz, 3H), 0.94 (s, 
9H), 0.22 (s, 3H), 0.13 (s, 3H). 
 
13CNMR (125 MHz, CDCl3) 
δ 159.6, 129.9, 129.8, 114.1, 95.4, 76.7, 68.9, 68.8, 61.8, 55.5, 35.9, 26.2, 18.7, 18.4, -3.9, -
4.0. 
 
HRMS (ESI) 
Calculated for C20H33N3O4Si (M + Na)+:   430.2138 
Found:                  430.2156 
 
 
 
 
alcohol 5.15 
 SI13 (6.5 g, 15.9 mmol, 1 eq) was dissolved in DCM:H2O 9:1 (160 mL). The solution 
was cooled to 0 °C, and DDQ (4.3 g, 19.1 mmol, 1.2 eq) was added. The reaction was warmed to 
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room temperature and stirred for 2 hrs. The reaction was quenched with saturated aqueous 
sodium bicarbonate and extracted with ether. The organic layer was washed with water, and 
saturated sodium chloride. The organic layer was dried with sodium sulfate and filtered. The 
solvent was removed under reduced pressure, and column chromatography (SiO2; Ether:Hexane 
1:19) purification followed by (C18 SiO2, water:MeCN 1:4) yielded 5.15 as a solid (3.47 g, 12.1 
mmol, 76 %). 
 
 
 
TLC (EtOAc:Hexane 1:4) 
Rf = 0.31, stained by CAM 
      (H2O:MeCN 1:4) 
Rf = 0.50, stained by CAM 
 
HRMS (ESI) 
Calculated for C12H25N3O3Si (M + Na)+:   310.1563 
      Found:                  310.1566 
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